Gordon B. Mills, M.D., Ph.D. April 18, 2020

# PRESENT TITLE AND AFFILIATION

Director, Precision Oncology, Knight Cancer Institute

Director, SMMART Trials, Knight Cancer Institute Professor, Cell, Developmental and Cancer Biology

Wayne and Julie Drinkward Endowed Chair, Precision Oncology, Knight Cancer Institute Oregon Health & Science University (OHSU)

Associate Director Clinical Research Ad Interim Knight Cancer Institute

# CITIZENSHIP

Canadian

Resident Alien: USA A074593667

# HOME ADDRESS

5303 Amberwood Court Lake Oswego, OR 97035

# OFFICE ADDRESS

2720 SW Moody Avenue KCRB 2000

Portland, OR 97201

503-346-4660 - Office

[millsg@ohsu.edu](mailto:millsg@ohsu.edu)

# PHYSICAL ADDRESS

3181 SW Sam Jackson Park Road Mailcode: KR-PM, Portland, OR 97201

# EDUCATION

# B. Med. Sci. University of Alberta Edmonton, Alberta, Canada 1975

M.D. University of Alberta 1977

FRCS Canada (Obstetrics and Gynecology) 1982

Ph.D. (Biochemistry) University of Alberta 1984

**Post Graduate Training**

Research Fellow, Department of Obstetrics 1976

and Gynecology, Flinders Medical Center

Adelaide, Australia (Supervisor, W.P. Jones)

Straight Intern (Obstetrics and Gynecology) 1977-78

University of Alberta

Graduate Studies (Biochemistry) 1978-84

University of Alberta

Honorary Resident (Obstetrics and Gynecology) 1978-80

University of Alberta

Resident (Obstetrics and Gynecology) 1980-82

University of Alberta

Research Fellow: Division of Immunology 1982-85

The Hospital for Sick Children

Toronto, Ontario, Canada (Supervisor, E. Gelfand)

**CREDENTIALS**

Royal College of Physicians and Surgeons of Canada

Specialty - Obstetrics and Gynecology – 60741 1982

Texas State Board of Medical Examiners - J9856 1996-2018

ORCID - 0000-0002-0144-9614 2013

# PROFESSIONAL MEMBERSHIP/ACTIVITIES

Texas Medical Association

Harris County Medical Society

American Association for Cancer Research

American Society of Clinical Oncology

Fellow of the Royal College of Surgeons Canada

Fellow of American Association for Science

Member of the Association of American Physicians

# EXPERIENCE/SERVICE

**Oregon Health & Science University**

Professor, Cell, Developmental and Cancer Biology 2018-

Director, Precision Oncology, Knight Cancer Institute 2018-

Director, SMMART Trials, Knight Cancer Institute 2018-

Wayne and Julie Drinkward Endowed Chair, 2018- Precision Oncology, Knight Cancer Institute

# MD Anderson Cancer Center

**Academic and Professional Appointments**

Chief, Section of Molecular Therapeutics 1994-2018

Professor, Medicine 1994-2018

Member Graduate Studies Biological Sciences 1994-2018

Member, Tumor Biology Program 1994-2018

Professor, Department of Immunology 1995-2018

Chairman, Department of Molecular Oncology 1995-01

Medical Director Clinical Cancer Genetics (Ad Interim) 1996-01

Co-Director Clinical Genetics Research Program (Ad Interim) 1996-97

Associate Head, Division of Medicine 1998-00

Research Resources and Space 1999-13

Professor, Breast Medical Oncology 2000-18

Chairman, Department of Molecular Therapeutics 2001-06

Director Kleberg Center for Molecular Markers 2004-18

Building Director SCRBII 2004-18

Chairman, Department of Systems Biology 2006-18

Co-Director Institute for Personalized Cancer Therapy 2010-18

# University of Toronto

Associate Professor, Department of Obstetrics and Gynecology University of Toronto 1990-94

Associate Professor, Department of Immunology University of Toronto 1990-94

Associate Professor, Department of Clinical Biochemistry University of Toronto 1990-94

Active Staff, Gynecologic Oncology 1985-94

Department of Obstetrics and Gynecology Toronto General Hospital 1985-94

Director, Oncology Research Toronto General Hospital 1990-94

Medical Research Council of Canada Scientist University of Toronto 1991-94

MacLaughlin Scientist University of Toronto 1986-92

Medical Research Council of Canada Scholar University of Toronto 1986-91

Assistant Professor Department of Obstetrics and Gynecology University of Toronto 1985-90

Assistant Professor, Department of Immunology University of Toronto 1985-90

Assistant Professor, Department of Clinical Biochemistry University of Toronto 1989-90

**INSTITUTIONAL COMMITTEE ACTIVITIES KNIGHT CANCER INSTITUTE**

Member Search Committee Chair of Pathology 2019

Member IAB Brendan Colson Center for Pancreatic Health 2018-

Member Search Committee Division Head: Heme Onc 2019

Co Chair Search Committee for OU/OHSU Computational Biology Director 2020

**INSTITUTIONAL COMMITTEE ACTIVITIES MD ANDERSON**

Member, Executive Council-Division of Medicine 1995-2018

Member, Promotions Committee-Division of Medicine 1995-98

Member, Surveillance Committee 1995-96

Member, Clinical Research Committee 1995-96

Member, Credentials Committee of the Medical Staff 1995-00

Member, Disease Site Executive Committee (Ovary) 1995-03

Member, Executive Committee Ovarian Cancer Program 1995-2018

Member, Research Institutional Direction Working Group 1995-96

Member, Program Planning Committee 1995-96

Member, Steering Committee Human Cancer Genetics 1996-01

Chair, Cancer Genetics Implementation Committee 1996-01

Member, Search Committee Medical Specialties 1997-98

Member, Multidisciplinary Program Review Committee 1997-02

Member, Search Committee Human Cancer Genetics 1997-98

Member, Search Committee Medical Director Clinical Cancer Genetics 1997-99

Member Planning Committee- Millennium Cancer Conference 1998-00

Member Physician Scientist Program Supervisory Committee 1998-02

Member Search Committee Chair Surgical Gynecology 1999

Ad Hoc Member Division of Medicine Research Space Committee 1999-01

Member Genomics Planning Committee 1999-01

Member Institutional Research Space Committee Advisory Group 1999-00

Member Clinical Faculty Review Committee 1999-00

Member Steering Committee Breast Cancer Program 2000-18

Member Research Council 2000-06

Member Executive Council Science Faculty 2000-18

Member Advisory Committee Cardiology 2000

Member Search Committee for Molecular Therapeutics 2000-03

Member of Advisory Committee of the Cancer Therapeutics 2000-02

Development program

Member Endowed Positions and Awards Committee 2000-03

Chair Ad Hoc Proteomics Committee of the ECSF 2000 Member Division of Cancer Prevention Center Steering Committee 2000-18

Chair Endowed Positions and Awards Committee 2001-03

Co Chair Research Space Subcommittee of the Research Council 2001-03

Internal Advisory Board Prostate SPORE 2001-18

Internal Advisory Board Bladder SPORE 2001-18

Internal Advisory Board Brain SPORE 2001-04

Internal Advisory Board Lung PO1 2001-18

Internal Advisory Board Melanoma SPORE 2001-18

Internal Advisory Board GI SPORE 2001-02

Search Committee Brain Tumor Department Chair 2001-02

Executive Committee Brain Tumor Program 2001-18

Executive Committee Radiation Oncology Program 2001

Member Emphasis Committee Immunology 2001

Member MRAC (Multidisciplinary Research Advisory Committee) 2002 Internal Advisory Board Leukemia SPORE 2002-18

Internal Advisory Board Head and Neck SPORE 2002-18

Chair Technology Review Committee 2002-18

Member Technology Transfer Committee 2002-18

Co Chair Lockton Search Committee 2003-04

Internal Advisory Board Lymphoma SPORE 2003-18

Chair Senior Scientist Search Committee Brain Tumor Center 2003-04

Search Committee Cellular and Molecular Oncology 2003-04

Search Committee Chair Experimental Therapeutics 2004-05

Co-chair: MDACC Annual Conference: Targeted Therapeutics 2004

Co-chair: MDACC Annual Conference: Challenges to the 2005 implementation of molecular markers and molecular imaging

Chair Search Committee for Chair Bioinformatics and Computational 2006-07

Biology

Search Committee for Division Head Cancer Prevention 2006-07

Search Committee for Modeling Experimental Therapeutics 2006 Executive committee Blanton-Davis Ovarian Cancer Research Program 2006-11

Research Animal Priority Committee 2006-18

Member Research Advisory Committee 2006-12

Co-Chair MDACC Annual Conference: Individualized risk assessment 2007 External Collaborations committee DKFZ 2007-18

Co-Chair MDACC Annual Conference: Systems Biology of Cancer 2008

Search Committee Chair Clinical Cancer Prevention 2008

Search Committee Chair Epidemiology 2008

Search Committee Faculty Recruitment Cancer Biology 2008 Search Committee Chair Cancer Biology 2010-12

Search Committee Division Head Quantitative Biology 2010 Research Strategies Advisory Committee RSAC 2010-12

Member RSAC/Research Council 2011-18

Committee on Institutes and Centers 2011-18

Search Committee Chair Breast Medical Oncology 2012-14

Member Institutional Research Effectiveness Committee 2012-18

Internal Advisory Board Lung SPORE 2012-18

Internal Advisory Board Institute for Applied Cancer Science 2014-18

Search Committee Chair Genomic Science 2016

Co Chair Member Search Committee Chair Epidemiology 2017

Co Chair MDACC Annual Meeting Metabolism 2017

# The University of Toronto

Research Advisory Committee Department of Obstetrics and 1988-95

Gynecology

Animal Care Committee Toronto Hospital 1989-93

Steering Committee Gynecologic Oncology Program of Toronto 1989-95

Research Committee Gynecologic Oncology Program of Toronto 1989-95

Research Advisory Committee Toronto Hospital 1991-95

Oncology Steering Committee Toronto Hospital 1992-95

Chairman: Space and Resources Subcommittee Toronto Hospital 1992-95

Research Trainee Education Subcommittee Toronto Hospital 1992-95

Staff Term Evaluation Committee: Department of Obstetrics and 1993-95

Gynecology: University of Toronto

Postgraduate Education Gynecologic Oncology Program of Toronto 1993-95

Finances committee Department of Obstetrics and Gynecology 1993-95

Toronto Hospital

Planning and Priorities Task Force Toronto Hospital 1993-95

# EXTERNAL COMMITTEES

External Advisory Board UCSF SPORE in Breast Cancer 1999-2006

Advisory Committee on Research (ACOR) Alberta Cancer Board 1995-2000

Search Committee, Corrine Boyer Chair in Ovarian Cancer Research 1998-99

Program Committee, AACR Pharmacology and Experimental 1999

Therapeutics: Therapeutic Agents I: Small molecule approaches

Program Committee, AACR Molecular Mechanisms 2001

External Advisory Board Indiana Ovarian Cancer DoD PO1 2001

Gertrude B. Ellion Selection Committee AACR 2001

Molecular Therapeutics Subcommittee ASCO 2001

Scientific Committee Molecular Targets and Cancer Therapeutics AACR/EORTC 2001

Chair External Advisory Board Breast SPORE UCSF 2001-10

External Advisory Board Breast SPORE Baylor 2001-10

External Advisory Board Breast PPG Baylor 2001-08

Chair, External Advisory Board of Breast Spore at Mayo Clinic 2001-

Chair, External Advisory Board Breast SPORE Vanderbilt 2001-

External Advisory Board Ovary SPORE Seattle 2002-10

Organization Committee TAT 2002-10

Chair 2004 AACR Research Awards for Broad-Junior Faculty 2004

Consultant Integrative Cancer Biology Program 2004-08

Chair SAB Sylvester Cancer Center Miami 2004-10

SAB ICBP Program UCSF/LBNL 2004-08

Chair Advisory Board Life Sciences Program LBNL 2004

Chair FASEB Lipids Conference 2004

Member PAACT 2004-06

AACR Scientific Committee 2005

Organizing Committee: Challenges to implementation of targeted 2006

Therapeutics AACR meeting

AACR Scientific Committee 2006

AACR Organizing Committee: Cancer Prevention Meeting 2006

Advisory Board Wash U Breast SPORE 2006-08

Target Selection Committee TCGA 2006

Advisory Board Duke Breast SPORE 2006-10

Management Committee CPTAC 2006-10

Data Analysis Committee TCGA 2007-16

Ovarian Cancer Steering Committee TCGA 2007-10

AACR Molecular Diagnostics in Cancer Therapeutic Development Chair 2007

AACR Scientific Committee 2008

Deans Advisory Board Natural Sciences and Mathematics University of Houston 2008-14

Steering Committee TCGA 2009-18

Scientific Advisory Council Komen Foundation 2010-

AACR Scientific Committee 2010

AACR Molecular Diagnostics in Cancer Therapeutic Development Chair 2010 Landon Foundation-AACR Innovator Award for Research in 2012

Personalized Cancer Medicine Scientific Review Committee 2012

Komen Research Advisory Committee: Novel Therapeutics and 2012 Resistance: Therapeutic Implications of Tumor Genomics

Landon Foundation-AACR Innovator Award for Research in

Personalized Cancer Medicine Scientific Review Committee 2013

Co-Chair, Systems Biology for Cancer Research Think Tank 2013 Komen PDF Basic and Translation Review Committee 2013-17

University of Oklahoma NIC Award External Advisory Board Member 2013-18

Organizing committee AACR meeting on Sensitivity and Resistance to 2014 targeted therapeutics

Open Academy for Advance Science in Oncology Fellow 2015

Review Committee Innovative Science Awards AACR 2017

Review Committee UO1 Cancer Systems Biology 2017-2018

AACR Board of Directors 2017-

Yale CCSG External advisory board 2017

AACR Publications Committee 2017

AACR Industrial Exhibits Committee 2017

AACR NextGen Grants for Transformative Cancer Research Review Committee 2017-18

Komen Career Development Award Review Committee 2017-19

Pezcoller Award Committee 2019

Sabin Fellowship Award Review 2020

Ontario Institute for Cancer Research Chair EAB 2020

# INDUSTRY CONSULTATION, ADVISORY BOARDS, LICENSED PATENTS, AND SPONSORED RESEARCH

**Current**

Astra Zeneca

Catena Pharmaceuticals

Critical Outcomes Technology

Immunomet

Ionis

Lilly

PDX Bio

Symphogen SAB

Signalchem Lifesciences

Tarveda Biosciences

# Closed

Abbott SAB

Ambit SAB

Amira SAB

Arcxis Biotechnologies SAB Asuragen SAB

Atairgin/LPL Technologies

Aushon SAB

Celgene SAB Delta Dot SAB

Echelon Pharmaceuticals Salt Lake City UT Enzon Pharmaceuticals SAB

GSK Pharmaceuticals LPATH Pharmaceuticals

Maxim Pharmaceuticals/Cytovia, Inc., La Jolla, CA

Medimmune

Novartis SAB

Nuevolution SAB

Pfizer Pharmaceuticals

Provista Diagnostics

PTV Sciences SAB

Roche/Genentech

Semafore SAB

Spindle Top Sciences SAB

Takeda/Millennium

Tarveda Biosciences

Tau Therapeutics SAB Wyeth Pharmaceuticals

# HONORS AND AWARDS

Harry W. Bass Memorial Bursary 1971-72

Edmonton Pipefitters Scholarship 1973-75

Manheim-Boerhinger Scholarship

(Research award tendered with W.R. Jones in Adelaide, Australia) 1976

Visiting Consultant, Hanover Medical School 1978

Medical Research Council Fellow 1978-80

Fellow of Royal College of Surgeons Canada 1982

Alberta Heritage Trust Fund Fellowship 1982-85

Gordon Fisher Prize for excellence in research 1988

Medical Research Council of Canada Scholar 1986-91

MacLaughlin Scientist 1986-93

Medical Research Council of Canada Scientist 1991-93

Ransom Horne Jr. Professorship in Cancer Research 1998-01

Olga Keith And Harry Carothers Wiess Chair for Cancer Research 2001-04

Anne Rife Cox Chair in Gynecology 2004-10

Inaugural Waun Ki Hong award for Mentorship 2006

Rafael Research Alumni Association Visiting Professorship at Rambam 2008

The Peter Steck Memorial award of the Brain Tumor Foundation 2008

Waun Ki Hong Award for Excellence in Team Science 2009

MD Anderson Best Boss Award 2009

Olga Keith Wiess Distinguished University Chair for Cancer Medicine 2010-18

Fellow American Association for the Advancement of Science 2012-

Robert M. Chamberlain Distinguished Mentor Award Nominee 2013

Komen Brinker Award for Excellence in Science 2014 2014

SU2C/AACR Laura Ziskin Prize 2014

Presidents Recognition for Faculty Excellence 2014

Robert M. Chamberlain Distinguished Mentor Award Nominee 2014

Provost’s Award for Mentorship in Basic Sciences 2014

Member of the Association of American Physicians 2015

Finneran Family Prize for Excellence in Translational Research 2016

President’s Recognition for Faculty Excellence 2016

Top 10 Innovations The Scientist Magazine 2016

Web of Science Highly Cited Investigator 2017-

Harvey Baker Lecture 2019

American Association of Cancer Research Team Science Award 2020

# OPERATING GRANTS

**As PI or Project leader**

Academic

U2C CA233280-01(Gray; Mills; Corless; Goecks) 9/1/2018 – 8/31/2023 1.20 calendar

NIH/NCI $24,364 (salary only)

*Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers*

The major goal of this project is to develop an atlas of cells and their state through applying state of the art analysis tools to tumor samples taken at multiple times to Metastatic Breast Cancers.

1P50 CA217685-01 (Bast; Sood) 9/22/2017 – 8/31/2022 0.60 calendar

NIH/NCI $65,000

*U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer*

*Project 1: High Grade Cancers: Capitalizing on Parpness in Ovarian Carcinoma*

The major goal of this project is to utilize a comprehensive analysis of cell line, animal models and patient samples to systematically identify rational therapeutic strategies with PARPi therapy.

1U01 CA217842-01 (Mills; Deneen) 9/6/2017 – 7/31/2022 1.20 calendar

NIH/NCI $167,002

*Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer*

The major goal of this project is to generate functional annotation of genomic aberrations in cancer.

00002690 (Mills) 9/1/2012 – 9/30/2022 1.20 calendar

Adelson Medical Research Foundation $367,586

*Novel Therapeutic Opportunities in Ovarian Cancer*

The major goal of this project is to determine the functional consequences of genomic aberrations in ovarian cancer.

SAC110052 (Mills) 11/1/2015 – 10/31/2021 0.11 calendar

Susan G. Komen Breast Cancer Foundation $160,000

*Combinatorial Adaptive Resistance Therapy in Breast Cancer*

The major goal of this project is to determine resistance to targeted therapy in breast cancer cell lines.

5U24 CA210950-02 (Akbani; Weinstein; Mills) 9/1/2016 – 8/31/2021 1.20 calendar

NIH/NCI $18,960 (salary only)

*Integrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platform*

The major goal of this project is to analyze cancer proteomics data from the RPPA platform for various projects specified by the NCI.

U24 CA210949-02 (Weinstein; Akbani; Mills) 9/1/2016 – 8/31/2021 0.60 calendar

NIH/NCI $18,960 (salary only)

*GDAN- Batch effects in molecular profiling data on cancers: detection, quantitation, interpretation, and correction*

The major goal of this project is to identify and remove batch effects bias in large sample sets from NCI.

5U24 CA209851-03 (Liang; Mills) 9/1/2016 – 8/31/2021 0.65 calendar

NIH/NCI $13,310 (salary only)

*TCPA: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data*

The major goal of this project is to expand the scope of TCPA by adding new functionalities and datasets, and to enhance and improve its existing analytic capabilities.

5P50 CA098258-12 (Lu) 9/14/2010 – 8/31/2021 0.60 calendar

NIH/NCI $118,491

*M.D. Anderson Gynecologic SPORE for Uterine Cancers*

*Project 4: A Framework for identification of Novel Targeted Therapy Combinations in Endometrial Cancer*

The major goal of this project is to determine and understand specific aberrations in the P13K and RAS/RAF pathways in endometrial cancer.

545152 (Mills) 1/1/2018 – 12/31/2020 0.60 calendar

Ovarian Cancer Research Foundation $136,039

*Rational combination therapy in ovarian cancer*

The major goal of this project is to use systems biology approaches to identify rational combinations in ovary with BRD4 inhibitors.

BCRF‐17‐108 (Mills) 10/1/2016 – 9/30/2020 0.60 calendar

Breast Cancer Research Foundation $208,333

*An immunocompetent breast cancer model for exploration of targeted therapeutics and immunotherapy*

The goal of this project is to exploit a novel series of breast cancer models to evaluate combinations of targeted and immunotherapy approaches.

5U24 CA199461-03 (Weinstein) 9/1/2015 – 8/31/2020 0.36 calendar

NIH/NCI $5,688 (salary only)

*Next-Generation Clustered Heat Maps for Fluent, Interactive Exploration of Omic Data*

The major goal of this project is to mature NG-CHM technology for fluent use and sharing by biologists and clinical researchers.

5U54 HG008100-05 (Gray; Heiser; Korkola) 9/10/2014 – 6/30/2020 0.48 calendar

NIH/NHGRI $157,022

*Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks (Data Generation)*

The major goal of this project is to contribute to development of the NIH Library of Integrated Network-based cellular signatures (LINCS).

5U54 HG008100-05 (Gray; Heiser; Korkola) 9/10/2014 – 6/30/2020 0.46 calendar

NIH/NHGRI $7,280 (salary only)

*Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks (Admin)*

The major goal of this project is to contribute to development of the NIH Library of Integrated Network-based cellular signatures (LINCS).

# CLOSED GRANTS AND SPONSORED RESEARCH MD ANDERSON CANCER CENTER

UO1 CA70172 (PI J. Abbruzzese) 08/01/95-03/31/99 Effort 5%

Phase II/III Trials of Anticancer agents $264,185

Role on grant: Co-Investigator

PO1 CA64602 (PI R. Jaffe) 04/15/96-01/31/08 Effort 5%

Project #4 Role of PI3K in the Diagnosis, Prognosis and Therapy of Ovarian Cancer

Role on grant: Project Director $ 209,801

PO1 CA64602 (PI R. Jaffe) 04/15/96-01/31/05 Effort 5%

Project 3 AHRI, A Novel Ovarian Cancer Tumor Suppressor Gene

Role on Grant: Collaborator $ 174,886

PO1 CA64602 (PI R. Jaffe) 04/15/96-01/31/06 Effort 10%

Project #2 Role of LPA in the Diagnosis, Prognosis and Therapy of Ovarian Cancer

Role on Grant: Project PI $183,820

RO1 CA71418-01 (PI Gordon B. Mills) 09/01/96-08/31/99 Effort 15%

National Institutes of Health $126,337

The Putative Tumor Suppressor PTP1C in Breast Cancer Role on Grant: PI

NCI P32 extension (PI Ellen Gritz) 09/01/96-08/31/97 Effort 5%

Training Program in Cancer Genetics Cancer Genetic Counseling

Role on Grant: Co-Investigator $99,999

Binational Science Foundation (PI Karl Skorecki) 01/07/97-31/06/2000 Effort 2%

Targets of the Von-Hippel-Lindau $45,000

Tumor Suppressor Gene in Renal Carcinoma my component $5,000

Role on Grant: Co PI

NIH/NCI (P.I. Francis Ali-Osman) 02/17/97 - 11/31/02 Effort 2%

1T32CA 73954 $138,233

Pediatric Oncology Research Training Program

Role on Grant: Co-Investigator

RO1 CA74247 (P.I.: Gordon B. Mills) 04/01/97-01/31/02 Effort 10%

CD28 signaling through the EMT/ITK tyrosine kinase $118,689

Role on Grant: PI

RFA CA97-004 (P.I. Louise Strong) 03/01/98-02/28/01 Effort 5%

Texas Cancer Genetics Consortium $899,794

Role on Grant Clinical Core Co-Director

Millenium Pharmaceuticals (R. Bast P.I.) 04/01/98 - 03/31/01 Effort 0%

Differentially expressed genes in ovarian cancer $100,000

and identification of novel markers for drug sensitivity and resistance”

Role on Grant: Co Principal Investigator

NIH/NCI (P.I. John Mendelsohn) 07/01/98-06/30/08 Effort 5%

P32 core grant $3,871,584

Gynecological Cancer Director My component 0

NIH/NCI (P.I. John Mendelsohn) 07/01/98-06/30/03 Effort 0%

P32 core grant $3,871,584

Tissue procurement and analysis core My component $252,470

Role on Core: Co-Investigator

NIH/NCI (PI Margaret Kripke) 09/01/98-08/31/03 Effort 2%

Training Grant Immunology $138,233

Role on Grant: Co-Investigator

RO1 CA79003 (PI: R. Bast) 09/01/98-08/31/01 Effort 2%

NOEY2, A Novel Ovarian Cancer Tumor Suppressor Gene $160,000

Role on Grant: Collaborator My component 0

NIH/NCI Training Grant (PI Moshe Talpaz) 09/01/98-08/31/03 Effort 2%

Bioimmunotherapy $138,233

Role on Grant: Co-Investigator

Komen Foundation P.I. Gordon B. Mills 04/01/99 - 03/30/01 Effort 10%

Role of the MMAC1 Tumor Suppressor in Human Breast Cancer

Role on grant: PI $98,760

RO1 CA82716 P.I. Gordon B. Mills 07/01/99 - 06/30/05 Effort 12%

Role of the MMAC1 Tumor Suppressor in $196,753

Human Breast Cancer

DAMD 17-99-1-9505: P.I. David Gershenson 07/01/99-06/30/02 Effort 6%

Chemoprevention of Ovarian Cancer $345,000

Role on Grant Collaborator Project 2 and 3 Admin Core Co PI

NIH/NCI U19 Powell Brown 09/30/99 - 09/29/05 Effort 13%

Prevention of Cancer in Genetically Identified $734,263

Individuals

Role on Grant: Co PI, CoPI on core A

P32 SPORE in Prostate Cancer (PI C. Logothetis) 12/01/00-11/31/01 Effort 10%

The PI3K pathway as a target in Prostate Cancer Pilot Project

Role on Grant: Principal Investigator $ 50,000

Lynne Cohen Foundation PI 01/01/02-31/12/07 Effort 0%

ILK as a therapeutic target in ovarian cancer $100,000

DAMD 17-02-01-0694 CoE Hortobagyi (PI) 09/01/02-08/31/07 Effort 10%

Breast cancer center of excellence in $160,072

Therapeutic Development Task #1 Mills (PI)

DOD Urban (PI) 09/01/02-08/31/07 Effort 5%

Breast Cancer Center of Excellence in $50,000

Molecular Markers

Subcontract Mills (PI)

P50 supplement NCI/Avon collaborative grants 12/01/02-11/31/05 Effort 10%

Urban (PI) $166,667

Project #3 Lysophospholipids

Kinetek P.I Gordon B. Mills 2002 Effort 5%

Targeting ILK in cancer $100,000

PO1CA099031 PI MC. Hung 04/01/2003-03/31/08

Growth Factor Receptor Signaling in Breast Cancer $93,959

Co-PI Admin core

P50 SPORE in Lung Cancer Minna/Roth PIs 04/01/03-03/31/08 Effort 5%

Project #4 The PI3K Pathway as a Target for $150,000

Lung Cancer Prevention and Therapy

Role on project Co PI

QLT 01/08/04-7/31/06 Effort 0%

ILK as a therapeutic target $100,000

Eli Lilly 01/08/04-1/1/07 Effort 0%

Molecular Imaging of PI3K/AKT/PDK1 $150,000

Leukemia Lymphoma Society (Kornblau PI) 01/11/05-12/31/07 Effort 1%

Proteomics of Acute Myelogenous Leukemia $120,000

Role Co-Investigator

SPORE Intervention Supplement Grandis PI 07/01/05-06/30/07 Effort 1%

Targeted therapy for head and neck cancer $43,659

P50 SPORE in Breast Cancer (Hortobagyi/Hung PI) 09/01/05-8/31/10 Effort 5%

Project #1 Molecular Epidemiology of $185,000

Early Stage Breast Cancer Mills 0

Role on Project Co PI

LS2006-00018106AB (Mills - PI) 09/01/06- 09/01/12 0.12 calendar

GlaxoSmithKline $1,236,362.00 (total period)

Molecular predictor of drug response in ovarian cancer

5 P50CA058183-17 (Lee-PI) 09/30/06-11/30/11 0.12 calendar

NIH/NCI $14,260

Project 5 Targeting IGF-1R in Breast Cancer

Role: Subcontract PI

Keryx LS2006-00017594AB 07/01/06- 06/30/08 Effort 1%

Molecular Marker Study $46,689

Role on Project Co PI

R21 CA120248 Gonzalez-Angulo (PI) 09/1/06-8/31/2008 Effort 0%

Preoperative therapy in breast cancer

Role: Consultant

ASCO CDA Gonzalez-Angulo (PI) 07/1/06-6/30/09 Effort 5%

The PI3K/PTEN/AKT Signal Transduction $168,500

Cascade as a Predictor for Response to Therapy and Therapeutic Target in Breast Cancer

Role: Mentor

1K23CA121994-01 (Mills - PI) 7/1/06-6/30/11 0.60 calendar The P13K/PTEN/AKT Signal Transduction

Cascade in Breast Cancer 0$

Role: Mentor

CA92160-06 Tigyi (PI) 12/01/06-11/30/07 Effort 5%

Ligand Recognition by Phospholipid $49,305 Growth Factor Receptors

Role on Project Subcontract

5 U24 CA126479-04 (Leibler - PI) 09/28/06 – 08/31/11 0.36 calendar

NIH/NCI $158,138

Clinical Proteomic Technology Assessment for Cancer

Role: Subcontract PI

SR2006-00017373DH/Mills 11/1/2006- 10/31/2007 Effort 0%

Using RPPA to Elucidate Cellular Protein and $81,000 Protein Phosphorylation Levels with PLK Inhibitors

R21 CA126700 Ding (PI) 04/17/07- 03/31/2010 Effort 5%

NIH/NCI R21 $18,400

Effective Mammalian Two Hybrid Screening Approach

Semafore LS2007-0002048LE/Mills 06/1/2007- 5/31/2008 Effort 1%

Using RPPA and IHC to elucidate cellular protein $99,446 and protein phosphorylation levels with PI3K inhibitor

AstraZeneca Bast (PI) 07/1/07-6/30/09 Effort 1%

AstraZeneca R&D Strategic Alliance $240,000

Functional Characterization of Kinase Inhibitors,

Related Pathways, and Activity In Vivo

Role: Co-Investigator

NCI Foundation siRNA consortium 07/01/07-06/31/10 Effort 1%

Mentor $41,000

Mentor to PDF in program

Komen Foundation (PI G. Mills) 10/01/07-9/31/10 Effort 20% Special program in Molecular Markers Development $275,000

Role on Project PI

5 RO1 CA92160 09 (Tigyi – PI) NIH/NCI 08/01/01 – 07/31/11 0.12 calendar

Ligand Recognition by Phospholipid $67,321

Growth Factor Receptors

Role: Collaborator

LS2006-00017874AB (Mills - PI) 05/16/07-09/30/2011 0.12 calendar

LPath Therapeutics $267,339 (total period)

Role of lysolipids in cancer pathophysiology and therapy

PO1 CA55164 (P.I.:Michael Andreeff) 04/01/07-03/31/12 0.12 calendar

Therapy of AML $ 78,453

Role on Grant: Core co leader

Goal: To improve the understanding of the molecular mechanisms underlying AML

5 R01 CA123219 05 (Mills - Co-PI) 04/08/08-02/28/13 0.90 calendar

NIH/NCI $112,000

Role of aberrant splicing of EVI1 in Ovarian Cancer Pathophysiology Role: Co-PI

Goal: Determine the role of EVI1 in ovarian cancer biology

CeMines, Inc. (Mills - PI) 05/19/08 – 09/30/11 0.12 calendar

Peptide Arrays for Early Detection of Cancer $135,135 (total period)

Goal: To develop proteins arrays for cancer detection

KG 081099 (Mills - PI) 08/28/08-05/31/12 0.12 calendar

Komen Foundation $200,000

Implications of Targeted Therapies: Accurate Determination of Mutation Status

LS2007-0021802RG 03/18/08 - 06/30/12 0.12 calendar

Exelexis, Inc. (Mills - PI) $400,400 (total period)

Molecular Predictors of Drug Response in Ovarian Cancer

Goal: To develop predictors to Exelis drugs in ovarian cancer

LS2009-00029536RG (Mills - PI) 09/01/09 - 11/30/12 0.12 calendar

GlaxoSmithKline $686,373 (total period)

Validating Bioenergetics Targets

Goal: To explore the role of TKTL1, PFKP, and MCT1 across breast and ovarian cancer

SR2009-00027384LG (Mills-PI) Celgene 09/11/09-09/30/12 0.12 calendar

Identification of predictive and pharmacodynamic markers,

regulatory loops and on and off target

activity for Celegene compounds.

Goal: To perform RPPA analysis data on breast cancer cell lines

LS2011-00034138RG 01 (Mills - PI) 02/01/11 - 03/31/13 0.12 calendar

AstraZeneca $225,866 (total period)

Investigation of Activities of AZD5363, a novel inhibitor of

AKT/PKB, and AZD5582, an IAP inhibitor in breast,

endometrial, and ovarian cancer

Goal: To evaluate AKT inhibitor in panels of breast, ovarian and endometrial cancer and in

combination with standard of care agents.

Ovarian Cancer Research Fund (Bast – PI) 01/01/09 – 12/31/12 0.12 calendar

Autophagy in Ovarian Cancer-PP-2 $66,000

Role: Collaborator

Goal: To eliminate persistence of dormant autophagic ovarian cancer cells and develop new therapeutic strategies that will lead to cure of ovarian cancer.

NIH/NCI 5 U24 CA126477 06 (Fisher – PI) 09/28/06 – 08/31/13 0.12 calendar

Targeted and Global Proteomic Strategies $39,998

for Early Breast Cancer Detection.

Role: PI subcontract

Goal: Consortium of LBNL, UCSF, the Buck Institute, MDACC, and UBC to evaluate proteomic technologies that will enable the early detection of tumors through the application of blood-based tests

LS2011-00035556LG 01 07/28/11 – 7/27/13 0.12 calendar

GlaxoSmithKline (Mills- PI) $150,000 (total period)

Combinatorial Adaptive Resistance Therapy to Find Rational Drug Combinations

Goal: To determine resistance to targeted therapy in breast cancer cell lines

SU2C-AACR-DT0209 02 11/01/10 – 10/31/13 0.60 calendar

AACR (Mills Co -PI) $425,950

An Academic Industry Dream Team

Capitalizing on the Phosphatidylinositide 3

Kinase Pathway as a Target in Women.

Goal: To combine efforts from 3 nationally recognized cancer centers whose combine goal is to find

new targeted therapeutics and set up clinical trials that will eliminate women’s cancer.

5 U24 CA143883 SI (Mills - PI) supplement 09/01/2012-08/31/2013 0.0 calendar NIH/NCI $100,000

An Integrative Pipeline for Analysis & Translational

Application of TCGA Data

Goal: To perform functional proteomics analysis of samples from the TCGA

RP100768 03 (Mills – PI) 05/01/10 – 10/31/13 1.20 calendar

Cancer Prevention Research Institute of Texas $287,703

Mechanisms underlying delayed recurrence of ER positive breast cancer

Goal: To understand the mechanisms resulting in delayed recurrence of ER positive breast cancer.

RP100773 03 (Mills – PI) 05/01/10 – 10/31/13 0.84 calendar

Cancer Prevention Research Institute of Texas $297,465

Discovery and validation of novel cancer drug targets

through synthetic lethal screening

Goal: To implement comparative human and drosophila studies to identify genes that are synthetic lethal with tumor suppressor genes including PTEN and p53.

5 R01 CA123219 05 (Mills – Co-PI) 04/08/08 – 02/28/13 0.90 calendar

NIH/NCI $112,000

Role of aberrant splicing of EVI1 in Ovarian Cancer Pathophysiology

Goal: Determine the role of EVI1 in ovarian cancer biology

LS2009-00029536RG (Mills – PI) 09/01/09 – 09/30/13 0.12 calendar

GlaxoSmithKline $686,373 (total period)

Validating Bioenergetics Targets

Goal: To explore the role of TKTL1, PFKP, and MCT1 across breast and ovarian cancer

W81XWH-11-BCRP (Lin - PI) 09/15/12- 09/14/14 0.12 calendar

DOD $3,975

Molecular Determinants and Clinical Implications of Breast Cancer Dormancy Role:Co-Investigator

Goal: The major goal of this project is to determine if cellular dormancy promotes genomic aberrations and facilitates the development of more malignant and treatment-resistant subpopulations.

LS2012-00035876RG 01 (Mills – PI) 11/08/11 - 12/28/14 0.12 calendar

AstraZeneca $150,000

Uncovering Metabolic Heterogeneity in Breast Cancer Subtypes Role: PI

Goal: To determine subtype-specific nutrient dependency and nutrient stress adaptation mechanisms in

breast cancer cells and determine its impact in a selected sub-set of cell lines.

LS2012-12104525SH (Mills - PI) 09/01/2012-12/31/2014 0.12 calendar

Astrazeneca $94,234

Combinatorial adaptive resistance therapy to find rational drug combinations to AZD drugs. Goal: To find rational effective drug combinations for AZD drugs

7 U54 CA112970 07 (Gray – PI) 09/30/04 – 02/28/15 0.24 calendar

NIH $48,833

Model-based predictions of responses to RTK pathway therapies (Project 1) Role: Co-Investigator

Goal: Identify regulatory loops and cross talk in the PI3K pathway through targeted perturbations and to develop robust predictive experimentally based multi scale models of the PI3K network.

7 U54 CA112970 07 (Gray – PI) 09/30/04 – 02/28/15 0.36 calendar

NCI/NIH $5,391

Model-Based Predictions of Responses to RTK Pathway Therapies –P4 Role: Project 4 Leader

Goal: To determine the integration of pathways that controls the pathophysiology of different breast cancer lineages.

00001061 (Mills - PI) 01/07/2013-07/31/15 0.12 calendar

AstraZeneca $100,000

Rational combinational therapy of PARP inhibitors with inhibitors of the P13K pathway

Goal: To determine the effects of PARP inhibitors in combination with inhibitors of the P13K pathway

LS2006-00016301 (Mills - PI) 07/01/09 – 07/31/15 0.12 calendar

AstraZeneca $100,000

Inhibition of PARP in Women with Sporadic Ovarian Cancer

Goal: To determine effects of PARP inhibitors in ovarian cancer

00001757 (Mills) 04/1/2014 – 12/31/2015 extension 0.12 calendar

Entertainment Industry Foundation $113,636

Rational combination therapy for ER positive breast cancer

Goal: To mentor Taru Muranen using RPPA for the identification of adaptive resistance to therapy in ER positive breast cancer that could be rational targets.

00001060 (Mills - PI) 01/07/2013-12/30/15 0.12 calendar AstraZeneca $100,000

Functionalization of the cancer genome, enabling the identification of new opportunities for the existing AZ drug portfolio and the identification of novel targets for drug discovery

Goal: To explore opportunities resulting from the functionalization of the cancer genome and applying these to existing AZ drugs and future drug discovery

KG 081694 04 (Brown – PI) 10/01/09 – 07/31/16 0.6 calendar

Komen Promise Grant $75,000

Developing Effective Therapies for ER-negative Breast Cancer using Genomics and Proteomics

Role: Co-PI

Proj 1: Target Identification in ER-negative BCs

Goal: To develop therapies for ER-negative tumors

5U24CA143883 03 (Mills) 05/01/14 – 04/30/16 0.12 calendar

NIH/NCI $139,446

Biological Annotation of TCGA data - supplemental funds

Goal: To preform and analyze TCGA samples.

MD Anderson Institutional Support (Mills) 8/1/2015-7/31/2016 0.6 calendar

Multidisciplinary Research Program (MRP) $166,666

Goal: Functional Consequences of RNA Editing in Cancer

5 U24 CA143883 05 (Mills, Weinstein, Yung – PIs) 09/29/09 – 07/31/16 0.6 calendar

NIH/NCI $8,985

An Integrative Pipeline for Analysis & Translational Application of TCGA Data

Goal: To develop and implement approaches for analysis of TCGA data.

5 P01 CA099031 10 (Hung – PI) 04/01/03 – 08/31/16 0.12 calendar

Growth Factor Receptor Signaling in $213,938

Breast Cancer

Role Project PI

Goal: To determine the role of Rab25 and aberrations in vesicle recycling in regulating receptor signaling and bioenergetics in breast cancer

LS2016- 00053238-RM (Mills) 09/1/2016-08/01/2017 0.12 calendar

Tesaro Inc. $53,965

Molecular Signatures of PARP Inhibitor Sensitivity in SCL PDX Models

Goal: To identify patients likely to benefit from Niraparib

RP140462 (Liang -PI) 06/01/2014-05/31/18 0.6 calendar

CPRIT $275,750 [10,000]

Systematic Functional Characterization of Expressed Pseudogenes in Cancer

Role: Collaborator

Goal: To determine the function consequences of expressed pseudogenes in cancer.

5 U01 CA168394 05 (Mills – PI) 05/01/2012 – 04/30/2018 1.2 calendar

NIH/NCI $262,560

Biological annotation of TCGA data

Goal: To generate functional annotation of mutations from TCGA

1R01 CA172490 (Lin-PI) 2/01/2013-1/31/2018 0.12 calendar   
NIH/NCI $1,797

Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer

Role: Collaborator

Goal: To access clinical endometrial cancer tissue specimens for CHD4 aberrations

00001713 (Mills) 02/01/2015-01/31/2018 0.12 calendar

Critical Outcome Technologies $25,000

The Mechanisms of Anti-Cancer Activity of COTI-2

Goal: To determine the p53 dependent and independent effects of COTI2 on tumor cells

114980 (Mills) 02/20/2015-02/19/2018 0.12 calendar

NanoString technologies $157,981

NanoString Strategic Alliance

Major goals: To develop Multi-Omics technology for analysis of research and clinical samples

Goal: To determine resistance to targeted therapy in breast cancer cell lines.

LS2016-00051961-Project 3 (Mills) 11/20/2015-11/19/2017 0.12 calendar

Karus Therapeutics Ltd. $151,181

Strategic Alliance: Examining adaptive resistance mechanisms and differential response across genotypes that could lead to rational drug combinations

Goal: To identify rational drug combinations with drugs from Karus Therapeutics

LS2016- 00052905-RM (Mills) 07/16/2016-07/25/2018 0.12 calendar

Tesaro Inc. $128,784

Preclinical Testing of Immune Checkpoint Inhibitors and their Combination with PARP Inhibitors Using Model Derived Syngeneic Transplants (MDTS)

Goal: To determine if cellular dormance promotes genomic aberrations and facilitates the development of more malignant and treatment -resistant subpopulations.

LS2016-00052821 (Mills) 10/05/2016-10/04/2018 0.12 calendar

ImmunoMet $105,049

Identifying Markers of Response and

Rational Combination Therapies to OxPhos Inhibitors

Goal: To identify biomarkers and rational combinations with Immunomet OxPhos inhibitors

1RO1CA172511-011 04 (Bondy-PI) 01/01/2013-12/31/2018

Risk Prediction for ER negative breast My component $1,797

cancer recurrence Role: Collaborator

Goal: Study inclusion of information on somatic events or tumor ‘genotype’ will improve risk discrimination for individual ER–/ESBC patients for recurrence, distant metastasis, treatment response, and overall survival

1U54CA224065-01 (Meric-Bernstam, Mills coPI) 09/30/2017-08/31/2018 0.12 calendar

UT PDX Development and Trial Center (NCI) My component $1,870

Optimizing DNA damage repair-targeted combination therapy

Major goals: To develop PDX and determine therapeutic sensitivity.

RP150535 (Meric-Bernstam- PI) 06/01/2015-05/31/2020 0.12 calendar

Core Facility Support Awards $1,499,996

Precision Oncology Decision Support Core 2000 Mills component

Role: Collaborator

LS2017-00054547-RP (Mills) 08/15/2017-08/14/2018 0.12 calendar

AstraZeneca $42,669

AZ Apoptotic/IO RPPA

Goal: To determine effect of AZ apoptotic targeted drugs on functional proteomics

RP170640 Role PI 09/01/2017-08/31/2018 0.60 calendar

(CPRIT) $95,000

Capitalizing on Therapeutic Liabilities in RAS-Mutant Cancers With a Rational Combination Therapy With PARP and MEK Inhibitors

Goal: To move combination therapies with PARP inhibitors to the clinic

FP00003032 (Mills) 9/1/2012 – 9/30/2018 0.48 calendar

Adelson Medical Research Foundation $866,151

*Functional proteomics platform*

The major goal of this project is to perform functional proteomics analysis of melanoma and ovarian samples from the AMRF consortium.

LS2017-00054215-LG (Peng; Mills) 7/1/2017 – 6/30/2018 0.24 calendar

Pfizer Pharmaceuticals $112,500

*Project 3: Identification of molecular mechanisms underlying Talazoparib+anti-PD-L1 synergy*

The major goal of this project is to identify molecular mechanisms by which PARP inhibitors induce immune activation.

15050691 (Mills) 11/30/2015 – 12/1/2018 0.60 calendar

AstraZeneca Strategic Alliance Collaboration $10,000,000

*Strategic Collaboration Agreement*

The major goal of this project is to perform innovative biomarker driven, information rich, trials.

HHSN261200800001E (Mills) 9/1/2015 – 8/31/2020 0.12 calendar

NIH/NCI - Leidos Biomedical Research, Inc. $1,896 (salary only)

*Functional Proteomics Contract*

The major goal of this project is to provide high-resolution comprehensive functional proteomics data through the performance of RPPA.

**CLOSED GRANTS CANADA**

National Cancer Institute of Canada: MA#1055 1986-94 513,881

Regulation of Growth of Ovarian Cancer Cells

Medical Research Council of Canada: #MA-9867 1987-94 638,734

Regulation of T lymphocyte proliferation by IL2

Medical Research Council of Canada: #MT-11314 1991-94 236,658

Role of the unique EMT and TTK kinase in

T lymphocyte activation and proliferation

Leukemia Research Foundation: Leukemia growth regulation 1986-94 49,843

Johnson and Johnson PRI 1991-93 25,000

Role of growth factors in diagnosis prognosis

and treatment of ovarian cancer

Genesis Foundation: Growth regulation of ovarian cancer 1986-92 106,100

Monsanto Corporation: Role of VPF in malignant ascites 1991 5,000

Malignant Hyperthermia Association: 1987-89 26,000

Non-invasive tests of malignant hyperthermia:

Cytoplasmic Ca2+ and pyrogen: Jointly with Dr. Klip

Physicians’ Services Incorporated Foundation: 1987-89 94,000

Non-invasive tests of malignant hyperthermia:

Cytoplasmic Ca2+ and pyrogen: Jointly with Dr. Klip

Cangene Corporation 1988 10,000

University of Toronto Clinical Research Equipment Fund 1987 100,000

Dual-excitation fluorescence multiplexed measurement system

Jointly with Drs. Grinstein, Klip, Skorecki, and Rotstein

Medical Research Council of Canada: 1987 195,225

Dual-excitation fluorescence multiplexed measurement system.

Jointly with Drs. Grinstein, Klip, Skorecki, and Rotstein

Dean’s Fund, University of Toronto: 1986 5,000

Proliferation of normal and neoplastic lymphocytes

Medical Research Council of Canada: 1986 15,000

Unconditional Grant with Scholarship

Alberta Heritage Trust Fund for Cancer 1979-83 194,912

Research: Jointly V. Paetkau:

Immunotherapy with IL2-activated lymphocytes

**PATENTS AWARDED**

Ovarian Cancer Ascites Factor, in Isolated Form 5,326,690

Method for Detecting Gynecological Carcinomas 5,994,141

Substituted alpha-hydroxy acid caspase inhibitors and the use thereof 6,495,522

Particle transfection: rapid and efficient transfer of polynucleotide molecules

into cells 6,503,755

Caspase inhibitors for the treatment and prevention of chemotherapy and

radiation therapy induced cell death 6,566,338

Caspase inhibitors and the use thereof 6,716,818

Endogenous Granzyme B in Non-Immune Cells 7,074,911

Novel compositions and Methods for the Identification, prevention and therapy

of human cancers 7,195,868

Compositions and methods for the identification, assessment, prevention and

therapy of breast and ovarian cancers 7,494,775

Genetic alterations associated with cancer 7,670,767

Compositions kits and methods for the identification, assessment, prevention

and therapy of ovarian cancers 7,799,518

Compositions and methods for the identification, assessment, prevention and

therapy of human cancer 8,080,368

Methods for Treating Ovarian Cancer by Modulating SnoN 8,211,646

Predictive and therapeutic markers in Ovarian cancer 8,404,829

Compositions and mehtos for binding lysophosphatidic acid 9,163,091

Gene Signature To Predict Homologous Recombination (HR) Deficient Cancer 9,850,542

Simultaneous quantification of a plurality of proteins in a user defined region 10,501,777

of a cross-sectioned tissue

Compositions kits and methods for the identification, assessment, prevention

and therapy of breast and ovarian cancers 10,533,227

**PATENTS – PENDING**

Efficient Functional Genomics platform 20160122925

Genetic alteractions associated with cancer 20100034814

Proteomic patterns of cancer prognosis and predictive signature 21080108091

**Disclosures MD Anderson**

Mechanisms and therapeutics of obeisity

Novel agonists and antagonists for LPA receptors.

Novel human two hybrid systems for identification of protein protein interactions

Predictive and Therapeutic Markers in Acute Myelogenous Leukemia Prognostic and predictive markers in breast cancer

Lysophosphatidic Acid (LPA) as an Early Diagnostic in Gynecological Cancer

Specific Copy Number Aberrations as Predictors of Breast Cancer Recurrence and Treatment

Response

Classifiers Predicting Recurrence Risk of Tamoxifen-treated ER+ Breast Cancers

Genetic Alterations Associated with Cancer

Arsenic Trioxide Targets TGFß Signaling Mediators LOH based diagnostic method and system

Use of Rab25 Gene as Marker and Indicator for Ovarian Cancer Development & Progression

Lysophosphatidic Acid (LPA) Receptor Inhibitor: D-3-deoxy-phosphatidyl-myo-ether-lipid (DPIEL) and Their Derivatives/ Analogues

A series of Novel Retrovirus Based, Molecular Two-Hybird Screens (ReMTH) for Protein- Protein Interactions in Mammalian Cells

Identification of Selective Inhibition of Phoso-S6 Ribosomal Protein in XK469 Sensitive

Leukemia Cell Lines Using Functional Proteomic Analysis

Serum Diacylglycerol Fatty Acid Fingerprint Analysis for Detection of Breast Cancer The Novel Transgenic Mouse Models of Human Breast Cancer

New Ovarian Cell Line

Proteomic Patterns of Breast Cancer Prognosis and Predictive Signature

Use of Reverse Phase Proteins Array for the Proteomic Classification of Leukemia and for

Allocation to Targeted Therapy

A Novel Preemptive Strategic Combination of Small Molecule Agents in Targeting Cancer Energy Metabolism and Growth Signaling Regulatory Network in Cancer Chemoprevention and Therapeutics

AKT3 Activating Mutation

A Novel Transgenic Murine Model of Obesity Autotaxin Transgenic Mouse

An Improved Classification Scheme for Breast Cancer Based on Disease Dynamics Overexpression of SnoN/SkiL, Amplified at the 3Q26.2 Locus in Ovarian Cancers: A Role in

Ovarian Pathogenesis

A Test for the Stratification of Triple Receptor-Negative Breast Cancer Patients Based on

Prognosis

Rational Development of Combination Drug Treatment Compositions and Methods for Determining Cancer Susceptibility LDHB as a Biomarker in Breast Cancer

Efficient Functional Genomics Platform

Systematic Identification Of Combinatorial Drivers and Targets In Cancer Cells eFISMIC: An Integrated Informatic System for Personalized Cancer Therapy miRNA 124 as a Molecular Marker and Therapeutic Agent for Cancer Therapy

A method for Generation of 3D cell Aggregates from 2D Cultures of Precursor Cells

Functional DNA Repair Signature as a Guide for PARPi in Personalized Cancer Medicine Patient Mutations in Tumor Guide PARP Inhibitors

Mouse-Derived Syngeneic Transplants (MDST): A collection of Transplantable Cancer Models For The Development And Testing of Targeted Cancer Therapeutics

Verteporfin Inhibits Cancer Cell Growth and Suppresses the Expression of the Major Immune

Checkpoint Pathway Component PD-L1

Combinational Therapy with PARPi and MEK/ERKi in KRAS/BRAF Mutated Cancers MD Anderson Cell Lines Project: A Web Platform For Exploring And Analyzing Cell Line

Proteomic Data

TumorLikeMine: An Evidence-Based Web Platform That Facilities Clinical Decisions For Precision Cancer Medicine

The Cancer Proteome Atlas: A Web Platform for Exploring And Analyzing Cancer Patient Proteomic Data

A Gene Signature To Predict PARPi Response in Breast and Ovarian Cancers MD Anderson’s Precision Oncology Decision Support (PODS) Platform

Genes and Methods to Credential Individual Samples For Proteogenomic Analysis Combinational Therapy with PARP and BRD4 Inhibitors in Both PARPi Sensitive and

Resistant Cancers Across Multiple Tumor Lineages

RNA-Editing Derived Epitopes Function As Cancer Antigens to Elicit Immune Responses Tumor Cell STING As An Effective Therapeutic Target

Identification of Protein and mRNA Response Signatures to PARP Inhibitors in Lung Cancer

Development of Protein Models For The Identification of PARP Inhibitor Protein Response

Markers in Lung Cancer

Lysophosphatidic Acid (LPA) as an Early Diagnosis in Gynecological Cancer Overexpression of Phosphatidylinositol 3 Kinase (PI3K) in Ovarian Cancer

# GRANT REVIEWER/SERVICE ON NIH/OTHER STUDY SECTIONS

Immunology: National Cancer Institute of Canada 1986-90

Genesis Research Foundation 1990-94

Site Visit National Institute of Health PO1 1990

Scholarship Renewal Alberta Heritage Foundation for Medical Research 1989-92

Fellowship Panel: Medical Research Council of Canada 1993-94

Molecular Biology: Panel AICB Army Breast Cancer Review 1994

Site Visit PO1 National Institute of Health 1994

Immunology and Transplantation: Medical Research Council of Canada 1995-97

Advisory Council on Research: Alberta Cancer Board 1995-00

Site Visit GCRC Birmingham Alabama 1996

Metabolic Pathology NIH/NCI Ad Hoc reviewer 1998

Metabolic Pathology NIH/NCI Ad Hoc reviewer 1998

Site Visit: PO1 NCI Animal Models of Ovarian Cancer 1998

Metabolic Pathology NIH/NCI Member 1998-03

Animal Models for Research NIH/NCI Ad hoc 1999

Monsanto Grants Program Member 1999-03

Program Project Grant Dennis Slamon Irvine 2000

Arthritis Society of Canada Member Study Section 2001

Path B/Met Path Special Emphasis panel 2001

DAMD Ovarian cancer review panel 2005

SBIR CPTAC 2007

Cell and Molecular Biology NCI Review panel 2008

Stand up to cancer Innovative grants 2009

NCI ARRA Grand opportunity panel 2009

CBCRA Canadian Cancer Society Chair 2010

Komen PDF committee Chair 2010

Komen Methylation Research Committee 2010

Komen Basic Biology 2012

European FP7 2012

Rappaport Research Grants Committee 2012

NIH ZRG1 BMCT-C(09) 2012

Komen operating grant review 2012-2013

AACR Fellowship reviews 2014

Komen Fellowship review 2014-17

U01 Cancer Systems Biology 2017-18

Innovative Grants Program AACR 2017

Komen Career Development award 2017-2019

AAS Saudi Arabia reviews 2019

Pezcollar Award AACR 2019

Komen Career Catalyst Research Grants 2019

Sabin Family Grants 2020

LRP NCI 2020

# PUBLICATIONS - PEER REVIEWED MANUSCRIPTS

**1088 papers published or in press with 51 under review. >110,000 citations, H index 155**

1. Gerhart S, Mills, G, Monticone, V, Paetkau, V. 1976, Quantitative analysis of the proliferative activity induced in murine thymocytes by concanavalin A. J Immunol 117:1314-1319
2. Mills G, Monticone, V, Paetkau. 1976, The role of macrophages in thymocyte mitogenesis. J Immunol 117:1325-1330
3. Paetkau V, Mills, G, Gerhart, S, Monticone, V. 1976, Proliferation of murine thymic lymphocytes in vitro is mediated by the concanavalin A-induced release of a lymphokine (costimulator). J Immunol 117:1320-1324
4. Shaw J, Monticone, V, Mills, G, Paetkau, V. 1978, Effects of costimulator on immune responses in vitro. J Immunol 120:1974-1980
5. Mills GB, Carlson, G, Paetkau, V. 1980, Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (Interleukin 2): in vivo activity. J Immunol 125:1904-1909
6. Mills GB, Paetkau, V. 1980, Generation of cytotoxic lymphocytes to syngeneic tumor by using co-stimulator (Interleukin 2). J Immunol 125:1897-1903
7. Dosch HM, Ledgley, CJ, White, D, Lam, P, Mills, GB. 1985, Lymphocyte function in human bone marrow. II. Characterization of an interleukin 2-sensitive T precursor-cell population. J Clin Immunol 5:345-356
8. Gelfand EW, Cheung, RK, Mills, GB, Grinstein, S. 1985, Mitogens trigger a calcium- independent signal for proliferation in phorbol-ester-treated lymphocytes. Nature 315:419-420
9. Mills GB, Lee, JW, Cheung, RK, Gelfand, EW. 1985, Characterization of the requirements for human T cell mitogenesis by using suboptimal concentrations of phytohemagglutinin. J Immunol 135:3087-3093
10. Mills GB, Cragoe, EJ, Jr., Gelfand, EW, Grinstein, S. 1985, Interleukin 2 induces a rapid increase in intracellular pH through activation of a Na+/H+ antiport. Cytoplasmic alkalinization is not required for lymphocyte proliferation. J Biol Chem 260:12500-12507
11. Mills GB, Ledgley, CJ, Hibi, T, White, D, Lam, P, Dosch, HM. 1985, Lymphocyte function in human bone marrow. I. Characterization of two T cell populations regulating immunoglobulin secretion. J Immunol 134:3036-3041
12. Mills GB, Cheung, RK, Grinstein, S, Gelfand, EW. 1985, Interleukin 2-induced lymphocyte proliferation is independent of increases in cytosolic-free calcium concentrations. J Immunol 134:2431-2435
13. Mills GB, Cheung, RK, Grinstein, S, Gelfand, EW. 1985, Increase in cytosolic free calcium concentration is an intracellular messenger for the production of interleukin 2 but not for expression of the interleukin 2 receptor. J Immunol 134:1640-1643
14. Roifman CM, Mills, GB, Chu, M, Gelfand, EW. 1985, Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells. Cell Immunol 95:146-156
15. Gelfand EW, Cheung, RK, Grinstein, S, Mills, GB. 1986, Characterization of the role for calcium influx in mitogen-induced triggering of human T cells. Identification of calcium- dependent and calcium-independent signals. Eur J Immunol 16:907-91
16. Grinstein S, Mack, E, Mills, GB. 1986, Osmotic activation of the Na+/H+ antiport in protein kinase C-depleted lymphocytes. Biochem Biophys Res Commun 134:8-13
17. Mills, GB, Stewart, DJ, Mellors, .A, Gelfand, E. 1986 Interleukin 2 does not induce phosphatidylinositide hydrolysis in T cells J. Immunol. 136:3019-3024
18. Mills GB, Cheung, RK, Cragoe, EJ, Jr., Grinstein, S, Gelfand, EW. 1986, Activation of the Na+/H+ antiport is not required for lectin-induced proliferation of human T lymphocytes. J Immunol 136:1150-1154
19. Roifman CM, Mills, GB, Cheung, RK, Gelfand, EW. 1986, Mitogenic response of human thymocytes: identification of functional Ca2+-dependent and independent signals. Clin Exp Immunol 66:139-149
20. Teodorczyk-Injeyan JA, Sparkes, BG, Mills, GB, Peters, WJ, Falk, RE. 1986, Impairment of T cell activation in burn patients: a possible mechanism of thermal injury-induced immunosuppression. Clin Exp Immunol 65:570-581
21. Gelfand, E.W., Cheung, R.K., Mills, G.B., Grinstein, S. 1987 Role of membrane potential in the response of human T lymphocytes to phytohemagglutinin. J. Immunol. 138:527-531
22. Benedict SH, Mills, GB, Gelfand, EW. 1987, Interleukin 2 activates a receptor-associated protein kinase. J Immunol 139:1694-1697
23. Estrov Z, Roifman, C, Mills, G, Grunberger, T, Gelfand, EW, Freedman, MH. 1987, The regulatory role of interleukin 2-responsive T lymphocytes on human marrow granulopoiesis. Blood 69:1161-1166
24. Gelfand EW, Cheung, RK, Mills, GB. 1987, The cyclosporins inhibit lymphocyte activation at more than one site. J Immunol 138:1115-1120
25. Kumagai N, Benedict, SH, Mills, GB, Gelfand, EW. 1987, Requirements for the simultaneous presence of phorbol esters and calcium ionophores in the expression of human T lymphocyte proliferation-related genes. J Immunol 139:1393-1399
26. Mills GB, May, C. 1987, Binding of interleukin 2 to its 75-kDa intermediate affinity receptor is sufficient to activate Na+/H+ exchange. J Immunol 139:4083-4087
27. Roifman CM, Mills, GB, Stewart, D, Cheung, RK, Grinstein, S, Gelfand, EW. 1987, Response of human B cells to different anti-immunoglobulin isotypes: absence of a correlation between early activation events and cell proliferation. Eur J Immunol 17:1737-1742
28. Teodorczyk-Injeyan JA, Sparkes, BG, Mills, GB, Falk, RE, Peters, WJ. 1987, Impaired expression of interleukin-2 receptor (IL2R) in the immunosuppressed burned patient: reversal by exogenous IL2. J Trauma 27:180-187
29. Gelfand EW, Cheung, RK, Mills, GB, Grinstein, S. 1988, Uptake of extracellular Ca2+ and not recruitment from internal stores is essential for T lymphocyte proliferation. Eur J Immunol 18:917-922
30. Balazsovits J, Mills, G, Falk, J, Falk, R. 1988, Prostaglandins inhibit proliferation of the murine P815 mastocytoma by decreasing cytoplasmic free calcium levels [( Ca+2]i). Prostaglandins 36:191-204
31. Kumagai N, Benedict, SH, Mills, GB, Gelfand, EW. 1988, Cyclosporin A inhibits initiation but not progression of human T cell proliferation triggered by phorbol esters and calcium ionophores. J Immunol 141:3747-3752
32. Kumagai N, Benedict, SH, Mills, GB, Gelfand, EW. 1988, Induction of competence and progression signals in human T lymphocytes by phorbol esters and calcium ionophores. J Cell Physiol 137:329-336
33. Kumagai N, Benedict, SH, Mills, GB, Gelfand, EW. 1988, Comparison of phorbol ester/ calcium ionophore and phytohemagglutinin-induced signaling in human T lymphocytes. Demonstration of interleukin 2-independent transferrin receptor gene expression. J Immunol 140:37-43
34. Mills GB, Girard, P, Grinstein, S, Gelfand, EW. 1988, Interleukin-2 induces proliferation of T lymphocyte mutants lacking protein kinase C. Cell 55:91-100
35. Mills GB, May, C, McGill, M, Roifman, CM, Mellors, A. 1988, A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 48:1066-1071
36. Schaffer FM, Benedict, SH, Petsche, D, Lau, A, Williams, BR, Mills, GB, Gelfand, EW. 1988, Interferon and phorbol esters down-regulate sIgM expression by independent pathways. J Cell Physiol 134:245-252
37. Teodorczyk-Injeyan JA, Sparkes, BG, Falk, RE, Peters, WJ, Mills, GB. 1988, Interleukin-2 secretion and transmembrane signalling in burned patients. J Trauma 28:152-157
38. Bjorge JD, Kudlow, JE, Mills, GB, Paterson, AJ. 1989, Inhibition of stimulus-dependent epidermal growth factor receptor and transforming growth factor-alpha mRNA accumulation by the protein kinase C inhibitor staurosporine. FEBS Lett 243:404-408
39. Church JG, Mills, GB, Buick, RN. 1989, Activation of the Na+/H+ antiport is not required for epidermal growth factor-dependent gene expression, growth inhibition or proliferation in human breast cancer cells. Biochem J 257:151-157
40. Ebanks R, Roifman, C, Mellors, A, Mills, GB. 1989, The diacylglycerol analogue, 1,2-sn- dioctanoylglycerol, induces an increase in cytosolic free Ca2+ and cytosolic acidification of T lymphocytes through a protein kinase C-independent process. Biochem J 258:689-698
41. Mills GB, May, C, Hill, M, Gelfand, EW. 1989, Role of protein kinase C in interleukin 1, anti-T3, and mitogenic lectin-induced interleukin 2 secretion. J Cell Physiol 141:310-317
42. Mills GB, May, C, Hill, M, Ebanks, R, Roifman, C, Mellors, A, Gelfand, EW. 1989, Physiologic activation of protein kinase C limits IL-2 secretion. J Immunol 142:1995-2003
43. Nasmith PE, Mills, GB, Grinstein, S. 1989, Guanine nucleotides induce tyrosine phosphorylation and activation of the respiratory burst in neutrophils. Biochem J 257:893-897
44. Stanley JB, Gorczynski, RM, Delovitch, TL, Mills, GB. 1989, IL-2 secretion is pertussis toxin sensitive in a T lymphocyte hybridoma. J Immunol 142:3546-3552
45. Teodorczyk-Injeyan JA, Sparkes, BG, Mills, GB, Falk, RE, Peters, WJ. 1989, Increase of serum interleukin 2 receptor level in thermally injured patients. Clin Immunol Immunopathol 51:205- 215
46. Burdett E, Mills, GB, Klip, A. 1990, Effect of GTP gamma S on insulin binding and tyrosine phosphorylation in liver membranes and L6 muscle cells. Am J Physiol 258:C99-108
47. Cruz TF, Mills, G, Pritzker, KP, Kandel, RA. 1990, Inverse correlation between tyrosine phosphorylation and collagenase production in chondrocytes. Biochem J 269:717-721
48. Grinstein S, Furuya, W, Lu, DJ, Mills, GB. 1990, Vanadate stimulates oxygen consumption and tyrosine phosphorylation in electropermeabilized human neutrophils. J Biol Chem 265:318-327
49. Haliotis T, Trimble, W, Chow, S, Bull, S, Mills, G, Girard, P, Kuo, JF, Hozumi, N. 1990, Expression of ras oncogene leads to down-regulation of protein kinase C. Int J Cancer 45:1177- 1183
50. Kandel RA, Pritzker, KP, Mills, GB, Cruz, TF. 1990, Fetal bovine serum inhibits chondrocyte collagenase production: interleukin 1 reverses this effect. Biochim Biophys Acta 1053:130-134
51. Klip A, Mills, GB, Britt, BA, Elliott, ME. 1990, Halothane-dependent release of intracellular Ca2+ in blood cells in malignant hyperthermia. Am J Physiol 258:C495-503
52. Lazarus AH, Mills, GB, Delovitch, TL. 1990, Antigen-induced Ca2+ signaling and desensitization in B cells. J Immunol 144:4147-4155
53. McGroarty RJ, Mills, GB, de Harven, E. 1990, Immunogold labeling of the low-affinity (55 kd) IL2 receptor on the surface of IL2 receptor-bearing cultured cells and mitogen-activated peripheral blood lymphocytes. J Leukoc Biol 48:213-219
54. Mills GB, May, C, Hill, M, Campbell, S, Shaw, P, Marks, A. 1990, Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 86:851-855
55. Mills GB, Zhang, N, May, C, Hill, M, Chung, A. 1990, Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. Cancer Res 50:3036-3042
56. Mills GB, Hill, M, McGill, M, May, C, Stanley, J, Stewart, DJ, Mellors, A, Gelfand, EW. 1990, Interrelationship between signals transduced by phytohemagglutinin and interleukin 1. J Cell Physiol 142:539-551
57. Mills GB, May, C, McGill, M, Fung, M, Baker, M, Sutherland, R, Greene, WC. 1990, Interleukin 2-induced tyrosine phosphorylation. Interleukin 2 receptor beta is tyrosine phosphorylated. J Biol Chem 265:3561-3567
58. Schuh AC, Sutherland, DR, Horsfall, W, Mills, GB, Dube, I, Baker, MA, Siminovitch, K, Bailey, D, Keating, A. 1990, Chronic myeloid leukemia arising in a progenitor common to T cells and myeloid cells. Leukemia 4:631-636
59. Stanley JB, Gorczynski, R, Huang, CK, Love, J, Mills, GB. 1990, Tyrosine phosphorylation is an obligatory event in IL-2 secretion. J Immunol 145:2189-2198
60. Fung MR, Scearce, RM, Hoffman, JA, Peffer, NJ, Hammes, SR, Hosking, JB, Schmandt, R, Kuziel, WA, Haynes, BF, Mills, GB, Greene WC, 1991, A tyrosine kinase physically associates with the beta-subunit of the human IL-2 receptor. J Immunol 147:1253-1260
61. Jordan ML, Vidgen, DF, Wright, J, Odell, M, Mills, GB. 1991, Sustained increases in cytosolic calcium during T lymphocyte allosensitization, proliferation, and acquisition of locomotor function. Transplantation 51:464-468
62. Klotz LH, Kulkarni, C, Mills, G. 1991, End stage renal disease serum contains a specific renal cell growth factor. J Urol 145:156-160
63. Lazarus AH, Mills, GB, Crow, AR, Delovitch, TL. 1991, Antigen-induced Fc receptor- dependent and -independent B cell desensitization. An elevation in [Ca2+]i is not sufficient and protein kinase C activation is not required for these pathways of surface IgM-mediated desensitization. J Immunol 147:1739-1745
64. Padeh S, Levitzki, A, Gazit, A, Mills, GB, Roifman, CM. 1991, Activation of phospholipase C in human B cells is dependent on tyrosine phosphorylation. J Clin Invest 87:1114-1118
65. Roifman CM, Chin, K, Gazit, A, Mills, GB, Gilon, C, Levitzki, A. 1991, Tyrosine phosphorylation is an essential event in the stimulation of B lymphocytes by Staphylococcus aureus Cowan I. J Immunol 146:2965-2971
66. Sutherland DR, Yeo, E, Ryan, A, Mills, GB, Bailey, D, Baker, MA. 1991, Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. Blood 77:84-93
67. Teodorczyk-Injeyan JA, Sparkes, BG, Mills, GB, Peters, WJ. 1991, Immunosuppression follows systemic T lymphocyte activation in the burn patient. Clin Exp Immunol 85:515-518
68. Teodorczyk-Injeyan JA, Sparkes, BG, Mills, GB, Peters, WJ. 1991, Soluble interleukin 2-receptor alpha secretion is related to altered interleukin 2 production in thermally injured patients. Burns 17:290-295
69. Bacus SS, Stancovski, I, Huberman, E, Chin, D, Hurwitz, E, Mills, GB, Ullrich, A, Sela, M, Yarden, Y. 1992, Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res 52:2580-2589
70. Mills GB, Arima, N, May, C, Hill, M, Schmandt, R, Li, J, Miyamoto, NG, Greene, WC. 1992, Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells. Int Immunol 4:1233-1243
71. Mills GB, Schmandt, R, McGill, M, Amendola, A, Hill, M, Jacobs, K, May, C, Rodricks, AM, Campbell, S, Hogg, D. 1992, Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J Biol Chem 267:16000-16006
72. Simon HU, Mills, GB, Hashimoto, S, Siminovitch, KA. 1992, Evidence for defective transmembrane signaling in B cells from patients with Wiskott-Aldrich syndrome. J Clin Invest 90:1396-1405
73. Teodorczyk-Injeyan JA, Sparkes, BG, Lalani, S, Peters, WJ, Mills, GB. 1992, IL-2 regulation of soluble IL-2 receptor levels following thermal injury. Clin Exp Immunol 90:36-42
74. Cyopick P, Culliton, R, Brockhausen, I, Sutherland, DR, Mills, GB, Baker, M. 1993, Role of aberrant sialylation of chronic myeloid leukemia granulocytes on binding and signal transduction by chemotactic peptides and colony stimulating factors. Leuk Lymphoma 11:79-90
75. Franklin RA, Mazer, B, Sawami, H, Mills, GB, Terada, N, Lucas, JJ, Gelfand, EW. 1993, Platelet-activating factor triggers the phosphorylation and activation of MAP-2 kinase and S6 peptide kinase activity in human B cell lines. J Immunol 151:1802-1810
76. Gibson S, Leung, B, Squire, JA, Hill, M, Arima, N, Goss, P, Hogg, D, Mills, GB. 1993, Identification, cloning, and characterization of a novel human T-cell-specific tyrosine kinase located at the hematopoietin complex on chromosome 5q. Blood 82:1561-1572
77. Hack N, Sue, AQA, Mills, GB, Skorecki, KL. 1993, Expression of human tyrosine kinase- negative epidermal growth factor receptor amplifies signaling through endogenous murine epidermal growth factor receptor. J Biol Chem 268:26441-26446
78. Matthews KE, Mills, GB, Horsfall, W, Hack, N, Skorecki, K, Keating, A. 1993, Bead transfection: rapid and efficient gene transfer into marrow stromal and other adherent mammalian cells. Exp Hematol 21:697-702
79. Radvanyi LG, Mills, GB, Miller, RG. 1993, Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death J Immunol 150:5704-5715
80. Tsao PW, Mills, GB, Diaz, RJ, Radde, IC, Martell, MF, Augustine, JM, Parkinson, D, Waddell, J, Wilson, GJ, Coles, JG. 1993, Identification of a subpopulation of reactive large granular mononuclear cells in allogeneic heart transplantation. J Heart Lung Transplant 12:230-238
81. Yuan S, Trachtenberg, J, Mills, GB, Brown, TJ, Xu, F, Keating, A. 1993, Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 53:1304-1311
82. August A, Gibson, S, Kawakami, Y, Kawakami, T, Mills, GB, Dupont, B. 1994, CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line. Proc Natl Acad Sci U S A 91:9347-9351
83. Hogg D, Guidos, C, Bailey, D, Amendola, A, Groves, T, Davidson, J, Schmandt, R, Mills, G. 1994, Cell cycle dependent regulation of the protein kinase TTK. Oncogene 9:89-96
84. Hurteau J, Rodriguez, GC, Whitaker, RS, Shah, S, Mills, G, Bast, RC, Berchuck, A. 1994, Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74:93-99
85. Hurteau JA, Simon, HU, Kurman, C, Rubin, L, Mills, GB. 1994, Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. Am J Obstet Gynecol 170:918-928
86. Schmandt R, Hill, M, Amendola, A, Mills, GB, Hogg, D. 1994, IL-2-induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression. J Immunol 152:96-105
87. Simon HU, Tsao, PW, Siminovitch, KA, Mills, GB, Blaser, K. 1994, Functional platelet- activating factor receptors are expressed by monocytes and granulocytes but not by resting or activated T and B lymphocytes from normal individuals or patients with asthma. J Immunol 153:364-377
88. Simon HU, Mills, GB, Kozlowski, M, Hogg, D, Branch, D, Ishimi, Y, Siminovitch, KA. 1994, Molecular characterization of hNRP, a cDNA encoding a human nucleosome-assembly-protein- I-related gene product involved in the induction of cell proliferation. Biochem J 297 Pt 2):389- 397
89. Tsao PW, Mills, GB, Diaz, RJ, Radde, IC, Parkinson, D, Waddell, J, Wilson, GJ, Coles, JG. 1994, Evidence that increases in lymphocyte tyrosine phosphorylation precede cardiac allograft rejection. Effects of cyclosporine and potential use in clinical management. Transplantation 58:451-457
90. Xu FJ, Boyer, CM, Bae, DS, Wu, S, Greenwald, M, O’Briant, K, Yu, YH, Mills, GB, Bast, RC, Jr. 1994, The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. Int J Cancer 59:242-247
91. Truitt, K.E., Mills, G.B., Turck, C.W., Imboden, J.B., 1994 SH2-dependent association of phosphatidylinositol 3’-kinase 85 kDa regulatory subunit with the interleukin-2 receptor β chain J. Biol Chem. 269:5937-5943
92. Branch DR, Mills, GB. 1995, pp60c-src expression is induced by activation of normal human T lymphocytes. J Immunol 154:3678-3685
93. Goldsmith MA, Lai, SY, Xu, W, Amaral, MC, Kuczek, ES, Parent, LJ, Mills, GB, Tarr, KL, Longmore, GD, Greene, WC. 1995, Growth signal transduction by the human interleukin-2 receptor requires cytoplasmic tyrosines of the beta chain and non-tyrosine residues of the gamma c chain. J Biol Chem 270:21729-21737
94. Hurteau JA, Woolas, RP, Jacobs, IJ, Oram, DC, Kurman, CC, Rubin, LA, Nelson, DL, Berchuck, A, Bast, RC, Jr., Mills, GB. 1995, Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 76:1615- 1620
95. Kawakami Y, Yao, L, Tashiro, M, Gibson, S, Mills, GB, Kawakami, T. 1995, Activation and interaction with protein kinase C of a cytoplasmic tyrosine kinase, Itk/Tsk/Emt, on Fc epsilon RI cross-linking on mast cells. J Immunol 155:3556-3562
96. Mogil RJ, Radvanyi, L, Gonzalez-Quintial, R, Miller, R, Mills, G, Theofilopoulos, AN, Green, DR. 1995, Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int Immunol 7:1451-1458
97. Pani G, Kozlowski, M, Cambier, JC, Mills, GB, Siminovitch, KA. 1995, Identification of the tyrosine phosphatase PTP1C as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling. J Exp Med 181:2077-2084
98. Phipps DJ, Reed-Doob, P, MacFadden, DK, Piovesan, JP, Mills, GB, Branch, DR. 1995, An octapeptide analogue of HIV gp120 modulates protein tyrosine kinase activity in activated peripheral blood T lymphocytes. Clin Exp Immunol 100:412-418
99. Shi Y, Radvanyi, LG, Sharma, A, Shaw, P, Green, DR, Miller, RG, Mills, GB. 1995, CD28- mediated signaling in vivo prevents activation-induced apoptosis in the thymus and alters peripheral lymphocyte homeostasis. J Immunol 155:1829-1837
100. Shi Y, Frankel, A, Radvanyi, LG, Penn, LZ, Miller, RG, Mills, GB. 1995, Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 55:1982-1988
101. Teodorczyk-Injeyan JA, Cembrzynska-Nowak, M, Lalani, S, Peters, WJ, Mills, GB. 1995, Immune deficiency following thermal trauma is associated with apoptotic cell death. J Clin Immunol 15:318-328
102. Truitt KE, Shi, J, Gibson, S, Segal, LG, Mills, GB, Imboden, JB. 1995, CD28 delivers costimulatory signals independently of its association with phosphatidylinositol 3-kinase. J Immunol 155:4702-4710
103. Xu Y, Fang, XJ, Casey, G, Mills, GB. 1995, Lysophospholipids activate ovarian and breast cancer cells. Biochem J 309 ( Pt 3):933-940
104. Xu Y, Casey, G, Mills, GB. 1995, Effect of lysophospholipids on signaling in the human Jurkat T cell line. J Cell Physiol 163:441-450
105. Xu Y, Gaudette, DC, Boynton, JD, Frankel, A, Fang, XJ, Sharma, A, Hurteau, J, Casey, G, Goodbody, A, Mellors, A, Holub, B., and Mills, G.B 1995, Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1:1223-1232
106. Frankel A, Mills, GB. 1996, Peptide and lipid growth factors decrease cis- diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin Cancer Res 2:1307-1313
107. Gibson S, August, A, Kawakami, Y, Kawakami, T, Dupont, B, Mills, GB. 1996, The EMT/ITK/ TSK (EMT) tyrosine kinase is activated during TCR signaling: LCK is required for optimal activation of EMT. J Immunol 156:2716-2722
108. Gibson S, August, A, Branch, D, Dupont, B, Mills, GM. 1996, Functional LCK Is required for optimal CD28-mediated activation of the TEC family tyrosine kinase 271:7079-7083
109. Jurisicova A, Casper, RF, MacLusky, NJ, Mills, GB, Librach, CL. 1996, HLA-G expression during preimplantation human embryo development. Proc Natl Acad Sci U S A 93:161-165
110. Phipps DJ, Read, SE, Piovesan, JP, Mills, GB, Branch, DR. 1996, HIV infection in vitro enhances the activity of src-family protein tyrosine kinases. Aids 10:1191-1198
111. Radvanyi LG, Shi, Y, Mills, GB, Miller, RG. 1996, Cell cycle progression out of G1 sensitizes primary-cultured nontransformed T cells to TCR-mediated apoptosis. Cell Immunol 170:260- 273
112. Radvanyi LG, Shi, Y, Vaziri, H, Sharma, A, Dhala, R, Mills, GB, Miller, RG. 1996, CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 156:1788-1798
113. Teng JM, Liu, XR, Mills, GB, Dupont, B. 1996, CD28-mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3-kinase, and protein kinase C. J Immunol 156:3222-3232
114. Wiener JR, Kassim, SK, Yu, Y, Mills, GB, Bast, RC, Jr. 1996, Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. Gynecol Oncol 61:233-240
115. Yousefi S, Hoessli, DC, Blaser, K, Mills, GB, Simon, HU. 1996, Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med 183:1407-1414
116. Fang X, Gibson, S, Flowers, M, Furui, T, Bast, RC, Jr., Mills, GB. 1997, Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J Biol Chem 272:13683-13689
117. Shi Y, Wang, R, Sharma, A, Gao, C, Collins, M, Penn, L, Mills, GB. 1997, Dissociation of cytokine signals for proliferation and apoptosis. J Immunol 159:5318-5328
118. Marengere LE, Okkenhaug, K, Clavreul, A, Couez, D, Gibson, S, Mills, GB, Mak, TW, Rottapel, R. 1997, The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28. J Immunol 159:3220-3229
119. Okita M, Gaudette, DC, Mills, GB, Holub, BJ. 1997, Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. Int J Cancer 71:31-34
120. Shi YF, Hill, M, Novak, A, Chen, ZQ, Wang, RX, Liew, CC, Mills, GB. 1997, Human hematopoietic cell express two forms of the cytokine receptor common gamma-chain (gamma c). Cell Res 7:195-205
121. Somani AK, Bignon, JS, Mills, GB, Siminovitch, KA, Branch, DR. 1997, Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase. J Biol Chem 272:21113-21119
122. Teng DH, Hu, R, Lin, H, Davis, T, Iliev, D, Frye, C, Swedlund, B, Hansen, KL, Vinson, VL, Gumpper, KL, Ellis, L, El-Naggar, A, Frazier, M, Jasser, S, Langford, LA, Lee, J, Mills, GB, Pershouse, MA, Pollack, RE, Tornos, C, Troncoso, P, Yung, WK, Fujii, G, Berson, A, Steck, PA, et al. 1997, MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57:5221-5225
123. Wang R, Fang, Q, Zhang, L, Radvany, L, Sharma, A, Noben-Trauth, N, Mills, GB, Shi, Y. 1997, CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. J Immunol 158:2856-2861
124. Xu FJ, Stack, S, Boyer, C, O’Briant, K, Whitaker, R, Mills, GB, Yu, YH, Bast, RC, Jr. 1997, Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 3:1629-1634
125. Xu HJ, Zhou, Y, Ji, W, Perng, GS, Kruzelock, R, Kong, CT, Bast, RC, Mills, GB, Li, J, Hu, SX. 1997, Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 15:2589-2596
126. Davies MA, Lu, Y, Sano, T, Fang, X, Tang, P, LaPushin, R, Koul, D, Bookstein, R, Stokoe, D, Yung, WK, Mills, GB, Steck, PA. 1998, Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58:5285-5290
127. Fang X, Jin, X, Xu, HJ, Liu, L, Peng, HQ, Hogg, D, Roth, JA, Yu, Y, Xu, F, Bast, RC, Jr., Mills, GB. 1998, Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 16:1-8
128. Gibson S, Truitt, K, Lu, Y, Lapushin, R, Khan, H, Imboden, JB, Mills, GB. 1998, Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK. Biochem J 330 ( Pt 3):1123-1128
129. Haas-Kogan D, Shalev, N, Wong, M, Mills, G, Yount, G, Stokoe, D. 1998, Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8:1195-1198
130. Koul D, Obeyesekere, NU, Gutterman, JU, Mills, GB, Choubey, D. 1998, p202 self-associates through a sequence conserved among the members of the 200-family proteins. FEBS Lett 438:21-24
131. Koul D, Lapushin, R, Xu, HJ, Mills, GB, Gutterman, JU, Choubey, D. 1998, p202 prevents apoptosis in murine AKR-2B fibroblasts. Biochem Biophys Res Commun 247:379-382.
132. Lu Y, Cuevas, B, Gibson, S, Khan, H, LaPushin, R, Imboden, J, Mills, GB. 1998, Phosphatidylinositol 3-kinase is required for CD28 but not CD3 regulation of the TEC family tyrosine kinase EMT/ITK/TSK: functional and physical interaction of EMT with phosphatidylinositol 3-kinase. J Immunol 161:5404-5412
133. Patton SE, Martin, ML, Nelsen, LL, Fang, X, Mills, GB, Bast, RC, Jr., Ostrowski, MC. 1998, Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 58:2253-2259
134. Radvanyi LG, Raju, K, Spaner, D, Mills, GB, Miller, RG. 1998, Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice. Cell Immunol 183:1-12
135. Cuevas B, Lu, Y, Watt, S, Kumar, R, Zhang, J, Siminovitch, KA, Mills, GB. 1999, SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J Biol Chem 274:27583-27589
136. Fang X, Yu, S, Eder, A, Mao, M, Bast, RC, Jr., Boyd, D, Mills, GB. 1999, Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 18:6635-6640
137. Furui T, LaPushin, R, Mao, M, Khan, H, Watt, SR, Watt, MA, Lu, Y, Fang, X, Tsutsui, S, Siddik, ZH, Bast, RC, Mills, GB. 1999, Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 5:4308-4318
138. Gershenson DM, Deavers, M, Diaz, S, Tortolero-Luna, G, Miller, BE, Bast, RC, Jr., Mills, GB, Silva, EG. 1999, Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res 5:4053-4058
139. Hagopian GS, Mills, GB, Khokhar, AR, Bast, RC, Jr., Siddik, ZH. 1999, Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res 5:655-663
140. Pustilnik TB, Estrella, V, Wiener, JR, Mao, M, Eder, A, Watt, MA, Bast, RC, Jr., Mills, GB. 1999, Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 5:3704-3710
141. Lu Y, Lin, YZ, LaPushin, R, Cuevas, B, Fang, X, Yu, SX, Davies, MA, Khan, H, Furui, T, Mao, M, Zinner, R, Hung, MC, Steck, P, Siminovitch, K, Mills, GB. 1999, The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18:7034-7045
142. Shayesteh L, Lu, Y, Kuo, WL, Baldocchi, R, Godfrey, T, Collins, C, Pinkel, D, Powell, B, Mills, GB, Gray, JW. 1999, PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102
143. Wolf JK, Mills, GB, Bazzet, L, Bast, RC, Jr., Roth, JA, Gershenson, DM. 1999, Adenovirus- mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol 75:261-266
144. Wolf JK, Kim, TE, Fightmaster, D, Bodurka, D, Gershenson, DM, Mills, G, Wharton, JT. 1999, Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. Gynecol Oncol 73:27-34
145. Xu F, Yu, Y, Le, XF, Boyer, C, Mills, GB, Bast, RC, Jr. 1999, The outcome of heregulin- induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5:3653-3660
146. Yu Y, Xu, F, Peng, H, Fang, X, Zhao, S, Li, Y, Cuevas, B, Kuo, WL, Gray, JW, Siciliano, M, Mills, GB, Bast, RC, Jr. 1999, NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 96:214-219
147. Zebrowski BK, Liu, W, Ramirez, K, Akagi, Y, Mills, GB, Ellis, LM. 1999, Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6:373-378
148. Zhang J, Somani, AK, Watt, S, Mills, GB, Siminovitch, KA. 1999, The Src-homology domain 2-bearing protein tyrosine phosphatase-1 inhibits antigen receptor-induced apoptosis of activated peripheral T cells. J Immunol 162:6359-6367
149. Eder AM, Sasagawa, T, Mao, M, Aoki, J, Mills, GB. 2000, Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 6:2482-2491
150. Fang X, Yu, S, LaPushin, R, Lu, Y, Furui, T, Penn, LZ, Stokoe, D, Erickson, JR, Bast, RC, Mills, GB. 2000, Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein- mediated activation of mitogen-activated protein kinase. Biochem J 352 Pt 1:135-143
151. Fang X, Yu, SX, Lu, Y, Bast, RC, Jr., Woodgett, JR, Mills, GB. 2000, Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97:11960-11965
152. Hu L, Zaloudek, C, Mills, GB, Gray, J, Jaffe, RB. 2000, In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6:880-886
153. Kruzelock RP, Cuevas, BD, Wiener, JR, Xu, FJ, Yu, Y, Cabeza-Arvelaiz, Y, Pershouse, M, Lovell, MM, Killary, AM, Mills, GB, Bast, RC, Jr. 2000, Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene 19:6277-6285
154. Le XF, Vadlamudi, R, McWatters, A, Bae, DS, Mills, GB, Kumar, R, Bast, RC, Jr. 2000, Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res 60:3522- 3531
155. Imai A, Furui T, Tamaya T, Mills GB, 2000 A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells J. Clin Endrocrinol Metab 85:3370-3375
156. Le XF, McWatters, A, Wiener, J, Wu, JY, Mills, GB, Bast, RC, Jr. 2000, Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 6:260-270
157. Mao M, Fang, X, Lu, Y, Lapushin, R, Bast, RC, Jr., Mills, GB. 2000, Inhibition of growth- factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J 352 Pt 2:475-482
158. Ramondetta L, Mills, GB, Burke, TW, Wolf, JK. 2000, Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin Cancer Res 6:278-284
159. Suzuki S, Moore, DH, 2nd, Ginzinger, DG, Godfrey, TE, Barclay, J, Powell, B, Pinkel, D, Zaloudek, C, Lu, K, Mills, G, Berchuck, A, Gray, JW. 2000, An approach to analysis of large- scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60:5382-5385
160. Asselin E, Mills, GB, Tsang, BK. 2001, XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61:1862-1868
161. Aytac U, Claret, FX, Ho, L, Sato, K, Ohnuma, K, Mills, GB, Cabanillas, F, Morimoto, C, Dang, NH. 2001, Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res 61:7204-7210
162. Cuevas BD, Lu, Y, Mao, M, Zhang, J, LaPushin, R, Siminovitch, K, Mills, GB. 2001, Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem 276:27455-27461
163. Braunstein I, Cohen-Barak, O, Shachaf, C, Ravel, Y, Yalon-Hacohen, M, Mills, GB, Tzukerman, M, Skorecki, KL. 2001, Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells. Cancer Res 61:5529-5536
164. Ho L, Aytac, U, Stephens, LC, Ohnuma, K, Mills, GB, McKee, KS, Neumann, C, LaPushin, R, Cabanillas, F, Abbruzzese, JL, Morimoto, C, Dang, NH. 2001, In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 7:2031-2040
165. Hu YL, Tee, MK, Goetzl, EJ, Auersperg, N, Mills, GB, Ferrara, N, Jaffe, RB. 2001, Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93:762-768
166. Le XF, Marcelli, M, McWatters, A, Nan, B, Mills, GB, O’Brian, CA, Bast, RC, Jr. 2001, Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. Oncogene 20:8258-8269
167. Liu B, Fang, M, Lu, Y, Mills, GB, Fan, Z. 2001, Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer 85:303-311
168. Mujoo K, Haridas, V, Hoffmann, JJ, Wachter, GA, Hutter, LK, Lu, Y, Blake, ME, Jayatilake, GS, Bailey, D, Mills, GB, Gutterman, JU. 2001, Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis. Cancer Res 61:5486-5490
169. Shridhar V, Lee, J, Pandita, A, Iturria, S, Avula, R, Staub, J, Morrissey, M, Calhoun, E, Sen, A, Kalli, K, Keeney, G, Roche, P, Cliby, W, Lu, K, Schmandt, R, Mills, GB, Bast, RC, Jr., James, CD, Couch, FJ, Hartmann, LC, Lillie, J, Smith, DI. 2001, Genetic analysis of early- versus late- stage ovarian tumors. Cancer Res 61:5895-5904
170. Wolf BB, Schuler, M, Li, W, Eggers-Sedlet, B, Lee, W, Tailor, P, Fitzgerald, P, Mills, GB, Green, DR. 2001, Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem 276:34244-34251
171. Zhu Y, Spitz, MR, Lei, L, Mills, GB, Wu, X. 2001, A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61:7825- 7829
172. Bondar VM, Sweeney-Gotsch, B, Andreeff, M, Mills, GB, McConkey, DJ. 2002, Inhibition of the phosphatidylinositol 3’-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1:989-997
173. Buchholz TA, Wu, X, Hussain, A, Tucker, SL, Mills, GB, Haffty, B, Bergh, S, Story, M, Geara, FB, Brock, WA. 2002, Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. Int J Cancer 97:557-561
174. Euhus DM, Smith, KC, Robinson, L, Stucky, A, Olopade, OI, Cummings, S, Garber, JE, Chittenden, A, Mills, GB, Rieger, P, Esserman, L, Crawford, B, Hughes, KS, Roche, CA, Ganz, PA, Seldon, J, Fabian, CJ, Klemp, J, Tomlinson, G. 2002, Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 94:844-851
175. Fang X, Schummer, M, Mao, M, Yu, S, Tabassam, FH, Swaby, R, Hasegawa, Y, Tanyi, JL, LaPushin, R, Eder, A, Jaffe, R, Erickson, J, Mills, GB. 2002, Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582:257-264
176. Fang X, Yu, S, Tanyi, JL, Lu, Y, Woodgett, JR, Mills, GB. 2002, Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22:2099-2110
177. Hu L, Hofmann, J, Lu, Y, Mills, GB, Jaffe, RB. 2002, Inhibition of phosphatidylinositol 3’-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62:1087-1092
178. Koul D, Jasser, SA, Lu, Y, Davies, MA, Shen, R, Shi, Y, Mills, GB, Yung, WK. 2002, Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 21:2357-2364
179. Kuo MT, Liu, Z, Wei, Y, Lin-Lee, YC, Tatebe, S, Mills, GB, Unate, H. 2002, Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 21:1945- 1954
180. Petricoin EF, Ardekani, AM, Hitt, BA, Levine, PJ, Fusaro, VA, Steinberg, SM, Mills, GB, Simone, C, Fishman, DA, Kohn, EC, Liotta, LA. 2002, Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577
181. Tanyi JL, Lapushin, R, Eder, A, Auersperg, N, Tabassam, FH, Roth, JA, Gu, J, Fang, B, Mills, GB, Wolf, J. 2002, Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol 85:451-458
182. Umezu-Goto M, Kishi, Y, Taira, A, Hama, K, Dohmae, N, Takio, K, Yamori, T, Mills, GB, Inoue, K, Aoki, J, Arai, H. 2002, Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158:227-233
183. Bianco R, Shin, I, Ritter, CA, Yakes, FM, Basso, A, Rosen, N, Tsurutani, J, Dennis, PA, Mills, GB, Arteaga, CL. 2003, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812-2822
184. Clair T, Aoki, J, Koh, E, Bandle, RW, Nam, SW, Ptaszynska, MM, Mills, GB, Schiffmann, E, Liotta, LA, Stracke, ML. 2003, Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 63:5446-5453
185. Cui X, Zhang, P, Deng, W, Oesterreich, S, Lu, Y, Mills, GB, Lee, AV. 2003, Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17:575-588
186. Hasegawa Y, Erickson, JR, Goddard, GJ, Yu, S, Liu, S, Cheng, KW, Eder, A, Bandoh, K, Aoki, J, Jarosz, R, Schrier, AD, Lynch, KR, Mills, GB, Fang, X. 2003, Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem 278:11962-11969
187. Hu SX, Wang, S, Wang, JP, Mills, GB, Zhou, Y, Xu, HJ. 2003, Expression of endogenous granzyme B in a subset of human primary breast carcinomas. Br J Cancer 89:135-139
188. Knuefermann C, Lu, Y, Liu, B, Jin, W, Liang, K, Wu, L, Schmidt, M, Mills, GB, Mendelsohn, J, Fan, Z. 2003, HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22:3205-3212
189. Le XF, Hittelman, WN, Liu, J, McWatters, A, Li, C, Mills, GB, Bast, RC, Jr. 2003, Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 22:484-497
190. Lee HY, Srinivas, H, Xia, D, Lu, Y, Superty, R, LaPushin, R, Gomez-Manzano, C, Gal, AM, Walsh, GL, Force, T, Ueki, K, Mills, GB, Kurie, JM. 2003, Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 278:23630-23638
191. Liang K, Jin, W, Knuefermann, C, Schmidt, M, Mills, GB, Ang, KK, Milas, L, Fan, Z. 2003, Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2:353-360
192. Lu Y, Yu, Q, Liu, JH, Zhang, J, Wang, H, Koul, D, McMurray, JS, Fang, X, Yung, WK, Siminovitch, KA, Mills, GB. 2003, Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278:40057-40066
193. Luo RZ, Fang, X, Marquez, R, Liu, SY, Mills, GB, Liao, WS, Yu, Y, Bast, RC. 2003, ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 22:2897-2909
194. Mansouri A, Ridgway, LD, Korapati, AL, Zhang, Q, Tian, L, Wang, Y, Siddik, ZH, Mills, GB, Claret, FX. 2003, Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278:19245- 19256
195. Ni Z, Anini, Y, Fang, X, Mills, G, Brubaker, PL, Jin, T. 2003, Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J Biol Chem 278:1380-1387
196. Qian L, Xu, Y, Hasegawa, Y, Aoki, J, Mills, GB, Prestwich, GD. 2003, Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor- selective agonist activity. J Med Chem 46:5575-5578
197. Shvartsman HS, Lu, KH, Lee, J, Lillie, J, Deavers, MT, Clifford, S, Wolf, JK, Mills, GB, Bast, RC, Jr., Gershenson, DM, Schmandt, R. 2003, Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90:44-50
198. Tanyi JL, Hasegawa, Y, Lapushin, R, Morris, AJ, Wolf, JK, Berchuck, A, Lu, K, Smith, DI, Kalli, K, Hartmann, LC, McCune, K, Fishman, D, Broaddus, R, Cheng, KW, Atkinson, EN, Yamal, JM, Bast, RC, Felix, EA, Newman, RA, Mills, GB. 2003, Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 9:3534-3545
199. Tanyi JL, Morris, AJ, Wolf, JK, Fang, X, Hasegawa, Y, Lapushin, R, Auersperg, N, Sigal, YJ, Newman, RA, Felix, EA, Atkinson, EN, Mills, GB. 2003, The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 63:1073-1082
200. Wiener JR, Windham, TC, Estrella, VC, Parikh, NU, Thall, PF, Deavers, MT, Bast, RC, Mills, GB, Gallick, GE. 2003, Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88:73-79
201. Mills G.B., and Moolenaar, WH. 2003 Emerging role of lysophosphatidic acid in cancer. Nature Cancer Reviews 3:582-591
202. Fang X, Yu, S, Bast, RC, Liu, S, Xu, HJ, Hu, SX, LaPushin, R, Claret, FX, Aggarwal, BB, Lu, Y, Mills, GB. 2004, Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279:9653-9661
203. Liu J, Yang, G, Thompson-Lanza, JA, Glassman, A, Hayes, K, Patterson, A, Marquez, RT, Auersperg, N, Yu, Y, Hahn, WC, Mills, GB, Bast, RC, Jr. 2004, A genetically defined model for human ovarian cancer. Cancer Res 64:1655-1663
204. Lu KH, Patterson, AP, Wang, L, Marquez, RT, Atkinson, EN, Baggerly, KA, Ramoth, LR, Rosen, DG, Liu, J, Hellstrom, I, Smith, D, Hartmann, L, Fishman, D, Berchuck, A, Schmandt, R, Whitaker, R, Gershenson, DM, Mills, GB, Bast, RC, Jr. 2004, Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10:3291-3300
205. Noh WC, Mondesire, WH, Peng, J, Jian, W, Zhang, H, Dong, J, Mills, GB, Hung, MC, Meric- Bernstam, F. 2004, Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013-1023
206. Sellappan S, Grijalva, R, Zhou, X, Yang, W, Eli, MB, Mills, GB, Yu, D. 2004, Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 64:3479-3485
207. Zhao S, Konopleva, M, Cabreira-Hansen, M, Xie, Z, Hu, W, Milella, M, Estrov, Z, Mills, GB, Andreeff, M. 2004, Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18:267-275
208. Cheng, K.W., Lahad J.P., Kuo W-L. Lapuk, A., Yamada, K., Auersperg N., Liu J., Smith- McCune, K., Lu, K.H., Fishman, D., Gray J.W., and Mills G.B., 2004. The Rab 25 small GTPase determines aggressiveness of ovarian and breast cancers: Nature Medicine: 10:1251-6
209. Mondesire, WH., Jian W., Zhang, H., Ensor, J. Hung MC, Mills GB, Meric-Bernstam F. 2004 Targeting mTOR synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells Clin Can Res. 10:7031-42
210. Liu S., Yu, S., Hasegawa, Y., LaPushin, R., Xu, H.J., Woodgett, J.R., Mills G.B., and Fang X. 2004 Glycogen Synthase Kinase 3b is a negative regulator of growth factor-induced activation of the c-Jun N-terminal Kinase J. Biol Chem: 279:51075-81
211. Le, X-F., Lammayot, A., Gold, D., Lu, Y., Mao WW. Chang, T., Patel A., Mills, G.B. and Bast R.C., 2005, Genes affecting cell cycle, growth/maintenance and drug sensitivity are preferentially regulated by Anti-HER2 antibody through PI3K-AKT signaling. J Biol Chem 280:2092-2104
212. Liu Z, Wang LE, Wang L, Lu KH, Mills GB, Bondy ML, Wei Q. 2005 Methylation and mRNA Expression of p15INK4b but Not p16INK4a are Independent Risk Factors for Ovarian Cancer. Clin Cancer Res 11:4968-4976
213. Dong, J., Peng, J., Zhang, H., Mondesire, WH, Jian, W., Mills, G.B., Hung, M.C., and Meric- Bernstam, F., 2005 The role of glycogen synthase kinase 3b in rapamycin mediated cell cycle regulation and chemosensitivity Cancer Research 65:1961-1972
214. Sheehan, K., Calvert, V.S., Kay, E., Lu, Y., Fishman D., Espina, V., Aquino, J., Speer, R., Araujo, R., Mills G.B., Liotta, L., Petricoin, E., and Wulfkuhle, J., 2005 Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma Molecular and Cellular Proteomics 4:346-355
215. Takeuchi, H., Kanzawa, T., Kondo, Y., Mills G.B., and Kondo, S., 2005. Synergistic Augmentation of Rapamycin-Induced Autophagy in Malignant Glioma Cells by Phosphatidylinositol 3-Phosphate Kinase/Protein Kinase B Inhibitors. Cancer Res 65:3336-46
216. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El- Naggar A, Bekele BN, Mills GB, Myers JN. 2005 Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther. 4:1146-56
217. Xu, Y., Aoki, J., Shimizu, K., Umezu- Goto, M., Hama, K., Takanezawa Y., Mills GB, Arai H., Qian L., Prestwich G.D., 2005 Structure activity relationships of Fluorinated Lysophosphatidic Acid Analogues: Discovery of High-Affinity LPA3 receptor agonists J Med Chem. 48:3319-3327
218. Mandal, M., Kim, S, Younes, M.N., Jasser, S.A. El-Naggar, A., Mills G.B., and Myers J.N., 2005, The AKT inhibitor KP372-1 suppresses AKT activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br. J. Cancer 92:1899-1905
219. Eder. A., Sui, X., Rosen D., Nolden, L., Cheng KW., Lahad, J., Kango-Singh, M., Lu KH., Warneke, CL., Atkinson EN, Bedrosian I., Keyomarsi K., Kuo, W., Gray, J.W., Yin J.C., Liu, J., Halder, G., and Mills G.B., 2005 Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer. Proc. Natl. Acad. Sci. 102:12519-12524
220. Nunez, M.I., Rosen D., Ludes-Meyers, Abba, M. C., Kil, H., Page, R., Klein-Szanto, J.P., Godwin A.K., Liu, J., Mills G.B., and Aldaz CM 2005 WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 5:64
221. Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, Mills GB, Liao WS, Chen X, Bast RC Jr, Luo RZ. 2005 A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res. 65:6701-10
222. Huang, G., Krig, S., Kowbel, D., Xu, H., Hyun, B., Volik, S., Feuerstein, B., Mills G.B., Yaswen, P., and Collins C., 2005 ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction Human Molecular Genetics 14:3219-25
223. Koul D., Shen, R., Bergh, S., Lu, Y. de Groot, J.F., Liu T-J. Mills G.B., and Yung WKA. 2005 Targeting integrin-linked kinase inhibits AKT signaling pathways and decreases tumor progression of human glioblastoma Mol Cancer Ther. 4:1681-8
224. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El- Naggar A, Bekele BN, Mills GB, Myers JN. 2005 Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther. 4:1146-56
225. Marquez, R.T., Baggerly, K.A., Patterson, A.P., Liu, J., Broaddus, R., Fumovitz, M., Atkinson, E.N., Smith D., Hartmann, L., Fishman, D., Berchuck, A., Whitaker, R., Gershenson, D., Mills G.B., Bast R.C., and Lu, K.H., 2005 Patterns of gene expression distinguish histotypes of epithelial ovarian cancer that correlate with those in normal fallopian tube, endometrium and colon Clin Cancer Res. 11:6116-26
226. Hennessy, B, Ram P., Mills GB. 2005 Exploiting the PI3K-Akt pathway for cancer drug discovery. Nature Reviews Drug Development 4:988-1004
227. Rosen, D.G., Yang, G., Deavers, M.T., Malpica, A., Kavanagh JJ., Mills, G.B., and Liu J., 2006 Cyclin E expression is correlated with tumor progression and predicts poor prognosis in human ovarian cancer. Cancer: 106:1925-32
228. Zhu, Q., Mayzone, L., Xia, L, Mills G.B., Lowell, C.A., Touw I.P., and Corey S.J. 2006 G-CSF induction of reactive oxygen species involves the LYN-PI3-kinase-AKT pathway and is increased in cells expressing a truncated G-CSF receptor associated with acute myeloid leukemia Blood 107:1847-56
229. Barcenas, C.H., Hosain GMM., Arun B., Zong, J., Zhou, X., Chen, J., Cortada JM., Mills G.B., Tomlinson, G.E., Miller, AR., Strong L.C. and Amos C.I. 2006 Assessing BRCA carrier probabilities in extended families. Journal Clinical Oncology: I24:354-360
230. Lee, Z., Swaby, R., Liang, Y., Yu, S., Liu, S., Lu, KH, Bast, R., Jr., Mills, G.B., and Fang, XJ. 2006 Lysophosphatidic acid is a major regulator of growth-regulated oncogene ‐ in ovarian cancer. Cancer Res. 66:2740-8
231. Qian, L, Xu, Y, Simper, T., Jian G., Aoki, A., Umezu-Goto, M., Arai, H., Yu, S., Mills G. B., Tsukahara, R., Makarova, N., Fujiwara, Y., Tigyi, G., and Prestwich, G. 2006 Phosphorothioate Analogues of Alkyl Lysophosphatidic Acid as LPA3 Receptor-Selective Agonists Chem Med Chem 1:376-383
232. O’Reilly, K., Rojo F., She, Q-B., Solit, D., Smith D. Mills, G.B., Lane, H., Hofmann, F., Hicklin, D.J., Ludwig, D.L., Baselga, J., and Rosen N., 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-8
233. Geograkis, GV, Li Y, Rassidakis GZ, Mederios, LK, Mills G. B., Younes A., 2006 Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol. 132:503-11
234. Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphey A Ludwick J, El-Naggar AK, Bucana C, Mills GB, Myers JN. 2006 The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol. I42:430-9
235. Visentin, B., Vekich J.A., Sibbald, B.J., Cavalli, A.L., Moreno, K.M., Matteo, R.G., Garland W.A., Lu, Y., Yu., S., Hall, H.S., Kundra V., Mills G.B., and Sabbadini R., 2006, Sphingosine- 1-phosphate is required for tumor growth, invasion and angiogenesis mediated by bFGF and VEGF in multiple tumor lineages: Validation of an anti-S1P antibody as a potential therapeutic Cancer Cell: 9:225-238
236. Zheng, Z, Samudio, I.J., Zhang, W., Estrov, Z, Pelicano, H., Harris, D.,Frolova O., Hail, N., Chen W., Kornblau, SM, Huang, P., Lu, Y., Mills G.B., Andreeff, M., Konopleva M., 2006 Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small- molecular KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia Cancer Research 66:3737-3746
237. Ding, Z., Liang, J, Lu, Y., Yu, Q., Songyang Z., Lin, S-Y. Mills G.B. 2006 ACTN4 Regulates AKT1 Function: A Retrovirus-Based Protein Mammalian Complementation Assay Screen Reveals Novel AKT1 Binding Partners Proc. Natl. Acad Sci 103:15014-19
238. Baker, D.L., Fujiwara, Y., Pigg, K.R., Tsukahara, R., Kobayashi, S., Uchiyama, A., Murakami- Murofushi, K., Koh, E., Bandle, R.W., Byun H-S., Bittman R., Fan, D., Murph, M., Mills G.B., Tigyi G., 2006 Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer invasion and metastases. J Biol Chem. 281:22786-9
239. Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR. 2006 Phosphorylation of TNF-a converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci 103:6901-6
240. Li, X., Lu, Y., Jin, W, Liang, K. Mills, G.B., Fan Z., 2006 Autophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity J. Biol Chem. 281:13837-43
241. Koul D., Shen, R., Bergh, S., Sheng, X., Shishodia, S, Lafortune, T.A., Lu, Y., De Groot, J. F., Mills G.B., Yung, WKA 2006 Inhibition of AKT survival pathway by a small-molecule inhibitor in human glioblastoma Mol Cancer Ther. 5:637-44
242. Liang K., Lu, Y., Li, X., Zeng, X. Glazer R.I., Mills, G.B., Fan Z., 2006 Differential roles of phosphoinositide-dependent protein kinase-1 and AKT1 expression and phosphorylation in breast cancer cell resistance to paclitaxel, doxorubicin and gemcitabine Mol Pharm 70:1045-52
243. Rai, R., Dai, H., Multani, A.S., Li, K, Lahad, J.P., Liang J., Mills G.B., Meric-Bernstam, F., and Lin S-Y. 2006 BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell: 10:145-57
244. Almeida, J.S., Chen C., Gorlitsky, R., Stanislaus R., Sires-de-Sousa, M., Eleuterio P., Carrico J., Maretzek, A., Gohn, A., Chang, A., Zhang F., Mitra R., Mills G.B., Wang, X., Deus, H.F., 2006 Data integration gets ‘Sloppy’ Nature Biotechnol. 24:1070-1071
245. Tibes, R., Qiu Y., Lu Y., Hennessy B., Mills G.B., and Kornblau S.M. 2006 Reverse Phase Protein Array (RPPA): Validation of a Novel Proteomic Technology and Utility for Analysis of Primary Leukemia Specimens and Hematopoetic Stem Cells (HSC) Mol Cancer Therapeutics 5:2512-21
246. Acconcia, F., Manavathi, B., Mascarenhas, J., Talukder, A.H. Mills G, and Kumar R., 2006 A role of integrin-linked kinase-estrogen receptor-alpha interaction in cell migration Cancer Res. 66:11030-11038
247. Ping B., He, X., Xia W., Lee D.F., Wei, Y., Yu, D., Mills G. Shi D., and Hung MC 2006 Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers Int J Oncol. 29:1103-10
248. Yang G., Rosen D.G., Zhang Z., Bast R.C., Mills G.B., Colacino JA, Mercado Uribe, I, and Liu J., 2006 The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to senescence of stromal fibroblasts and ovarian tumorigenesis Proceedings Natl Acad Sci 103;16472-7
249. Yang G., Rosen D.G., Mercado-Uribe I., Colacinol, J.A., Mills G.B., Bast R.C., Zhou, C., and Liu J., 2006 Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells Carcinogenesis 28:174-82
250. Iwamaru, A., Kondo Y, Iwado, E., Aoki, H., Fujiwars, K., Yokoyama T., Mills G.B., and Kondo S. 2007, Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene: 26:1840-51
251. Nanjundan, M., Smith-McCune, K., and Mills G.B., 2007 Identification of a Novel Splice Variant of AML1B in Ovarian Cancer Patients Conferring Loss of Wild Type Tumor Suppressive Functions in an Ovarian Surface Epithelial Cell Line Oncogene: 26:2574-84
252. Badour, K., McGafin M.K.H., Zhang J., Freeman S., Dong B., Vieira C., Flip. D., Julius M., Mills G.B., and Siminovitch K.A., 2007 Interaction of the Wiskott-Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cells Proceeding of National Academy Science 104:1593-8
253. Liang J., Shao, S., Xu, Z., Hennessy, B., Ding Z., Larrea, M., Kondo S., Dumont D., Gutterman, JU, Walker CL, Slingerland, J.M., and Mills G. B., 2007 The energy sensing LKB1- AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis Nature Cell Biology 9:218-24
254. Nanjundan M., Nakayama Y, Cheng, K.W., Lahad J.P., Liu J., Lu, K.H., Kuo W-L., Smith- McCune, K., Fishman, D., Gray J.W., and Mills G.B., 2007 Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 Amplicon, is Associated with Favorable Patient Prognosis in Ovarian Cancer Cancer Research 67:3074-84
255. Tabe, Y, Jin L., Xu, Y., Tsutsumi-Ishii, Y., McQueen T., Priebe, W., Mills, G.B., Ohsaka A., Nagaoka, I and Andreeff, M. and Konopleva M., 2007 Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow stromal cells. Cancer Research 67:684-694
256. Younes, MN, Yigitbasi, OG, Yazici, YD., Jasser SA., Becana CD, El-Naggar AK, Mills GB, Myers JN, 2007 Effects of the Integrin-Linked Kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck Arch Ontolaryngol Head Neck Surg 133:15-23
257. Fang, D., Hawke, D., Zheng, Y., Xian Y., Miesenhelder, J., Nika, H., Mills GB, Kobayashi, R., Hunter, Lu Z., 2007 Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity J Biol. Chem 282:11221-9
258. Amit, I., Citri A., Shay T., Lu, Y., Katz M., Zhang F., Tarcic G., Siwak, D., Lahad J., Jacob- Hirsch J., Amariglio N., Vaisman N., Segal E., Rechavi G., Alon U., Mills G.B., Domany E., and Yarden Y., 2007 A module of negative feedback regulators defines growth factor signaling Nature Genetics: 39:503-12
259. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. 2007 Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Downregulation of MMAC1/PTEN and Upregulation of Phosphorylated Akt. Cancer Res 67:5779-5788
260. Chu, I., Arnaout, A., Loiseau, S., Sun J., Seth., A., McMahon, C., Chun, K., Hennessy, B., Mills, G.B., Slingerland JM 2007 Src promotes estrogen dependent ERa proteolysis in human breast cancer J Clin Invest. 117:2205-2215
261. Zhang, Q, Bhola, Nl., Liu, VWY, Siwak DR. Thomas, SM, Gubish, CT., Siegfried, JM., Mills GB., Shin D., Grandis JR., 2007, Anti-tumor mechanisms of combined GRPR and EGFR targeting in head and neck cancer Mol Cancer Therapeutics 6:1414-24
262. Aoki, H., Iwado, E., Eller M.S., Kondo, Y., Fujiwara, K., Li, G-Z, Hess K.R., Siwak D.R., Mills G.B., Gilchrest, B.A., and Kondo S., 2007 Telomere 3’ overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells FASEB J 21:2918-30
263. Estrella, V., Pustilnik, T., Claret, F.X., Gallick G.E., Mills G.B., and Wiener J.R., 2007 Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38 pathway. Int J. Cancer 31:441-449
264. Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z., Mills, G.B., Mendelsohn, J., Fan Z. 2007 Epidermal growth factor (EGF) receptor ubiquitination as a mechanism of acquired resistance to the anti-EGF receptor monoclonal antibody Cetuximab. Cancer Research 67:8240-7
265. Fujiwara K, Iwado E, Mills GB, Sawaya R, Kondo S, Kondo Y. 2007 Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol. 31:753-60
266. Hu, J., He, X., Baggerly, K.A., Coombes, K.R., Hennessy, B.T. and Mills G.B., 2007 Nonparametric quantification of protein lysate arrays Bioinformatics 23:1986-94
267. Xu, Z-X., Liang, J., Haridas, V., Gaikwad, A., Mills, G.B., Hanausek, M., and Gutterman, J.U., 2007 A plant triterpinoid induces tumor cell autophagy by activation of AMPK. Cell Death and Differentiation 14:1948-1957
268. Lu, C.-H., Wyszomierski, S.L., Sun, M.H., Lan, K.-H. Neal, C., Mills, G.B., Esteva, F.J., and Yu D., 2007 Preclinical Testing Of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency, Clin. Can. Res., 13:5883-8
269. Hennessy B.T., Lu Y., Poradosu, E., Yu, Q, Yu, S., Hall, H., Carey MS., Ravoori M., Gonzalez- Angulo AM Birch R, Henderson IC, Kundra V., Mills G.B., 2007 Pharmacodynamic markers of perifosine efficacy. Clinical Cancer Research 13:7421-31
270. Berns K., Horlings, H., Hennessy, B., Madiredjo, M., Hijmans, E.M., Beelen K., Linn Stemke-Hale K., S.C., Hauptmann, M., Beijersbergen R.L., Mills G.B., van de Vijver, M.J., and Bernards R., 2007 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12:395-402
271. Guan Y., Kuo WL., Stillwell, J., Takano H., Lapuk A., Fridlyand J., Mao, JH, Yu, M., Miller MA, Santos JL, Kolloger SE, Carlson JW, Ginzinger, Celniker, SE., Huntsman, DG., Mills GB., Gray JW., 2007 Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer Clinical Cancer Research 13:5745-5
272. Caswell, P.T., Spence, H.J., Parsons, M., White D.P., Clark K., Cheng, K.W., Mills G.B., Humphries, MJ., Messent, AJ, Anderson KI, McCaffrey, M.W., Ozanne, B.W., and Norman J.C. 2007 Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments Developmental Cell 13:496-510
273. Gajewiak, J., Tsukahara, R., Tsukahara, T., Yu, S., Lu, Y., Murph, M., **Mills,** G.B., Tigyi, G., and Prestwich, G.D., 2007 Alkoxymethylenephosphonate Analogues of (Lyso)phosphatidic acid Stimulate Signaling Networks Coupled to the LPA2 Receptor ChemMedChem: 2:1789-179
274. Garlich, J.R., De. P., Dey, N., Su., Peng X., Miller, A., Murali R., Lu Y., Mills G.B., Kundra V.,Shu, H-K., Peng, Q., Durden D.L., 2008. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity Cancer Res 68:206-15. PMID:18172313
275. Muller, M., Obeyesekere, M., Mills G.B., and Ram P.T. 2008 Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bi-fan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. FASEB J 22:1393-403 PMID:18171696
276. Yang, J-Y., Zong, C., Xia, W., Yamaguchi H., Ding, Q., Xie, X., Lang, J., Lai, C., Chang C., Huang, W., Huang H., Kuo, H., Lee., D., Li L., Lien, H., Cheng, X., Chang, K., Hsiao, C., Tsai F., Tsia. C., Sahin, A., Muller W. Mills, G.B., Yu, D., Hortobagyi. G., and Hung MC. 2008 ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation Nature Cell Biol: 10:138-48 PMID:18204439 PMC2376808
277. Wei Y., Xia, W., Zhang, Z., Liu J., Wang, H., Adsay, N.W., Albarracin, C., Yu, D., Abbruzzese JL., Mills, G.B., Bast R.C., Hortobagyi, G.N., and Hung, M-C 2008 Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian and pancreatic cancers. Molecular Carcinogenesis: 47:701-70. PMID:18176935 PMC2580832
278. Astanehe, A., Arenillas, D., Wasserman, W.W., Leung, PC., Dunn SE Davies, B.R., Mills G.B., Auersperg N. 2008 Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Science: 121:664-74. PMID:18270270
279. Liu S, Fang X, Hall H, Yu S, Smith D, Lu Z, Fang D, Liu J, Stephens LC, Woodgett JR, Mills GB. 2008. Homozygous deletion of glycogen synthase kinase 3 beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A 105: 5248-53. PMID:18367674 PMC2278194
280. Amos, C.I., Xu, X., Broderick, P., Gorlov I. P., Gu, J., Eisen, T., Dong Q., Zhang Q., Gu, X., Vijayakrishnan, J., Sullivan K., Matakidou A, Wang Y., Mills G., Shete S., Spitz M., and Houlston 2008, A genome-wide association scan of tag SNPs identifies a sysceptibility locus for lung cancer at 15q25.1 Nature Genetics: 40:616-22 PMID:18385676 PMC2713680
281. Zhu, Q.-S., Ren W., Korchin B., Lahat, G., Dicker, A., Lu, Y., Mills G.B., Pollock R.E., and Lev D., 2008 Soft tissue sarcoma are highly sensitive to AKT blockade: A role for p53 independent up-regulation of GADD45 alpha Cancer Research 68:2895-903. PMID:18413758 PMC4174465
282. Shafee, N., Smith, C.R., Wei S., Kim Y, Mills G.B., Hortobagyi, G.N., Stanbridge, E.J., and Lee EY, 2008 Cancer stem cells contribute to cisplatin-resistance in Brca1/p53-mediated mammary tumor Cancer Research 68:3243-50 PMID:18451150 PMC2929908
283. Ji, Y., Lu, Y., and Mills G.B., 2008 Bayesian models based on test statistics for multiple hypothesis testing problems Bioinformatics 24:943-9 PMID:18245123
284. Murph M., Nguyen, G., Radhakrishna, H., and Mills GB 2008 Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. Biochem Biophsy Acta 1781:547-57 PMID:18501205 PMC2565514
285. Aoki H., Kondo, Y., Aldape, K., Yamamoto, A., Iwado, E., Yokoyama, T., Hollingsworkth, E. F., Kobayashi R., Hess, K.R., Shinojima N., Shinju T., Tamada, Y., Zhang l., Conrad, C.A., Bogler, O, Mills G. B., Sawaya, R., and Kondo K., 2008 Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3 Autophagy: 4:467-75 PMID:18259115
286. Stemke-Hale, K., Gonzalez-Angulo, A.M., Lluch, A., Neve RM, Kuo WL, Davies, M., Carey M., HuZ., Guan Y., Sahin A., Symmans, WF., Pusztai, L., Nolden, L.K. Horlings H., Berns K., Hung MC., van de Vijver M.J., Valero, V., Gray JW., Bernards, R., Mills G.B., and Hennessy BT 2008 An integrative analysis of PIK3CA, PTEN and AKT mutations in breast cancer Cancer Res. 68:6084-91 PMID:18676830 PMC2680495
287. Raphael, BJ., Volik S., Yu, P., Wu C., Huang G., Linardopoulou, E., Trask B., Walman R., Costello, J., Pienta K., Mills G.B., Bajsarowicz, Kobayashi, Y., Sridharan S., Paris, P., Tao, Q., Aerni S., Brown R.P., Bahir, A., Gray J.W., Cheng J., de Jong, P., Nefedov M., Ried T., Padilla- Nash H., Collins C. 2008 A sequence-based survey of the complex structural organization of tumor genomes Genome Biology 9:R59 PMID:18364049 PMC2397511
288. Grote, T., Siwak, DR., Fritsche H., Joy C., Mills G.B., Simeone D., Whitcomb D.C., and Logsdon C.D., 2008 Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 8:3051-3060 PMID:18615426 PMC2992687
289. Nanjundan, M., Cheng, K.W., Zhang F.X., Xu, Z-Z, Schmandt, R., Smith-McCune, K., Gray J.W. and Mills G.B. 2008 Overexpression of SnoN/SkiL amplified at the 3q26.2 locus in ovarian cancers, induces growth arrest and senescence in ovarian epithelial cells Molecular Oncology 2:164-181 PMID:19383336 PMC2598416
290. Lambert LA., Qiao, N., Hunt, K.H., Lambert D.H., Mills G.B., Meijer L., and Keyomarsi K., 2008 Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model Cancer Research: 68:7966-74 PMID:18829554 PMC2561224
291. Yu, S., Murph M.M., Lu, Y., Liu S., Hall, H.S, Liu J., Stephens C., Fang, X., Mills G.B., 2008 Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. Journal of the National Cancer Institute 100:1630-1642. PMID:19001604 PMC2720766
292. Davies, M.A., Stemke-Hale, K., Tellez, C., Calderone T., Prieto, V., Lazar, A., Gershenwald, J., and Mills G.B., 2008 A novel AKT3 mutation in melanoma tumors and cell lines British Journal of Cancer 68:7966-74 PMID:18813315 PMC2570525
293. Mossesson, Y., Mills G.B., and Yarden 2008 Derailed endocytosis: Derailed endocytosis: an emerging feature of cancer Nature Reviews Cancer 8:835-5 PMID:18948996
294. Short, JD., Houston, KD., Dere, R., Cai, SL, Kim J., Johnson C.L Broaddus RR., Shen J., Miyamoto, S., Tamanoi F., Kwiatkowski, D., Mills G.B., and Walker C.L., 2008 AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27 Cancer Research: 68:6496- 506. PMID:18701472 PMC3011867
295. Yokoyama, T., Iwado, E., Kondo, Y., Aoki, H., Hayashi, Y., Georgescu MM, Sawaya, R., Hess, K.R., Mills G.B., Kawamur, H., Hashimoto Y., Urata, Y., Fujiwara T., and Kondo S., 2008 Autophagy-inducing agents augment the antitumor effect of telomerase-selective oncolytic adenovirus OBP-405 on glioblastoma cells Gene Ther. 15:1233-9. PMID:18580968
296. Hasegawa, Y., Murph, M., Yu S., Tigyi G., Mills GB. 2008 Lysophosphatidic acid (LPA)- induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells Mol. Oncol. 2:54-69 PMID:19081821 PMC2597858
297. Lu, Z., Luo R.Z., Lu, Y., Zhang, X., Yu, Q., Khare S., Kondo S., Kondo Y., Yu, Y., Mills G.B., Liao W., Bast, R.C., 2008 The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells J Clin Invest 118:3917-29 PMID:19033662 PMC2582930
298. Stanislaus, R., Carey, M., Dues H.F., Coombes, K., Hennessy B.T., Mills GB., Almeida JS., 2008. RPPAML/RIMS: A meta data format and an information management system for Reverse Phase Protein Arrays BMC Bioinformatics 9:555-959 PMID:19102773 PMC2639439
299. Freire, P., Vilela M., Deus, H., Kim Y-W., Koul D., Colman, H., Aldape, K.D., Bogler O., Yung WKA., Coombes, K., Mills G.B., Vasconcelos AT., Almeida JS., 2008, Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLOS One 3:e4076-4079 PMID:19115005 PMC2605252
300. Kim, W-Y, Chang, D.J., Hennessy B., Kang, HJ., Yoo J., Han S-H., Park HJ., Geo SY, Mills G.B., Kim K-W., Hong WK., Suh Y-G., and Lee. H-Y 2008 Development of novel derivatives of a natural anticancer drug, Deguelin, using reverse phase protein array (RPPA) Cancer Prev. Res 1:577-87. PMID:19139008 PMC2738643
301. Kornblau S.M., Tibes, R., Qui, Y., Chen, W., Kantarjian H., Andreeff, M., Coombes, K., Mills G.B., 2009 Functional proteomic prolifing of AML predicts response and survival Blood 113:154-64 PMID:18840713 PMC2951831
302. Blando J., Portis, M., Benavides, F., Alexander, A., Mills G.B., Dave, B., Conti C.J., Kim, J., and Walker C. L. 2009 PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR dependent growth Am J Pathol. 174:1869-79. PMID:19395652 PMC2671275
303. Lai SY, Koppikar, P. Thomas SM., Childs EE., Egloff, AM., Seethala, RR., Branstetter, BF. Gooding WE., Siwak DR., Muthukrishnan, A., Mountz JM., Lui, VWY., Shin DM., Agarwala SS., Johnson R., Couture LA., Myers EN., Johnson JT., Mills G., Argiris., A., and Grandis JR., 2009 Intratumoral Epidermal growth factor receptor antisense DNA therapy in head and neck cancer: First human application and potential antitumor mechanisms. J Clin Onc 27:1235-42 PMID:19204206 PMC2667824
304. Yim E-Y, Peng G, Dai H, Hu R, Li K, Lu Y, Mills G, Meric-Bernstam F, Hennessy B, Craven R, Lin, S-Y. 2009. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15:304-315 PMID:19345329 PMC2673492
305. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM. 2009 Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3 kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Research 69:565-7 PMID:19147570 PMC2737189
306. Ihle, N., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., Mills G.B., Dent, P., Kirkpatrick, D.L., and Powis G., 2009 Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Research 69:143-50 PMID:19117997 PMC2613546
307. O’Reilly K., Warycha, M., Davies, M., Rodrik, V., Zhou K., Yee, H., Pavlick AC., Rosen N., Bhardwaj N., Mills G.B., Osman I. 2009 Phosphorylated 4E-BP1 is associated with poor survival in melanoma Clin Cancer Research 15:2872-8 PMID:19336517 PMC3995540
308. Gonzalez-Angulo A.M., Stemke-Hale, K., Palla S.L., Carey M., Agarwal, R., Meric-Bernstam F., Traina TA., Hudis C., Hortobagyi G.N., Gerald W.L., Mills G.B., and Hennessy B.T., 2009 Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer Clin Cancer Res. 15:2472-8 PMID:19276248
309. Chen Y., Guggisberg, N., Jorda, M., Gonzalez-Angulo AM., Hennessy, B., Mills G.B., Tan, C-K., and Slingerland J.M., 2009 Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors Clinical Cancer Research 15:3396-405 PMID:19451593
310. Pamuklar, Z., Federico, L., Liu S., Umezu-Goto, M. Dong A., Panchatcharam, M., Fulkerson Z. Berdyshev E., Natarajan B., Fang F., Van Meeteren L., Moolenaar W., Mills GB., Morris A.J., and Smyth S.S. 2009 Autotaxin/lysophospholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis J. Biol Chem 284:7385-94 PMID:19139100 PMC2652269
311. Wang, Y., Carlton, VE., Karlin-Neumann, G., Sapolsky, R., Zhang L., Moorhead, M, Wang, C.Z, Richardson, A.L., Warren, R., Walther, A., Bondy, M., Krahe, R., Tuna M., Thompson P., Spellman P.T., Gray, JW., Mills G.B., and Faham M., 2009 High quality copy number and genotype data from FFPE samples using molecular inversion probes (MIP). BMC Genomics 2:8 PMID:19228381 PMC2649948
312. Nikolova, DA, Asangani, IA., Nelson LD., Hughes, DPM., Siwak, D., Mills GB, Harms A., Buchholz E., Pilz, L, Mandgold, C., Allgayer, H., 2009 Cetuximab attenuates invasion, metatstasis and u-PAR gene exprein in non-small-cell lung cancer (NSCLC): u-PAR and E-cadherin are novel biomarkers of Cetuximab sensitivity. Cancer Research 69:2461-70 PMID:19276367
313. Zhang, L., Wei Q., Mao, L, Liu W., Mills G.B., and Coombes K., 2009 Serial dilution curve: a new method for analysis of reverse protein array data Bioinformatics 25:650-4 PMID:19176552 PMC2647837
314. Zou CY, Smith KD., Zhu QS, Liu J., McCutcheon, IE., Slopis, JM., Meric-Bernstam, F., Bornmann, WG., Mills GB., Lazar AJ., Pollock RE., and Lev D., 2009 Dual targeting of AKT and mTOR: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Can Ther 8:1-12 PMID:19417153
315. Zinner RG., Barrett BL., Popova E., Damien P., Volgin AY., Gelovani JG., Lotan R., Tran HT., Pisano C., Mills GB., Mao L., Hong WK., Lippman SM., Miller JH 2009 Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Molecular Cancer Therapeutics 8:521-32 PMID:19276160
316. Hennessy B.T., Gonzalez-Angulo, Stemke-Hale K., Gilcrease M.Z., Krishnamurthy, S., Lee, J-S., Fridlyand, J., Sahin A., Joy C., Liu W., Stivers, D., Baggerly, K., Carey M., Lluch, A., Monteagudo, C., He, X., Weigman, V., Fan, C., Palazzo, J., Hortobagyi, G.N., Nolden L.K., Wang N.J., Valero, V., Gray J.W., Perou, C.M., Mills G.B., 2009 Characterization of a naturally occurring breast cancer subset enriched in EMT and stem cell characteristics. Cancer Research 69:4116-24 PMID:19435916 PMC2737191
317. Liu, S., Umezu-Goto M., Murph M., Lu Y., Liu W., Zhang F., Yu., S., Stephens, C., Cui X., Murrow, G., Coombes K, Muller, W., Hung, MC., Perou C.M., Lee A., Fang X., Mills G.B., 2009 Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion and metastases Cancer Cell 15:539-50 PMID:19477432 PMC4157573
318. Miller T., Perez-Torres, M., Narasanna, A., Guix, A., Stal, O., Perez-Tenorio, G., Gonzalez- Angulo A., Hennessy, B., Mills G.B., Kennedy, J., Lindsley C., Arteaga 2009 Loss of Phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor 1 receptor signaling to promote antiestrogen resistance in breast cancer Cancer Research 69:4192-201 PMID:19435893 PMC2724871
319. Vasudevan K, Barbie, D., Davies M. Rabinovsky, R., McNear CJ., Kim JJ., Hennessy B.T., Tseng, H., Pochanard P., Kim SY., Dunn I., Schinzel, A., Sandy P., Hoersch, S., Sheng, Q., Gupta, P.,, Boehm, J., Reiling J.H., Silver S, Lu Y., Stemke-Hale K., Dutta B., Joy C., Sahin, A., Gonzalez-Angulo A., Lluch A., Rameh LE., Jacks T., Root DE., Lander E.S., Mills G.B., Hahn, W.C., Sellers W.R., Garraway LA. 2009 Akt-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16:21-32 PMID:19573809 PMC2752826
320. Li, T., Alemayehu, M., Aziziyeh, A., Pape C., Pampillo M., Mills G.B., Babway A., Bhattacharya M. 2009 β-arrestin/Ral signalling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells Molecular Cancer Research 7:1064-77 PMID:19609003
321. Murph, M., Liu W., Yu S., Lu, Y., Hall, H., Hennessy, B., Lahad, J., Schaner, M., Helland A., Kristensen G., Borresen-Dale A-L., Mills G.B., 2009 Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis in patient datasets. Plos One 4:5583 PMID:19440550 PMC2679144
322. Bast R.C., Hennessy B., and Mills G.B., 2009 The biology of ovarian cancer: New opportunities for translation Nature Cancer Reviews 9:415-426 PMID:19461667 PMC2814299
323. Dillon R., Marcotte, R., Hennessy, B., Woodgett, J.R., Mills G.B., and Muller W.J. 2009 Akt1 and Akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Research 69:5057-64 PMID:19491266 PMC4151524
324. Maurer, M., Su T., Koujak, S, Hopkins B.D., Saal L.H., Barkley CR., Wu, J., Nandula, S., Dutta, B., Xie Y., Chin YR., Kim D\_I., Ferris, J.S., Gruvberger-Saal, SK., Laakso. M., Wang, X., Memeo, L., Rojtman A., Matos T., Yu. J.S., Cordon-Cardo C., Isola J., Terry M.B., Toker A., Landry D.W., Mills, G.B, Zhao J.J., Murty VVS., Hibshooosh, H., and Parsons. R., 2009 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Research 69:6299-306 PMID:19602588 PMC2727605
325. Wu X., Ye, Y., Kiemeney, LA., Sulem P., Rafnar T., Matullo G., Andrew AS, Dinney CP., Czerniak, B., Zhang ZF., Kiltie AE., Bishop DT., Vineis P., Porru S., Buntix F., Kellen E., Zeegers MP., Kumar R., Rudnai P., Gurzau E., Koppova K., Mayordomo JI., Sanchez, M., Saez B., Lindblom A., de Verdier P., Steineck G., Mills G.B., Schned A., Chang S-C., Lin J., Hale K.S., Majewski T., Grossman H.B., Thorlaciu S., Thorsteinsdottir U., Aben K.., Witjes JA., Saeki N., Joshida T., Stefansson K., Amos CI., Karagas M.R., Gu J., 2009 Genetic variation in the prostate stem cell antigen PSCA gene confers susceptibility to urinary bladder cancer Nature Genetics 41:991-5 PMID:19648920 PMC3313685
326. Woodman, SE., Trent JC., Stemke-Hale K., Lazer, A., Pricl, S., Pavan G.M., Fermeglia M., Gopal YN., Yang D., Podoloff DA. Ivan D., Kim KB., Papadopoulos N., Hwu, P., Mills G.B., Davies M.A., 2009 Activity of dasatinib against L576P Kit melanoma: molecular, cellular and clinical correlates Mol Cell Ther 8:2079-85 PMID:19671763 PMC3346953
327. Agarwal, R, Gonzalez-Angulo, AM, Myhre, S., Carey, M., Overgaard J., Alsner, J., Lluch, A., Neve, R.N., Kuo W.L., Sorlie, T., Sahin A., Valero V., Keyomarsi, K., Gray JW., Borresen-Dale A-L., Mills G.B., and Hennessy BT., 2009 Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer Clin Cancer Res 15:3654-62 PMID:19470724 PMC2887710
328. Davies MA., Stemke-Hale, K., Lin E., Tellex C., Deng W., Gopal YN., Woodman S., Calderone TC., Ju Z., Lazar AJ., Prieto V., Mills G.B., and Gershenwald JE., 2009 Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clinical Cancer Res. 15:7538-7546 PMID:19996208 PMC2805170
329. Byers LA., Sen B., Saigal B., Diao, L., Wang, J., Nanjundan M., Mills G.B., Heymach JV. and Johnson F.M., 2009 Reciprocal regulation of c-src and stat3 activation in non-small cell lung cancer Clin Cancer Res 15:6852-61 PMID:19861436 PMC2935176
330. Han, C.H., Wei Q., Lu K.K., Liu Z., Mills G.B., Wang L-E 2010 Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer Int J Clin Exp Med 2:289-99 PMID:20057973 PMC2802047
331. Hong B., Lui, V., Hui, E., Lu Y., Leung, H., Wong E., Cheng A., Ng M., Mills G.B., Chan, ATC., 2010 Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1 in nasopharyngeal carcinoma (NPC) Biochemical Pharmacology 79: 842-852. PMID:19879857
332. Spizzo, R., Nicoloso, M.S, Lupin L., Lu, Y., Fogarty, J., Rossi S., Zagatti, B., Fabbri M., Veronese, A., Davuluri R., Croce C., Mills G.B., Negrini M., Calin, G.A., 2010 miR-145-TP53 loop regulates estrogen receptor alpha in human breast cancer. Cell Death and Differentiation 17:246-54 PMID:19730444 PMC3648637
333. Zheng, J., Mercado-Uribe, I., Rosen D.G., Liu P., Yang G., Malpica A., Naora, H., Auersperg, N., Mills G.B., Bast, R.C., and Liu, J., 2010 Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.Cell Cycle 9:140-146 PMID:20016289 PMC2931318
334. Tsavachidou-Fenner, D., Tannir, N., Tamboli P., Liu W., Petillo D., Teh B., Mills G.B., Jonasch E 2010 Gene and protein expression markers of response to combined anti-angiogenic and epidermal growth factor targeted therapy in renal cell carcinoma Anals of Oncology 21:1599- 606 PMID:20089566 PMC4092253
335. Amos CI., Gorlov IP., Dong Q., Wu X., Zhang H., Lu E., Scheet P., Greisinger A., Mills GB., Spitz MR., 2010 The Nicotinic Acetylcholine Receptor region on chromosome 15q25 and lung cancer risk in African-Americans: A case control study J. Natl Cancer Inst 102:1199-20 PMID:20554942 PMC2914761
336. Park E-S., Rabnovsky, R., Carey M., Hennessy B.T., Agarwal R., Liu W., Ju, Z., Deng W., Lu Y., Woo H-G., Kim S-B., Cheong J-H., Garraway LA., Mills G.B., Lee J-S., Davies M. 2010 Integrative analysis of proteomic signatures, mutations and drug responsiveness in the NCI 60 cancer cell line set Mol Can Ther 9:257-67 PMID:20124458 PMC4085051
337. Mazzone M., Selfors, L.M., Overholtzer M., Sale, S., Carroll D.L., Pandya D., Lu Y., Mills G.B., Artavanis-Tsakonas S., and Brugge J.S., 2010 Dose-dependent regulation of matrix adhesion and proliferation that controls phenotypic responses to notch pathway activation Proc Natl Acad Sciences 107:5012-7 PMID:20194747 PMC2841923
338. Alexander A., Cai S-L., Kim J., Nanez A., Sahin M., Mclean K., Inoki K., Guan K-L., Shen JJ., Person M., Kusewitt D., Mills G.B., Kasten MB., Walker CL., 2010 ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS Proc. Natl. Acad Sci 107:4153-8 PMID:20160076 PMC2840158
339. Short JD., Dere R., Houston K.D., Cai. S-L, Kim J., Bergeron, J.M., Shen J., Liang J., Beford., MT., Mills G.B., and Walker CL, 2010 AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability Mol Carcinogenesis 49:429-39 PMID:20146253 PMC3818129
340. Pontier SM., Huck L., White D.E., Rayment J., Sanguin-Gendreau V., Hennessy, B., Zuo, D.M., St. Arnaud, R., Mills G.B., Dedhar S., Marshall CJ and Muller W.J., 2010 Integrin-linked kinase (ILK) has a critical role in ErbB2 mammary tumor progression: Implications for human breast cancer Oncogene 29:3374-85 PMID: 20305688
341. Ding Z., Liang, J., Li, J., Lu, Y., Ariyaratna V., Lu, Z., Davies M., Westwich JK and Mills G.B., 2010 Physical association of PDK1 with AKT is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase (PI3K) PLOS ONE 5:39910 PMID:20361045 PMC2845649
342. Lu ZH, Shvartsman MB., Lee AY., Shao JM., Murray MM., Kladney RD., Fan D., Krajewski S., Fan D., Chiang GG., Mills GB., and Arbeit JM. 2010 Mammalian target of rapamycin activator Rheb is frequently overexpressed in human carinomas and is critical and sufficient for skin epithelial carcinogenesis Can Res. 70:3287-98 PMID:20388784 PMC2855737
343. Hennessy BT., Timms K., Carey MS., Gutin A, Meyer LA., Flake D., Abkevich V., Potter J., Pruss D., Glenn P., Li L., Li J., McCune KS., Gonzalez-Angulo, A, Markman M., Broaddus R., Lanchbury, J., Lu KH., Mills G.B., 2010 Somatic mutations in BRCA1 and BRCA2 are common in ovarian cancer J. Clin Onc. 28:3570-6 PMID:20606085 PMC2917312
344. Carey MS., Agarwal R., Gilks B., Swenerton, K., Kalloger S., Santos J., Ju, Z., Lu Y., Zhang F., Coombes K., Miller D., Huntsman D., Mills GB., and Hennessy BT., 2010 Functional proteomics analysis of advanced serous ovarian cancer using reverse phase protein array: TGFb pathway signaling indicates response to primary chemotherapy Clinical Cancer Research 16:2852-60 PMID:20460476 PMC2877659
345. Miller TW., Hennessy BT., Gonzalez-Angulo AM., Fox EM., Mills GB., Chen H., Highan C., Garcia-Echevarria, Shyr Y., Arteaga CL., 2010 Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer J Clin Invest. 120:2406-13 PMID:20530877 PMC2898598
346. Smith D., Haller D., Raffoul F., Patel S., Mills G.B., and Nanjundan, M., 2010 Arsenic trioxide induces a Beclin-1 independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian cancer Cell Death and Differentiation 17:1867-81 PMID:20508647 PMC2932795
347. Yang G., Chang B., Yang F., Cai KQ., Mercado-Uribe I., Xiao S, Wang H., Sen S., Hung M.C., Mills G.B., Chang S., Multani AS., and Liu J., 2010 Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clinical Cancer Research 16:3171-81 PMID:20423983 PMC2930838
348. Altman, MK., Gopal V., Jia W., Yu. S., Hall H., Mills GB., McGinnis AC, Bartlett MG., Jiang G., Madan, Prestwich G., Xu Y., Davies MA., Murph MM., 2010 Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothioate analogue of carba cyclic phosphatidic acid Molecular Cancer 9:140 PMID:20529378 PMC2895597
349. Loi, S., Haibe-Kains B., Lallemand, F., Durbecq, V., Larsimont D, Gonzalez-Angulo A., Pustzai, L., Symmans WF., Bardelli A., Ellis P., Tutt, A., Gillett, C., Hennessy B., Mills G.B., Phillips W., Piccart M., Speed T., McArthur G., Sotirou C., 2010, PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor positive breast cancer Proc Natl Acad Sci 107:10208-13 PMID:20479250 PMC2890442
350. Yang G., Rosen DG., Liu G., Yang F., Guo X., Xiao X., Mercado-Uribe, I., Huang J., Lin S-H., Mills G.B., and Liu J., 2010 CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis Clin Cancer Research 16:3875- 86 PMID:20505188 PMC2930833
351. Irie HY, Shrestha Y., Selfors L., Iida N., Wang, Z., Zou L., Yao J., Lu Y., Richardson, A., Polyak K., Mills G.B., Hahn W., and Brugge J., 2010 PTK6 regulates IGF-1 dependent anchorage- independent survival of breast and ovarian cancer cells PLoS One. 5:e11729. PMID: 20668531 PMC2909213
352. Cai D., Shames D.S., Raso G., Xie, Y., Kim YH, Pollack J, Girard L., Sullivan JP., Gao B., Peyton M., Nanjundan M., Heymach J., Mills G.B., Wistuba, I., Kodadek TJ., and Minna GD., 2010 Steroid receptor co-activator 3 (SRC-3) expression in lung cancer and its role in regulating cancer cell survival and proliferation Can Res. 70:6477-85 PMID:20663904 PMC2922434
353. Deus HF., Veiga DF., Freire PR., Weinstein J.N., Mills G.B., Almeida JS. 2010 Exposing the cancer genome atlas as a SPARQL endpoint. J Biomedical Informatics 43:998-1008 PMID:20851208 PMC3071752
354. Iadevaia, S., Lu, Y., Morales F.C., Mills G.B., and Ram PT 2010 Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis Cancer Research 70:6704-14 PMID:20643779 PMC2932856
355. Creighton CJ., Fu, X., Hennessy B., Casa A., Zhang Y., Gonzalez-Angulo A., Lluch A, Gray JW., Brown PH., Hilsenbeck SG., Osborne CK., Mills GB., Lee AV., and Schiff R., 2010 Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen receptor (ER) levels and activity in ER+ breast cancer Breast Cancer Research 12:R40 PMID:20569503 PMC2917035
356. Nanjundan M., Byers LA., Carey M., Siwak D., Raso M., Diao, L, Wang J., Coombes K., Mills G.B., Wistuba, I., Minna J. and Heymach JV., 2010 Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J. Thoracic Oncology 5:1894-904. PMID:21124077 PMC3374718
357. Cheng X, Xia W, Yang JY, Hsu JL, Lang J, Chou CK, Sun HL, Wyzomierski SL, Mills GB, Muller WJ, Yu, D, Hung MC. 2010 Activation of murine double minute 2 by Akt in Mammary Epithelium Delays Mammary Involution and Accelerates Mammary Tumorigenesis. Cancer Res 70:7684-9 PMID:20841468 PMC2948588
358. An, J., Wei, Q., Liu, Z., Lu, K.H., Cheng X., Mills, G.B., and Wang, L-E 2010 Messenger RNA expression and methylation of candidate tumor suppressor genes and risk of ovarian cancer-a case-control analysis Int J. Mol. Epidemiol Genet 1:1-10 PMID:20689651 PMC2916180
359. Liang K., Esteva F., Albarracin C., Stemke-Hale, K., Lu Y., Bianchini G., Yang CY., Li Y., Li X., Chen CT., Mills GB., Hortobagyi G, Mendelsohn J., Hung, M-C., Fan Z. 2010 Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via JAK2-mediated activation of src and inactivation of PTEN Cancer Cell: 18:423-35 PMID:21075308 PMC3022383
360. Luyimbazi, D., Akcakanat, A., Zhang, L., Singh G., Zheng, Y., Hung M-C., Mills G.B., Meric- Bernstam F., 2010 Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Can Ther: 9:2770-84 PMID:20876744 PMC2965451
361. Cheng X., Xian W., Yang JY., Hsu JL., Chou CK., Sun HL., Wyszomierski SL., Mills GB., Muller WJ., Yu D., Hung MC., 2010 Activation of p21/(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis Biochem Biophys Res Comm 403:103-7 PMID:21040707 PMC3001223
362. Gupte, R., Siddam A., Lu Y., Li W., Fujiwara, Y., Panupinthu N., Pham T-C., Baker D., Mills GB., Tigyi, G., and Miller DD. 2010 Synthesis and pharmacological evaluation of sterioiomers of 3-carba cyclic phosphatidic acid Bioorg Med Chem Lett 20:7525-8 PMID:21051230 PMC3040411
363. Hennessy, B., Lu, Y., Gonzalez-Angulo A. M., Myhre, S., Carey, M., Ju, Z., Coombes K., Liu, W., Meric-Bernstam F., Bedrosian I.,, Yu, Q., Yu., S., Siwak D., McGahren M., Li J., Sahin A., Overgaard J., Alsner J., Neve RM., Kuo W-L., Gray JW., Borresen-Dale A-L., Mills G.B., 2010 A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers Clinical Proteomics 6:129- 151 PMID:21691416 PMC3116520
364. Gonzalez-Angulo, AM., Hennessy BT., Meric-Bernstam F., Liu W., Ju Z., Sahin A., Carey MS., Myhre S., Speers C., Broaddus R., Lluch A., Aparicio, S., Brown P., Pusztai L., Symman WF., Alsner J., Overgaard J., Borresen-Dale A-L., Hortobagyi GN., Coombes KR., Mills GB., 2011 Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer Clinical Proteomics 6:129-51 PMID:21906370 PMC3170272
365. Han CH., Huang, YJ., Lu KH., Liu Z., Mills GB., Wei Q., and Wang L-E. 2011 Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. J Exp. Clin Can Res. 30:5 PMID: 21214932 PMC3025876
366. Zhu Q-S., Rosenblatt, K., Lahat G., Brobey R., Bolshakov S., Nguyen T., Lazar A., Dicker A., Mills G.B., Hung M-C., and Lev D., 2011 Vimentin is a novel AKT target mediating invasion and metastases Oncogene 30:457-70 PMID:20856200 PMC3010301
367. Lui VWY, Ho, K., Wong EYL., Ho K., Ng PKS, Lau CPY, Tsui SKW., Tang C-M., Tsao S-W., Cheng SH., NMHL, Hong B., Mok TSK., Chan TC and Mills G.B. 2011 Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death Oncogene 30:1127-34 PMID:21057531 PMC3428712
368. Suo J., Snider SJ., Mills GB., Creighton C., Schiff R., Lloyd RE., Chang EC., 2011 Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium Oncogene 30:724-36 PMID:20890303 PMC3017639
369. Park SY, Jeong KJ, Panupinthu N., Yu S., Lee J., Han JW., Kim JM., Lee JS., Kang JK., Park CG., Mills GB., Lee HY. 2011 Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression Oncogene 30:1351-9 PMID:21102517
370. Ghosh R., Narasanna A., Wang SE., Liu S., Balko JM., Gonzalez AM., Mills GB., Penuel E.., Winslow J., Sperinde J., Leitzel K., Kostler WJ., Lipton A., Bates M., and Arteaga CL., 2011, Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers Cancer Research 71:1871-1882 PMID:21324925 PMC3221734
371. Gonzalez-Angulo AM., Timms KM., Liu S., Chen H., Litton JK., Potter J., Lanchbury JS., Stemke-Hale K., Hennessy BT., Arun BK., Hortobagyi GN., Do KA., Mills GB., and Meric- Bernstam F., 2011 Incidence and outcome of BRCA mutation carriers with unselected triple receptor negative breast cancer Clin Can Res. 17:1082-9 PMID:21233401 PMC3048924
372. Gupte R., Patil R., Liu, J., Wang Y., Lee SC., Fujiwara Y., Fells J., Bolen AL., Emmons- Thompson, Yates R., Siddam A, Panupinthu N., Pham T., Baker DL., Parrill AL., Mills GB., Tigyi G., and Miller DD., 2011 Benzyl and Napthalene-methyl phosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic actions. ChemMedChem 6:922-35 PMID:21465666 PMC3517046
373. Park ES., Kim SJ., Kim SB., Woo HG., Kim SM., Park YY, Mills G.B., Fidler IJ., and Lee JS 2011 Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci 108:17456-61 PMID:21987811 PMC3198333
374. Kim SJ., Kim JS., Park ES., Lee JS., Lin Q., Langley RR., Mary M., He J., Kim SW., Weihua Z., Balasubramanian K., Fan D., Mills G.B., Hung MC., Fidler IJ. 2011 Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy Neoplasia 13:286-298 PMID:21390191 PMC3050871
375. Miller TW., Balko, JM., Ghazoui Z., Dunbier, A., Anderson H., Dowsett, M., Gonzalez-Angulo AM., Mills GB., Miller WR., Wu H., Shyr. Y., and Arteaga CL., 2011 A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance Clin Cancer Res 17:2024-2034 PMID:21346144 PMC3221728
376. Rexer, B., Ham A-J., Rinehard, C., Hill S., Granja-Ingram N., Gonzalex-Angulo A., Mills G.B., Dave B., Chang J., Liebler, DC., Arteaga, C., 2011 Phosphoproteomic mass spectroscopy profiling links src family kinases to escape from HER2 tyrosine kinase inhibitors Oncogene 30:4163-4174 PMID:21499296 PMC3204390
377. Lu Y., Muller M., Smith D., Dutta B., Komurov K., Iadevaia, S., Ruths D., Tseng J-T., Yu S., Yu Q., Nakhleh, L., Balazsi G., Donnelly J., Schurdak M., Morgan-Lappe S., Fesik S., Ram PT., Mills G.B., 2011 Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling Oncogene 30:4567-4577 PMID:21666717 PMC3175328
378. Cheung LWT., Hennessy BT., Lie J., Yu, S., Myers AP., Djordjevic B., Lu Y., Stemke-Hale K., Zhang F., Ju Z., Cantley LC., Scherer SE., Liang H., Lu KH., Broaddus RR., and Mills GB. 2011 High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discovery: 1:170-185 PMID:21984976 PMC3187555
379. Gonzalez-Angulo, AM., Ferrer-Lozano J., Stemke-Hale K., Sahin A., Liu S., Barrera JA., Burgues O., Lluc Am., Chen H., Hortobagyi, GN., Mills GB., Meric Bernstam F., 2011, PI3K pathway mutations and PTEN levels in primary and metastatic breast cancers Mol Can Ther 10:1093-101 PMID:21490305 PMC3112276
380. Zwang Y., Sas-Chen A., Drier Y., Shay T., Avraham R., Lauriola M., Shema E., Lidor-Nili E., Jacob-Hirsch J., Amariglio N., Lu Y., Mills G.B., Rechavi G., Oren M., Domany E., Yarden Y., 2011 Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals Molecular Cell 42:524-535 PMID:21596316 PMC3100487
381. Liu P., Cheng H., Santiago S., Raeder M., Lin H., Zhang F., Isabella A., Yang J., Semaan DJ., Chen C., Fox EA., Gray NS., Monahan J., Schlegel R., Roberts TM., Beroukhim R., Mills GB., Zhao JJ., 2011 Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and –independent mechanisms Nature Med 17:1116-20 PMID:21822287 PMC3169724
382. Valero V., Wingate H., Chada S., Liu Y., Palaloni F., Mills G., Keyomarsi K. and Hunt KK. 2011 MDA-7 results in downregulation of AKT comcomitant with apoptosis and cell cycle arrest in breast cancer cells Cancer Gene Therapy 18:510-9 PMID:21546925 PMC3875403
383. Stronach EA., Alfraidi, A., Rama N., Datler C., Studd J., Agarwal R., Guney TG., Courley, C., Timms K., Hennessy BT., Mills G.B., Mai A., Brown R., Dina R., Gabra H., 2011 HDAC4- regulated STAT1 activation mediates platimun resistance in ovarian cancer Cancer Research 71:4412-22 PMID:21571862 PMC3130134
384. Heiser LM., Sadanandam A., Kuo, W-L., Benz SC., Goldstein TC., Ng S., Gibb WJ., Want NJ., Ziyand S., Tong F., Bayani N., Hu Z., Billig JI., Dueregger A., Lewis S., Jakkula L., Korkola JE., Durinck S., Pepin F., Guan Y., Perdom E., Neuvial P., Bengsstom H., Wood KW., Smith PG., Vassilev L., Hennessy BT., Greshock JD., Bachman KE., Hardwicke MA., Park JW., Marton L., Wolf DW., Colisson EA. Neve RM., Mills GB., Speed TP., Feiler HS., Wooster RF., Haussler D., Stuart J., Gray JW., Spellman PT., 2011 Subtype and pathway specific responses to anti-cancer compounds in breast cancer. Proc. Natl. Acad. Sci 109:2724-9 PMID:22003129 PMC3286973
385. Claerhout, S., Lim JY., Choi W., Park YY., Kim K., Kim SB., Lee JS, Mills G.B., Cho JY., 2011 Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer PLOS One 6:e24662 PMID:21931799 PMC3170379
386. Miller TW., Fox EM., Balko JM., Ghazoui, Z., Dunbier A., Anderson H., Dowsett, M., Jiang A., Smith RA., Sanchez V., Maira S-M., Manning HC., Gonzalez-Angulo., AM., Mills GB., Highman C., Ye F., Miller WR., Shyr Y., and Arteaga CL., 2011 Era-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discovery 1: 338-351 PMID:22049316 PMC3204388
387. Brewster AM., Thompson P., Sahin AA., Do K., Egerton ME., Murray JL., Tsavachidis S., Zhou R., Liu Y., Zhang L., Mills GB., and Bondy M., 2011 Copy number imbalances between screen and symptom-detected breast cancers and impact on disease-free survival. Cancer Prevention Research 4:1609-16 PMID:21795423 PMC3188338
388. Thompson PA., Brewster A., Zhang L., Anh-Do K., Baladandayuthanapani V., Broom B., Edgerton M., Hahn KM., Murray JL, Sahin, A., Tsachavidis S., Wang Y., Zhang L., Hortobagyi G., Mills G.B., and Bondy M 2011 Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLOS One 6:e23543 PMID:21858162 PMC3155554
389. Hu, R., Peng G., Dai H., Breuer EK., Stemke-Hale K., Li K., Gonzalez-Angulo AM., Mills GB., Lin S-Y., 2011 ZNF688 functions as a tumor suppressor by regulating p53 protein stability and function in breast cancer Cancer Research 71:6524-34 PMID:21852383 PMC3193577
390. Nieman, KM., Kenny HA., Ladanyi A., Penicka C., Buell-Butbrod R., Zillhardt, MR., Carey MS., Mills GB., Yamada DS., Peter ME, Gwin K., and Lengyel E. 2011 Adipocytes promote ovarian cancer metatstasis and provide energy for rapid tumor growth. Nature Medicine 17:1498-503 PMID: 22037646 PMC4157349
391. Vaughan S., J., Bast R., Berchuck A., Berek J., Brenton J., Coukos G., Crum C., Drapkin R., Etemadmoghadam D., Friedlander M., Gabra H., Kaye S., Lord C., Lengyel E., Levine D., McNeish I., Menon U., Mills G., Nephew K., Oza A., Sood A., Stronach E., Walczak H., Bowtell D., and Balwkwill F., 2011 Rethinking ovarian cancer: Recommendations for improving outcomes. Nature Reviews Cancer 11:719-25 PMID: 21941283 PMC3380637
392. Fox EM., Miller TW., Balko JM., Kuba MG., Sanchez V., Smith RA., Liu S., Gonzalez-Angulo AM., Mills GB., Ye F., Shyr Y., Manning HC., Buck W., Arteaga CL., 2011 A kinome-widenscreen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Research 71:6773-6784 PMID:21908557 PMC3206206
393. Stronach, EA., Chen M., Maginn EM., Agarwal., R., Mills GB., Wasan H., and Gabra H., 2011 DNA-PK mediates AKT activation and apoptosis in clinical acquired platinum resistant ovarian cancer Neoplasia 13:1069-80 PMID:22131882 PMC3223610
394. Li J., Ding Z., Wang Z., Logothetis, Ca., Mills GB., and Kim J., 2011 Androgen regulation of 5a reductase isoenzymes in prostate cancer: implications for prostate cancer prevention Plos One 6: e28840. PMID:22194926 PMC3237548
395. Cheong J-H., Park ES., Liang J., Dennison JB., Tsavachidou D., Nguyen C., Cheng KW., Hall H., Zhang D., Lu Y., Ravoori M., Kundra V., Ajani J, Lee J-S., Hong WK., Mills GB., 2011 Dual inhibition of tumor energy pathway by 2-deoxy glucose and metformin is effective against a broad spectrum of preclinical cancer models Mol Can Ther 10:2350-62 PMID:21992792 PMC3237863
396. Pradeep, CR., Kostler, WJ., Zeisel A., Lauriola M., Granit R., Zhang F., Jacob-Hirsch, J., Rechavi G., Nair HB., Hennessy BT., Gonzalez-Angulo AM., Tekmal RR., Ben-Proath I., Mills GB., Domany E., and Yarden Y., 2012, Modelling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling Oncogene 31:907-17 PMID:21743488 PMC3193899
397. Cheng, H-Y., Dong A., Pancshatcharam, Mueller P., Yand F., Li Z., Mills G.B., Chun J., Morris AJ., and Smyth SS. 2012 Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling Arteriosclerosis, Thrombosis, and Vascular Biology 32:24-32 PMID:22015657 PMC3241874
398. Muranen T., Selfors, LM., Worster DT., Iwanicki M., Albeck JG., Morales F., Gao S., Mills GB and Brugge JS. 2012 Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21:227-39 PMID:22340595 PMC3297962
399. Djordjevic, B., Hennessy, B.T., Li, J., Barkoh, B.A., Luthra, R., Mills, G.B., Broaddus, R.R. 2012 Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry out-performs gene sequencing. Modern Pathol 25:699-708 PMID:22301702 PMC3341518
400. Mu H., Calderone TL., Davies MA., Prieto V., Wang H., Mills GB., Bar-Eli M., and Gershenwald J., 2012 Lysophosphatidic acid induced lymphangiognesis and interleukin-8 production in human lymphatic endothelial cells. Am J. Path 180:2170-81 PMID:22465753 PMC3349835
401. Cheng KW, Agarwal R., Mitra S., Lee J-S., Carey M., Gray J.W., and Mills G.B., 2012 Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress Embo Molecular Medicine 4:125-41 PMID:22253197 PMC3804249
402. Park YY., Kim K., Li J., Kim SB., Kim SM., Park ES., Lim JY., Hennessy B., Lu Y., Mills GB., Safe S., Lee JS. 2012 Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. Embo Mol Med 4:52-67 PMID:22174013 PMC3376834
403. Wang L-E., Ma H., Hale KS., Yin M., Meyer LA., Liu H., Li J., Lu KH., Hennessy BT., Li X., Spitz MR., Wei Q., Mills GB., 2012 Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes J Can Res. Clin Onc. 138:377-85 PMID:22146979 PMC3526101
404. Mitra R., Mueller P., Ji Y., Mills G., Lu Y., 2012 Sparse Bayesian Graphical Models for RPPA Time Course Data IEEE Int Workshop Genomic Signal Process Stat. 113-117. PMID: 25859417 PMC4387196
405. Meric-Bernstam F., and Mills GB 2012 Perspectives: Overcoming challenges to implementation of personalized cancer therapy Nature Reviews Clin Oncol 9:542-8 PMID:22850751
406. Worster, DT., Schmelzle, T., Solimini NL., Lightcap ES., Millard., Mills GB., Brugge JS., Albeck JG. 2012 Akt/ERK/p57 network controls the proliferative response of mammary epithelial cells to IGF-1 and EGF. Science Signaling 5:ra19 PMID:22394561 PMC4174537
407. Tarcic G., Avraham R., Ben-Chetrit, N., Amit, I., Shyi T., Lu Y., Zwang Y, Katz M., Jacob- Hirsch J., Virgilio L., Rechavi G., Mavrothalassitis G., Mills GB., Domany E., and Yarden Y., 2012 EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF Faseb Journal 26:1582-92. PMID:22198386 PMC3316897
408. Dutta, B., Pusztai. L., Qi Y., Andre F., Lazar, V., Bianchini, G., Ueno N., Agarwal R., Wang, B., Shiang CY., Hortobagyi G.N., Mills G.B., Symmans WF., and Balazsi G., 2012 A network- based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. British J Cancer 106:1107-16 PMID:22343619 PMC3304402
409. Ding Z., German P., Bai S., Feng Z., Gao M., Si W., Sobieski MM., Stepha CC., Mills GB., Jonasch E., 2012 Agents that Stabilize Mutated von Hippel Lindau Protein Result in Differential Post-Translational Modification and Subcellular Localization: Results of a High Throughput Screen to Identify Compounds that Modulate VHL Proteostasis J Biomol Screening: 17:572-80 PMID:22357874 PMC3895461
410. Gonzalez-Angulo AM., Iwamoto TI., Liu S., Chen H., Do K-A., Hortogagyi GN., Mills GB., Meric-Bernstam F., Symmans WF., and Pusztai L., 2012 Gene expression, molecular class changes and pathway analysis after neoadjuvant systemic therapy for breast cancer Clinical Cancer Research 18:1109-19 PMID:22235097 PMC3288822
411. Gubanova E., Brown B., Ivanov SV., Helleday T., Mills GB, Yarbrough WG., and Issaeva N 2012 Downregulation of SMG-1 in HPV-positive head and neck squamous carcinoma due to promoter hypermethylation correlates with improved survival Clinical Cancer Research 18:1257-1267 PMID:22247495 PMC4010255
412. Horiuchi D., Kusdra, L., Huskey NE., Chandriani, S., Lenburg M., Gonzalez-Angulo AM., Creasman KJ., Bazarof AV., Davis SE., Yaswen P., Mills GB., Esserman LJ., and Goga A., 2012 MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition J. Exp Med 209:679-96 PMID:22430491 PMC3328367
413. Meric-Bernstam F., Akcakanat A., Chen H., Do KA., Sangai T., Adkins F., Gonzalez-Angulo AM., Rahsid A., Crosby K., Dong M., Phan AT., Chang DZ., Wolff RA., Gupta S., Mills GB., and Yao J., 2012 PIK3CA/PTEN mutations and AKT activation as markers of sensitivity to allosteric mTOR inhibitors Clin Can Res 18:1777-89 PMID:22422409 PMC3307149
414. Wheeler S., Siwak D., Chai R., Seethala R., Wang L., Cieply K., Sherer C., Joy RC., Mills GB., Argiris AA., Siegfried J., Grandis JR., and Egloff AM 2012 Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous carcinoma Clin Can Res 18:2278-89 PMID:22351687 PMC3430124
415. Nikitopoulou I., Oikonomou, N., Karouzakis E., Mersinias V., Armake M., Sotsios Y., Karagianni N., Zhao Z., Xu Y., Prestwich GD., Masu M., Mills GB., Gay S., Kollia G., and Aidinis A., 2012 Autotaxin expression from synovial fibroblasts and lysophosphatidic acid signaling are essential for the development of rheumatoid arthritis J Exp Med 209-925-3 PMID:22493518 PMC3348105
416. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein G., Gonzalez-Angulo AM. 2012 cMET and phospho- cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18:2269-77 PMID:22374333 PMC3821167
417. Federico, L, Ren H., Mueller PA., Wu T., Liu S., Popovic J., Blalock EM., Moolenaar WH., Ovaa, H., Albers HM., Mills GB., Morris AJ., and Smyth SS., 2012 Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet induced obesity in mice. Mol Endocrinol 26:786-97 PMID:22474126 PMC3355557
418. Pareja F, Ferraro DA, Rubin C., Cohen-Dvashi H., Zhang F., Aulmann S., Ben-Cherite N., Pines G., Navon R., Crosseto N., Koestler W., Carvalho S., Lavi S., Schmitt F., Dikic I., Yachini Z., Sinn P., Mills GB., and Yarden Y., 2012 Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression Oncogene 31: 4599-608 PMID:22179831 PMC3326441
419. Duong MT., Akli A., Wei C., Wingate, H., Liu W., Mills G.B., Hunt K., and Keyomarsi K., 2012 LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis and associates with the activated b-RAF-ERK1/2-mTOR pathway breast cancer patients. Plos Genetics 8: e1002538 PMID:22479189 PMC3315462
420. Eltonsey, N., Gabisis V., Li X., Mills GB, and Stemke-Hale K., 2012 Detection algorithm for the validation of human cell lines Int J. Cancer: 131:E1024-30 PMID:22419365 PMC3772516
421. Nieto-Barajas L., Muller P., Ji Y., Lu Y., and Mills G 2012 A time-series DDP for functional proteomics profiles Biometrics 68: 859-68 PMID:22221181 PMC4091682
422. Astanehe A., Finkbeiner M., Krzywinski M., Fotovati A., Dhillon J., Berquin I., Mills G., Marra M., Dunn S. 2012 MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Oncogene 31:4434-46 PMID: 22249268
423. Kim N, He N. Zhang F, Lu Y, Yu Q, Stemke-HAle K, Greshock J, Wooster R, Yoon S, Mills GB 2012 Systematic analysis of genotype-specific drug response in cancer Int J Cancer 131:2456-64 PMID: 22422301 PMC4012336
424. Ji H., Ding Z., Hawke D., Mills GB and Lu Z., 2012 AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis Embo Report 13:554-60 PMID:22510990 PMC3367238
425. Fu S., Hennessy BT., Ng CS., Ju Z., Coombes K., Wolf JK., Sood AK., Levenback CF., Coleman RL., Kavanagh JJ., Gershenson DM., Markman M., Dice K, Howard A., Li J., Li Y., Stemke- Hale K., Dyer M., Atkinson E., Jackson E., Kundra V., Kurzrock R., Bast RC., and Mills GB., 2012 Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high- grade epithelial ovarian cancer. Gyne Onc 126:47-53 PMID:22487539 PMC3738300
426. Li X., Lu Y., Liang K., Hsu J-M., Albarracin C., Mills GB., Hung M-C., and Fan Z., 2012 Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR Oncogene 31:4372-83 PMID:22231447 PMC3326223
427. Balko JM., Cook RS., Miller TW., Bhola NE., Sanders ME., Granja-Ingram NM., Meszoely IM., Salter J., Dowsett. M., Stemke-Hale K., Gonzalez-Angulo AM., Mills GB., and Arteaga CL 2012 Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Medicine 18:1052-9 PMID:22683778 PMC3693569
428. Claerhout, S., Dutta B., Bossuyt, W., Zhang F., Nguyen-Charles C., Yu Q., Yu S., Balazsi G., Lu Y., and Mills GB. 2012 Abortive autophagy induced reticulum stress and cell death in cancer cells. Plos One 7:e39400 PMID:22745748 PMC3383753
429. Carter BZ., Qui Y., Huang X., Diao L., Zhng N., Coombes KR., Mak DH., Konopleva M., Cortes J., Kantarjian HM., Mills GB., Andreeff M., and Kornblau SM.,2012 Survivin is highly expressed in CD34(+)38(-) leukemic stem progenitor cells and predicts poort clinical outcomes in AML Blood 120:173-80 PMID:22645176 PMC3390955
430. Yu F-X, Zhao B., Panupinthu N., Jewell JL. Lian I., Wang, LH, Zhao J. Yuan H., Tumaneng K., Li H., Fu XD., Mills GB. Guan KL 2012 Regulation of the HIPPO-YAP pathway by G protein coupled receptor signaling Cell 150:780-91 PMID:22863277 PMC3433174
431. Oates CJ., Hennessy BT., Lu Y., Mills GB., and Mukherjee S., 2012 Network inference for steady-state data using Goldbeter-Koshland kinetics Bioinformatics. 28:2342-8 PMID:22815361 PMC3436851
432. Byers LA., Wang J., Nilsson M., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyteon M., Fan Y., Shen L., Liu W., Diao L., Duchemann B., Tumula P., Weber S., Kalhor N., Wistuba I., Girard L., Hong WK., Mills GB., Coombes K., Weinstein J., Minna J., and Heymach J., 2012 Proteomic profiling identifies dysregulated pathways and overexpression of novel therapeutic targets, including PARP1, in small cell lung cancer Cancer Discovery 9:798-811 PMID:22961666 PMC3567922
433. Hill SM., Lu Y., Molina J., Heiser LM., Spellman PT., Speed TP., Gray JW., Mills GB., and Mukherjee S., 2012 Bayesian inference of signaling network topology in a cancer cell line Bioinformatics 28:2804-2810 PMID:22923301 PMC3476330
434. Liang H., Cheung LWT., Li Jie., Ju Z., Yu S., Stemke-Hale K., Dogruluk T., Lu Y., Gu C., Liu C-G., Liu X., Scherer, SE., Verhaak R., Zhang F., Lu KH., Broaddus RR., Scott KL., Hennessy BT, Mills GB., 2012 Whole exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Research 22:2120-9 PMID:23028188 PMC3483541
435. Park, YY., Park ES., Kim SB, Kim SC., Sohn BH., Sung SL., Chu I-S., Heo J., Lim JY., Kin YH., Leem S-H., Mills GB., Byers LA., and Lee J-S., 2012 Development and validation of a prognostic gene expression signature for lung adenocarcinoma Plos One 7:e44225 PMID:22970185 PMC3436895
436. Liang ZD., Lee MY., Tsai WB., Hennessy BT., Mills GB., Savarag N., Kuo MT., 2012 Mechanistic basis for overcoming platinum resistance using copper chelating agents. Molecular Cancer Therapy 11:2483-94 PMID:22914438 PMC3496003
437. Simpkins F., Sun J., Gilbert CA., da Silva T., Ullmer W., Pedram A., Levin ER., Reis IM., Assam D., Xu X., Ince T., Rabinovich B., Yang J-Y., Verhaak RGW., Lu Y., Mills GB., Slingerland J. 2012 Src inhibition with saracatinib reverse fulvestrant resistance in ER- positive ovarian cancer models in vitro and in vivo Clinical Cancer Research. 18:5911-5923 PMID:22896656 PMC3698880
438. Sangai T., Akcakanat A., Chen H., Tarco E., Wu Y., Do K-A., Miller TW., Arteaga CL, Mills GB., Gonzalez-Angulo AM., Meric-Bernstam F., 2012 Biomarkers of response to AKT inhibitor MK-2206 in breast cancer Clinical Cancer Research 18:5816-28 PMID:22932669 PMC3772348
439. Abkevich, V., Timms KM., Hennessy BT., Potter J., Carey MS., Meyer LA., McCune KS., Broaddus R., Lu KH., Chen J., Tran TV., Williams D., Iliev D., Jammulapati S., Fitzgerald L., FitzGerald LM., Krivak T., DeLoia JA., Gutin A., Mills GB., Lanchbury JS., 2012 Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer Brit. J. Cancer 107:1776-82 PMID:23047548 PMC3493866
440. Guo H., Liu W., Ju Z., Tamboli P, Jonasch E., Mills GB., Lu Y., Hennessy G., Tsavachidou D. 2012 An efficient procedure for protein extraction from formalin-fixed, paraffin embedded tissues for reverse phase protein arrays Proteome Science 10:56 PMID:23006314 PMC3561137
441. Meric-Bernstam F., Chen H., Akcakanat A., Do K-A., Lluch A., Hennessy BT., Hortobagyi, GN., Mills GB., Gonzalez-Angulo AM 2012 Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 14:R138 PMID:23102376 PMC4053117
442. Quayle SN., Lee JY., Cheung LWT, Ding L., Wiedemeyer T., Dewan RW., Huang- Hobbs E., Zhuang L., Ligon KL., Wilson RK., Mills GB., Cantley LC., and Chin L. 2012 Somatic mutations of PIK3R1 promote gliomagenesis Plos One 7e49466 PMID:23166678 PMC3498106
443. Gonzalez-Angulo AM., Chen H., Karuturi MS., Chavez-MacGregor M., Tsavachidis S., Meric-Bernstam F., Do K-a., Hortobagyi GN., Mills GB., Bondy ML, Blumenschein 2013 Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. 119:7-15 PMID:22736407 PMC3461089
444. Hoshino D., Jourquin J., Emmons W., Miller T., Goldgof M., Costello K., Tyrson D., Brown B., Prasad N., Zhang B., Mills GB., Yarbrough W., Quaranta V., Seiki M., and Weaver AM., 2013 Network analysis of the focal adhesion-invadopodia transition indentifies an PI3-kinase PKCa invasive signaling axis. Science Signaling 5:ra66 PMID:22969158 PMC3583194
445. Jeong KJ., Cho KH., Panupinthu, N., Mills GB., Kang, J., Park CG., Lee HY 2013 EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol Mol Onc 7:121-9 PMID:23127547 PMC5528397
446. Byers LA., Diao, L., Wang J., Saintigny, P., Girard L., Peyton, M., Shen L., Fan Y., Giri U., Tumula PK., Nilsson MB., Gudikote J., Tran HR, Candnell, R., Bears DJ., Wanter SL.., Foulks. JM., Kanner SB. Gandhi V., Krett NL, Rosen ST., Kim ES., Herbst., R., Blumenschein GR., Lee J, Lippman S., Ang K., Mills GB., Hong WK., Weinstein JN., Wistuba II., Coombes KR., Minna JD., and Heymach JV. 2013 An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance Clin Can Res. 19:279-290 PMID:23091115 PMC356792
447. Albeck JG., Mills GB., and Brugge JS. 2013 Frequency-modulated pulses of ERK activity transmit quantitative proliferative signals in response to long-term EGF stimulation Mol Cell 24:249-61 PMID:23219535 PMC4151532
448. Yao Y., Suraokar, M., Darnay B., Hollier BG., Shaikenov TE., Asana T., Chen C-H., Chang B., Lu Y., Mills GB., Sarbassov D., Mani SA., Abbruzzese JL., and Reddy S. 2013 BSTA Promotes mTORC2-Mediated Phosphorylation of Akt1 to Suppress Expression of FoxC2 and Stimulate Adipocyte Differentiation Science Signalling 6:ra2 PMID:23300339 PMC3748614
449. Mao M., Mariadason J., Tian F., Taso C-C., Dayyani T., Nanda VY., Jiang ZQ., Wistuba II., Bollag G., Tang XM., Mills GB., Desai J., Gallick G., Davies MA., and Kopetz S., 2013 Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents Clinical Cancer Research 19:657-67 PMID:23251002 PMC3563727
450. Holder, AM., Gonzalez-Angulo AM., Chen, H., Akcakanat A., Do K-A., Symmans WF., Pusztai L., Hortobagyi G., Mills GB., and Meric-Bernstam F. 2013 High stearoyl-CoA desaturase 1 expression predicts shorter survival in breast cancer patients Breast Cancer Research 137:319- 27 PMID: 23208590 PMC3556743
451. Tuna M., Ju Z., Mills GB 2013 Soft tissue sarcoma subtypes have distince patterns of acquired uniparental disomy BMC Genomics 5:60 PMID:23217126 PMC3541987
452. Israelsen WJ., Dayton TL., Fiske BP., Hosios A., Bellinger G., Li J., Yu Y., Sasake M., Horner JW., Burga LN., Xie J., DePinho RA., Jack T., Wulf GM., Di Vivio D., Mills GB., Cantley LC., and Vander Heiden MG., 2013 PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155:397-409 PMID:24120138 PMC3850755
453. Hale K., Shipman, K., Kitsou-Mylona I., Gonzalez de Castro D., Hird V., Brown R., Flanagan JM., Gabra H., Mills GB., Agarwal R., El-Bahrawy M., 2013 Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. Modern Path: 26: 544-52 PMID:23174937 PMC3856435
454. Sansores-Garcia L., Atkins M., Shahmoradgoli MS., Dupont S., Piccolo S., Mills G.B., Halder G., 2013 Multiple ankyrin repeats single KH (MASK) is required for the activity of the Hippo pathway effector Yki Current Biology 23:229-35 PMID:23333314 PMC4089957
455. Gao M., Liang J., Lu Y., Guo H., German P., Bai S., Jonasch E., Yang X., Mills GB. Ding Z 2013 Site Specific Activation of AKT Protects Cells from Death Induced by Glucose Deprivation Oncogene 33:745-55 PMID:23396361 PMC3874430
456. Guo H., Gao, M., Lu Y., Liang J., Lorenzi PL., Jonasch E., Mills GB., Ding Z., 2013 Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules Oncogene 33:745-55 PMID:23912456 PMC3915040
457. Stordal B., Timms K., Renaud, M., Thery J., Farelly A., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Cary M., Li J., Li Y., Aslan O., O’Leary J., Mills GB., and Hennessy B. 2013 Brca1/2 mutational analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Molecular Oncology 7:567-79 PMID:23415752 PMC4106023
458. Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang F, M, Yi M, Keyomarsi K. 2013 Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res. 15:R3 PMID:23320734 PMC3672770
459. Park Y-Y., Kim SB., Han H-E., Sohn B-H, Kim JH., Liang J., Lu Y., Rodriguez-Aguayo C., Lopez-Berestein G., Mills GB., Sood AK., Lee JS 2013 Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology 58:182-91 PMID:23389994 PMC3923572
460. Tabchy A., Eltonsy N., and Mills GB 2013 Systematic identification of combinatorial drivers and targets in cancer cell lines. Plos One 8:e60339 PMID:23577104 PMC3618473
461. Myhre, S., Lingjaerde O-C., Hennessy BT., Aure MR., Carey MS., Alsner J., Tramm T., OvergaardJ., Mills GB., Sorlie T., Borresen-Dale A. L., 2013 Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins Mol Onc 7:704-18 PMID: 23562353 PMC5528474
462. Lui VWY., Li H. Hedberg M., Vangara B., Pendleton K., Zeng Y., Zhang Q., Gilbert B., Freilino M., Suerwein S., Peyser N., Diergaarde B., Want L., Xhiosea S., Seethala R., Johnson JT., Kim S., Duvvuril U., Ferris RT. Kwok-Shing P., Garraway LA., Mammerman P., Mills GB and Grandis JR., 2013 Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers Cancer Discovery 3:761-9 PMID:23619167 PMC3710532
463. Dennison JB., Molina JR., Mitra S., Gonzalez-Angulo AM., Balko JM., Kuba MG., Sanders ME, Pinto JA., Gomezez HL., Arteaga CL., Brown RE., Mills GB 2013 Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer Clinical Cancer Research 19:3703-13 PMID:23697991 PMC3727144
464. Yang J-Y., Yoshihara K., Tanaka K., Hatae M., Masuzaki H., Itamochi H., Takano M., Ushijima K., Tanyi J. Coukos G., Lu Y., Mills GB and Verhaak RGW 2013 Predicting Time to Ovarian Carcinoma Recurrence Using Protein Markers J Clin Invest 123:3740-50 PMID:23945238 PMC3754259
465. Irwin ME., Nelson LD., Santiago-O’Farrill JM., Knouse PD., Miller CP., Palla SL., Siwak DR., Mills GB., Estrov Z., Li S., Kornblau SM., Hughes DP. and Chandra J., 2013 Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One. 8:e70608 PMID:23936456 PMC3731286
466. Sohn J., Liu S., Chen H., Meng X., Do K-A., Mills GB., Hortobagyi GN., Meric-Bernstam, F., Gonzalez-Angulo AM., 2013 Functional proteomics characterization of residual triple- negative breast cancer after standard neoadjuvant chemotherapy. Anal Oncol 24:2522-6 PMID:23925999 PMC3784335
467. Zhang X., Claerhout S., Pratt A., Dobrolecki, LE., Petrovic A., Lai Q., Landis M., Wiechmann L., Schiff R., Wong H., Fuqua SW., Contreras A., Gutierrex C., Huang J., Pavlick AC., Froehlich AM., Wu M-F., Tsimelzon, A., Hilsenbeck SG., Shaw CA., Rimaw MF., Perou CM., Mills GB., Chang JC., Lewis MT., 2013 A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Research 73:4885-97 PMID:23737486 PMC3732575
468. Yoshihara K, Shahmorad-Goli M.., Martinez-Ledesma E., Vegesna R., Kim H., Torres-Garcia W., Trevino V., Shen H., Laird PW., Levine V., Carter SL., Getz G., Stemke-Hale K., Mills GB and Verhaak. 2013. RGW Inferring tumor purity and stromal and immune cell admixture from expression data. Nature Communications 4:2612 PMID:24113773 PMC3826632
469. Dutta P., Bui T., Kyle A., Bauckman KA., Keyomarsi K., Mills GB., Nanjundan M., 2013 EVI1 splice variants modulate functional responses in ovarian cells Mol Oncol: 7:647-68 PMID:23517670 PMC3805042
470. Dupuy, F., Griss T, Blagih, J., Bridon G. Avizonis D., Linh V. Dong Z, Siwak DR., Annis MG., Mills GB., Muller WJ., Siegel PM. and Jones RG., 2013 LKB1 is a central regulator of tumor intiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer and Metabolism 1:18 PMID:24280377 PMC4178213
471. Li J., Lu Y., Akbani R., Ju., Z., Liu W., Yang JY., Broom BM., Kane D., Weinstein JN., Cancer Genome Atlas Research Network, Mills GB., and Liang H 2013 TCPA: A Resource for Cancer Proteomics Data Nature Methods 10:1046-7 PMID: 24037243 PMC4076789
472. Cardnell R., Feng Y., Diao L., Fan y., Masrorpour F., Wang J., Shen Y., Mills GB., Minna J., Heymach J., and Byers LA 2013 Proteomic markers of DNA repair and PI3K pathway activation predict response to the novel, highly potent PARP inhibitor BMN 673 in small cell lung cancer Clin Cancer Research 19:6322-8 PMID:24077350 PMC3882158
473. Mao Y., Chen H., Liang H., Meric-Bernstam F., Mills GB., Chen K., 2013 CanDrA: Cancer- specific driver missense mutation annotation with optimized features Plos One 8:e77945 PMID:24205039 PMC3813554
474. Billiard J., Dennison JB., Briand J., Annan RS., Chai D., Colon M., Dodson CS., Gilber S., Greshock J., Jing J., Lu H., McSurdy-Freed J., Miller L., Mills GB., Quinn C., Schneck JL., Scott GF., Shaw TN., Waitt G., Wooser RF and Duffy KL., 2013 Quinoline 3-Sulfonamides Inhibit Lactate Dehydrogenase A and Reverse Aerobic Glycolysis in Cancer Cells Metabolism and Cancer: 1:19. PMID:24280423 PMC4178217
475. Fabian C., Kimler BF., Phillips TA., Donnelly JE., Sullivan DK, Petroff BK., Zalles CM., Metheny T., Aversman S., Klemp JK., Mills GB., Yeh H-W., Hursting SD., 2013 Favorable Modulation of Benign Breast Tissue and Serum Risk Biomarkers Is Associated with >10% Weight Loss in Postmenopausal Women Breast Cancer Research and Treatment 142:119-32 PMID:24141897 PMC3921968
476. Lindholm EM., Krohn M., Iadevaia, S., Kristian A., Mills GB., Maelandsmo GM., Engebraaten O., 2013 Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations Clin Can Res 20:404- 12 PMID:24192926 PMC4326070
477. Daemen, A., Griffith OL., Wang NJ., Korkola JE., Heiser LM., Enache OM., Sanborn A., Pepin F., Durinck S., Griffith M., Hur JS., Huh N., Chung J., Cope L., Fackler MJ., Umbricht C., Sukumar S., Sthe P., Sukhatme VP., Jakkula L., Lu Y., Mills GB., Cho RJ., Collisson EA., van’tVeer LF., Spellman PT and Gray JW., 2013 Modeling precision treatment of breast cancer Genome Biology 14:R110 PMID:24176112 PMC3937590
478. Hartman ZC., Poage G., Tsimelzon A., Hill J., Panupinthu N., Zhang Y., Mazumdar A., Hilsenbeck SG., Mills GB., and Brown PH., 2013 Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Research 73:34070-80 PMID:23633491 PMC3853111
479. Molinelli E., Korkut A., Wang W., Miller M., Gauthier., Jing X., Kaushik P., He Q., Mills G., Solit D., Pratilaso C., Weigt M., Braunstein A., Pagnani A., Zecchin R., Sander C., 2013 Perturbation Biology inferring signaling networks in cellular systems. Plos Computational Biology 9:e1003290 PMID:24367245 PMC3868523
480. Li S., Shen D., Liu W., Prat A., Hoog J., Liu S., Ding L., McMichael JF., Miller C., Larson D., Fulton RS., Harrison M., Mooney T, Tao Y., Luo J., Lin L., Giuntoli T., Bumb C., Cooper C., Kitchens RT., Johnson SN., Crowder RJ., Shao J., Goncalves R., Phommaly C., Davies S., Kavuri MS., Lin A., McEachern D., Don YY., Ma C., Pluard T., Naughton M., Bose R., Suresh R., McDowell R., Michel L., Aft R., DeSchryver K., Wilson R., Want S., Mills GB., Gonzalez-Angulo A, Maher C., Perou C., Mardi E., Ellis MJ. 2013 Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reports 4:1116-30 PMID:24055055 PMC3881975
481. Cheng KW., Agarwal R., Mitra S., and Mills GB. 2013 Rab25 small GTPase mediates secretion of tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) protecting cells from effects of TRAIL J Genet Syndr Gene Ther 4: pii 1000153 PMID:25520884 PMC4266180
482. Panupinthu N., Yu S., Zhang D., Zhang F., Lu Y., Grandis JR., Dunn SE Lee HY Mills GB 2013 Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer Oncogene 33:2846-56 PMID: 23851501 PMC4115609
483. Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DS, Mills GB, Sood A, Lee JS. 2014 Activation of YAP1 Is Associated with Poor Prognosis and Response to Taxanes in Ovarian Cancer. Anticancer Res. 34:811-7 PMID:24511017 PMC4082822
484. Lui V., Kwok-Shing P., Peyser N., Hritz M., Li H., Zeng Y., Ju Z., Gilbert B., Want Z., General I., Bahar Y., Vries JK., Hammerman P., Garraway L., Mills GB., Johnson DE., Grandis JR., 2014 Frequent Mutation of Receptor Protein Tyrosine Phosphatases Provides a Mechanism for STAT3 Hyperactivation in Head and Neck Cancer Proc Natl Acad Sci U S A. 111:1114-9 PMID:24395800 PMC3903220
485. Chavez-MacGregor M., Liu S., Gagliato D., Chen H., Do K-A., Pusztai L., Summans F., Nair L., Hortobagyi GN., Mills GB., Meric-Bernstam F., and Gonzalez Angulo AM., 2014 Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 23:316-23 PMID:24296856 PMC3946290
486. Javle M., Rashid A., Churi C., Kar S., Zuo M., Eterovic K., Gonzalez G., Ali S. Janku F., Shroff R., Aloiz T., Vauthey J-N., Curley S., Mills G., Roa I., 2014 Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling Human Pathology 45:701-8 PMID:24508317 PMC4428571
487. Peng G, Chun-Jen Lin C, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo Q, Siwko S, Hu R, Lee JS, Hennessy B, Hanash S, Mills GB, Lin SY. 2014 Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun. 5:3361 PMID:24553445 PMC4017859
488. Liu Y., Zhou R., Tsavachidis. S., Brewster A., Murray JL., Do KA., Sahin A., Hortobagyi GN., Taube JH., Mani SA., Batts LM., Mills GB., Kamrudin S., Bondy ML., Thompson PA., Borresen-Dale AL 2014 Genome-wide Molecular Inversion Probe Array Profiling Reveals DNA Copy Number Imbalances Associated with Breast Cancer Bone and Non-bone Metastasis Breast Cancer Fes Treat 143: 189-201 PMID 24305980 PMC3993091
489. Cheng H., Liu P., Fan Z., Bronson R., Maira A-M., di tomaso E., Myers A., Cantley L., Mills GB and Zhao J. 2014 A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 is highly responsive to mTOR inhibition Cancer Res 74:15- 23 PMID:24322983 PMC3982380
490. Werner HMJ., Mills GB., Ram PT 2014 Cancer Systems Biology: A peek into the future of patient cancer Nature Reviews Clin Onc 11:167-76 PMID: 24492837 PMC4321721
491. Akbani R., Ng KS., Werner HMJ., Shahmoradgoli M., Zhang F., Ju. Z., Liu W., Yang JY., Yoshihara K., Li J., Ling S., Seviour EG., Ram PT., Minna JD., Diao L. Tong P. Heymach Jv., Hill SM., Dondelinger F., Stadler N., Byers LA., Meric-Bernstam F., Weinstein HN., Broom BM., Verhaak RGW., Liang H., Mukherjee S., Lu Y, and Mills GB., 2014 A pan-cancer proteomic perspective on the Cancer Genome Atlas Nature Comms: 5:3887 PMID:24871328 PMC4109726
492. Mitra R., Muller P., Ji Y., Zhu Y., Mills GB., Lu Y., 2014 A Bayesian hierarchical model for inference across related reverse phase protein array experiments J Appl Stat. 41:2483-2492 PMID26246652 PMC4523276
493. Sewell A., Brown B., Biktasova A., Mills GB., Tyson DR., Issaeva N Yarbrough WG., 2014 Reverse Phase Protein Array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer Clin Can Res 20:2300-11 PMID:24599934 PMC4027970
494. Meric-Bernstam, F., Frampton GM., Ferrer-Lozano J., Yelensky R., Perez Didalgo, Wang Y., Palmer G., Ross JS., Miller VA., Su X., Eroles P., Barrera JA, Burgues O., Lluch AM., Zheng X., Sahin A., Stephens JA., Mills GB., Cronin MT and Gonzalez-Angulo AM., 2014 Concordance of Genomic Alterations Between Primary and Recurrent breast cancer Mol Can Ther 13:1382-9 PMID:24608573 PMC4348062
495. Davies AH., Reipas KM., Berns S., Fotovati A., Pambid MR., Stratford AL., Maxwell C., Mills GB., and Dunn SE., Firmino N., Astanehe A., Hu K., Maxwell C 2014 YB-1 tranforms human mammary epithelial cells through chromatin remodeling leading to the development of basal- like breast cancer Stem Cells 32:1437-50 PMID:24648416 PMC4321723
496. Gonzalez-Angulo AM., Akcakanat A., Liu S., Green MC., Murray JL., Chen H., Palla SL., Koenig KB., Brewster A., Valero V., Ibrahim NK., Moulder-Thompson S., Litton JK, Tarco E., Moore J., Flore P., Crawfor D., Dryden MJ., Symmans WF., Sahin A., Giordano SH., Pusztai L, Do K-A., Mills GB., Hortobagyi GN., and Meric-Bernstam F., 2014 Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by FEC in women with triple receptor- negative breast cancer Annals of Oncology 25:1122-7 PMID:24669015 PMC4037860
497. Davidowitz RA., Selfors LM., Iwanicki MP., Karst A., Piao H., Ince TA., Dering J., Konecny G., Matalunis U., Mills GB., Slamon DJ., Drapkin R., and Brugge JS., 2014 Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance J Clin Invest 124:2611-25 PMID:24762435 PMC4038562
498. Fu X., Creighton CJ., Biswal NC., Kumar V., Shea M., Herrera S., Contreras A., Gutierrex C., Want T., Nanda S., Giuliano M., Anur P., Rimawa MF.,Morrison G., Nardone A., Karlin KL., Westbrook TGF., Heiser LM., Spellman P., Guichard SM., Smith PD., Davies BR., Klinowska T., Lee AV., Mills GB., Hilsenbeck SG., Gray JW., Joshi A., Osboerne CK., Schiff R., 2014 Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian targer of rapamycin, protein kinase B or miogen- activated protein kinase kinaseBreast Cancer Research 16:430 PMID: 25212826 PMC4303114
499. Ding Z., German P., Bai S., Reddy S., Liu X., Sun M., Zhou L., Zhao X., Chen X., Zhao X., Zhang S. Mills GB., Jonasch E., 2014 Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein. Cancer Research 74:3127-36 PMID:24755468 PMC4047720
500. Lorenzi PL., Claerhout S., Mills GB., Weinstein JN., 2014 A curated census of autophagy- modulating proteins and small molecules Autophagy 10:1316-1326 PMID:24906121 PMC4203555
501. Zhou G., Wang J., Zhao M., Sano D., Xie T-X., Jasser SA., Sandulache V., Fitzgerald A., Zhang A., Xian X., Songyang Z., Yongkun W., Liang J., Mills GB., Hung MC., Caulin C., Myers JN., 2014 Gain of function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation Mol Cell 54:960-74 PMID:24857548 PMC4067806
502. Lee J., Tiwari A., Shum V., Mills GB., Mancini MA., Igoshin O and Balazsi G., 2014 Unraveling the regulatory connections between two controllers of breast cancer cell fate Nucleic Acids Research 42:6839-49 PMID:24792166 PMC4066784
503. Joy A., Ramesh A., Smirnov I., Misra A., Reiser M., Misra A., Shapiro WR., Mills GB., Kim S., and Fuerstein BG. 2014 AKT pathway genes define 6 prognostic subgroups in glioblastome multiforme Plos One 9: e100827 PMID:24984002 PMC4077731
504. Wolf J., Muller-Decker K., Flechtenmacher C., Zhang F., Shahmoradgoli M., Mills GB., Hoheisel JD and Boettcher M., 2014 An in vivo RNAi screen identifies SALL1 as a tumour suppressor in human breast cancer with a role in CDH1 regulation. Oncogene 14:4273-8 PMID:24292671
505. O’Leary P., Hennessy BT., Zagzozdzou A., O’Connor D., Brenan DJ., Li J., Mills GB. Gonzalez-Angulo AM., Madden SF., Sun H-D., Pu J-X., Ponten F., Uhlen M., Jirstrom K., Nowis D., Crown J., Zagozdzon R., Gallagher WM., 2014 Peroxiredoxin-1 protects against estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in estrogen receptor-positive breast cancer. Breast Cancer Research 16:R79 PMID:25011585 PMC4226972
506. Lehmann BD., Bauer JA., Schafer JM., Pendleton CS., Tang LJ., Johnson KC., Chen X., Balko JM., Gomez HL, Arteaga C., Mills GB., Sanders ME., Pietenpol J., 2014 PIK3CA

Mutations in androgen receptor-positive Triple Negative Breast Cancer Cells Confer Sensitivity to the Combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 16:406 PMID:25103565 PMC4187324

1. Yuan Y., Van Allen EM., Omberg L., Wagle N., Amin-Mansour A., Sokolow A., Byers LA., Xu Y., Hess K., Diao L., Han L., Huang X., Lawrence M., Weinstein J., Stuart J., Mills GB., Garraway LA., Morgolin AA., Getz G., Liang H., 2014 Assessing the clinical utility of cancer genomic data across tumor types. Nature Biotech 32:644-52 PMID:24952901 PMC4102885
2. Meric-Bernstam, F Akcakanat A., Chen H., Sahin A., Tarco E., Carkaci S., Adrada BE., Singh G., Do K-A., Garces ZM., Mittendorf E., Babiera G., Wagner J., Bedrosian I, Hwang R., Krishnamurthy S., Symmans F., Gonzalez-Angulo AM., Mills GB., 2014 Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Can Res 20:3870-83 PMID:24895461 PMC4112583
3. Hsu Y-H., Wu T-J., Chan L-C., Hsu JL., Yao J., Fan Y-F., Wei Y., Wu Y., Huan W-C., Liu C-L., Chang Y-C., Mang M-Y., Li C-W., Shen J., Chen M-K., Sahim AA., Sood A., Mills GB., Yu D., Hortobagyi GN., Hung M-C., 2014 Definition of PKC-a, CDK6, and MET as Therapeutic Targets for Triple-Negative Breast Cancer. Cancer Research 74:4822-35 PMID:24970481 PMC4154991
4. Pande M., Bondy ML., Do K-A., Sahin AA., Ying J., Mills GB., Thompson PA., Brewster AM., 2014 Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease free survival Breast Cancer Research and Treatment 147:381-7 PMID:25108739 PMC4174407
5. Watson IR., Li L., Cabeceiras PL., Mahdavi. M., Gutschner T., Wang G., Fang Z., Tepper JM., Stemke-Hale K., Tsai KY., Davies MA., Mills GB., Chin L, 2014 The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF Cancer Research 74:4845-52 PMID:25056119 PMC4167745
6. Subbiah V., Meric-Bernstam F., Mills GB., Mills-Shaw K., Bailey AM., Rao P., Ward JF., Pagliaro LC., 2014 Next Generation Sequencing Analysis of an Unusual Responder to Sunitinib (Sutent ®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. Journal of Hematology & Oncology 7:52 PMID:25085632 PMC4237879
7. Lu G., Zhang Q., Huang Y., Song J. Tomaino R., Ehrenberger T., Lim E. Liu W., Bronson RT., Bowman M., Dillon DA., Gygi SP. Mills GB., Richardson AL, Signoretti S., Yaffe YB., and Kaelin WG., 2014 Phosphorylation of ETS1 by Src Family Kinases Prevents its Recognition by the COP1 Tumor Suppressor. Cancer Cell 26:222-34 PMID:25117710 PMC4169234
8. Hu X., Feng SD., Zhang D., Zhao SD., Hu Z., Greshock J., Zhang Y., Yang LP.,Zhong X., Wang C., Jean S., Li C., Huang., Katsaros D., Montone K., Tanyi Y,L.,Lu C.,Boyd J., Nathanson KL., Li H., Mills GB., Zhang L., 2014 Functional genomic approach identifies oncogenic long non-coding RNA FAL-1 that associates with BMI1 and represses p21 expression in human cancer Cancer Cell 26:344-57 PMID:25203321 PMC4159613
9. Cheung LWT, Yu S., Zhang D., Li J., Panupinthu N., Mitra S., Ju Z., Yu Q., Liang H., Hawke DH., Lu Y., Broaddus RR., Mills GB., 2014 Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell 26:479-94 PMID:25284480 PMC4198486
10. He N., Kim N., Song M., Park C., Kim S., Park E., Yim HY., Kim K., Park JH., Kim KI., Zhang F., Mills GB., Yoon S., 2014 Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D Mol Can Ther 13:2463-73 PMID:25122068
11. Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno N, Gonzalez-Angulo AM. 2014 cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. J Cancer 15:745-53 PMID:25368674 PMC4216798
12. Liu S., Meng X., Chen H., Liu W., Miller T., Lu Y., Zhang F., Iurascu MG., Arteaga CL., Mills GB., Meric-Bernstam F., Gonzalez-Angulo AM 2014 Targeting tyrosine kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer Oncotarget 5:9049-64 PMID:24979294 PMC4253418
13. Hassan B., Akcakanat A., Sangai T., Evans KW., Adkins F., Eterovic AKT., Zao H., Chen K., Chen H., Ann-Do K., Xie SM., Holder AM., Mills GB., and Meric-Bernstam 2014 Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors Oncotarget 5:8544-57 PMID:25261369 PMC4226703
14. Madden SF, Clarke C, Stordal B, Carey MS, Broaddus R, Crown J, Gallagher WM, Mills GB, Hennessy BT. 2014 OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Mol Cancer 13:241 PMID:25344116 PMC4219121
15. Mazumder, T., Byers LA., Ng KS., Mills GB., Peng S., Diao L., Fan Y., Hale K., Heymach J., Myers JN., Glisson G., Johnson FM., 2014 A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma Mol Can Ther 13:2738-50 PMID:25193510 PMC4221385
16. Liu, W., Ju., Z., Lu J., Mills GB., Akbani R., 2014 A Comprehensive Comparison of Normalization Methods for SuperCurve Based Reverse Phase Protein Array (RPPA) Data Cancer Informatics 13:109-17 PMID:25374453 PMC4213190
17. Schwarz, L., Fox M., Balko, JM., Garrett, J., Kuba MG., Estrada M., Gonzalez-Angulo AM., Mills GB., Red\_Brewer M., Mayer IA., Abramson V., Rizzo M., Kelley MC., Meszoely IM., Arteaga CL., 2014 LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. J Clin Invest 124:5490-5502 PMID:25401474 PMC4348968
18. Chaluvally-Raghavan CR., Zhang F., Zhao Z., Pradeep S., Hamilton MP., Zhao X., Moss T., Lu Y., Yu S., Pecot CV., Aure MR., Peuget S., Rodriguez-Aguayo C., Han H-D., Zhang D., Liu W., Venkatanarayan A., Krohn M., Lopez-Berestein G., Kristensen VN., Gagae M., Ram P., Lorenzi PL., Borresen-Dale AL., Chin K., Gray J., Dusetti NJ. McGuire SE., Flores ER., Sood AK., and Mills GB, 2014 Copy number gain of microRNA-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers Cancer Cell: 26:863-79 PMID:25490449 PMC4261159
19. Gopal YNV., Rizos H., Chen G., Deng W., Frederick DT., Cooper ZA., Scolyer RA., Pupo G., Komurov K., Sehgal V., Zhang J., Pate L., Pereirar CG., Broom BM. Mills GB., Ram P., Smith PD., Wargo JA. Long GV., and Davies MA., 2014 Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and elevated Oxidative Phosphorylation in melanoma Cancer Research 74:7037-47 PMID:25297634 PMC4347853
20. Tangen IL., Werner HM., Berg A., Halle MK., Kusonmanol K., Trovik J., Horvik E., Mills GB., Krakstad, C., Salvesen HB., 2014 Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions Eur. J. Cancer 50:3003-10 PMID:25281525
21. Kaushik P., Molinelli E., Miller M., Liu W., Ju Z., Want W., Korkut A., Lu Y., Mills GB and Sander C. 2014 Spatial normalization of reverse phase protein array data. Plos One12;9:e97213 PMID:25501559 PMC4264691
22. Berg, A., Hoivik EA., Mjos S., Holst F., Werner HMJ., Tangen IL., Taylor-Weiner A, Gibson WJ., Kusonmano K., Wik W., Trovik J., Halle M., Oyan AM., Kalland K-H., Cherniack A., Beroukhim R., Stafansson I., Mills GB., Krakstad C., and Salvesen HB., 2014 Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients Oncotarget 6:1327-39 PMID:25415225 PMC4359236
23. Churi C., Schroff R., Wang Y., Rashid A., Kang J., Weatherly J., Zuo M., Meric-Bernstam F. Crane C., Mishra L., Vauthrey J-N., Wolff R., Mills GB. Javle M., 2014 Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications PLOS One 9: e115383 PMID:25536104 PMC4275227
24. Siroy AE, Boland GM., Milton D., Roszik J., Frankian S, Malke J., Haydu L., prieto VG., Gershenwald JE., Amaria RN. Patel AP., Papadopoulos NE., Bedikian A., Hwu W-J., Hwu P., Diab A., Woodman SE., Aldape KD., Luthra R., Patel KP., Shaw KR., Mills GB., Mendelsohn J., Meric-Bernstam F., Kim KB., Routbort MJ., Lazar AJ., Davies MA., 2014 Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma. Journal of Investigative Dermatology: 135:508-15 PMID:25148578 PMC4289407
25. Liu S., Meric-Bernstam, F., Parinyanitikul N., Wang B., Eterovic AK., Zheng X., Gagea M., Chavez-MacGregor M., Ueno NT., Lei X., Zhou W., Litton JK., Nair L., Tripathy D., Brown PH., Hortobagyi GN., Chen K., Mendelsohn J., Mills G., Gonzalez-Angulo A., 2014 Functional Consequence of the METT1010I polymorphism in Breast Cancer Oncotarget 6:2604-14 PMID:25605252 PMC4413604
26. Wiegand KC., Hennessy BT., Cheang M., Ju Z., McGahren M., Gilks B., Kalloger S., Finlayson S., Stemke-hale K., Lu Y., Zhang F., Huntsman D., Mills GB., and Carey MS. 2014 A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Genomics 14:120 PMID: 24559118 PMC3941949
27. Kim TH., Yoo J-Y., Kim HI., Gilbert J, Ku BJ., Li J., Mills GB., McCampbell, Broaddus RR., Lydon JP., Lim JM., Yoon H-G and Jeong J-W., 2014 Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation Cancer Research 74:7371-82 PMID: 25377472 PMC4268053
28. Zhou W., Chen.T., Zhao H., Etrovic.AK, Meric-Bernstam, F., Mills.GB, Chen K, 2014 Bias from removing read duplication in ultra-deep sequencing experiments. Bioinformatics 30:1073-1080 PMID:24389657 PMC3982159
29. Liu Y., Patel L., Mills GB., Lu KH., Sood A., Ding L., Kucherlapati R., Mardis ER., Levein DA., Shmulevich I., Broaddus R., Zhang W., 2014 Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J. Natl. Cancer Inst 106 pii: dju245 PMID: 25214561 PMC4200060
30. Boggs, A., Vitolo MI., Whipple RA., Charpentier MS., Slovic J., Ioffe OB., Tutle KC., Goloubeva OG., Lu Y., Mills GB., Martin SiS. 2015 α-Tubulin Acetylation Elevated in Metastatic and Basal-like Breast Cancer Cells Promotes Microtentacle Formation, Adhesion, and Invasive Migration. Cancer Research 75:203-15 PMID:25503560 PMC4350791
31. Kotlyar M., Pastrello C., Pivetta, F., Sardo AL., Cumbaa C., LI H., Naranian T., Niu, Y., Ding Z., Vafaee F., Froackes-Carter F., Stagljar I., Jurisicova A., Mills GB., Maestro R., and Jurisica I, 2015 In silico prediction of physical protein interactions and characterization of interactome orphans. Nat Methods 12:79-84 PMID:25402006
32. Ju, Z., Liu W., Roebuck P., Siwak D., Zhang N., Lu Y., Davies M., Mills GB., and Coombes K., 2015 Development of a robust classifier for quality control of reverse-phase protein arrays Bioinformatics 31:912-8 PMID:25380958 PMC4375399
33. Tuna M., Ju Z., Smid M., Amos., Mills GB., 2015 Prognostic Relevance of Acquired Uniparental Disomy in Serous Ovarian Cancer Molecular Cancer 14:29 PMID:25644622 PMC4320828
34. Gonzalez-Angulo A., Krop I., Akacanat A., Chen H., Liu S., Li Y., Culotta K. Tarco E., Piha- Piul S., Moulder-Thompson S., Velez-Bravo V., Sahin A., Doyle L., Do K-A., Winer E., Mills G., Kurzrock R., and Meric-Bernstam F., 2015 SU2C Phase Ib Study of Paclitaxel and MK- 2206 in Advanced Solid Tumors and Metastatic Breast Cancer J. Natl. Cancer Inst 16;107 PMID:25688104 PMC4342675
35. Chiu H-S, Llobet-Navas D., Yang X., Chung W-J., Ambest Impiombato A., Iyer A., Kim HR., Silva J., Lu Y., Ram P., Mills GB Sumazin P., and Califano A., 2015 Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks Genome Research 25:257-67 PMID:25378249 PMC4315299
36. Grubbs, E., Ng K., Lu X., Bui J., William MD., Chen K., Yelensky R., Palmer G., Perrier ND., Lee JE. Waguespack SG., Meric-Bernstam F., Mills GB., Shaw KR., Busaidy N., Cote G., 2015 RET fusion as a novel driver of medullary thyroid carcinoma Journal of Clinical Endocrinology and Metabolism 100:788-93 PMID:25546157 PMC4333032
37. Chen K., Meric-Bernstam F., Zhao H., Zhang Q., Ezzeddine N., Tang LY., Qi Y., Mao Y., Chen T, Cong Z., Zhou W., Zheng Z., Johnson A., Aldape KD., Routbort M., Luthra R., Kopetz S. Davies MA., de Groot J., Moulder S., Vinodil R., Farhangfar C., Shaw KM., Mendelsohn J, Mills GB., Eterovic AK., 2015, Clinical actionability enhanced through ultra-deep targeted exome sequencing of solid tumors Clinical Chemistry 61:544-53 PMID:25626406 PMC4511273
38. Jeon YJ., Khelifa S., Ratnikov B., Scott DA., Feng Y., Parisi F., Ruller C., Lau E., Kim J., Brill LM., Jian T., Rimm D., Cardiff R., Mills GB., Smith JW., Osterman AL., Kluger Y., and Ronai ZA. 2015, Regulation of Glutamine Carrier Proteins by RNF5 Determines Breast Cancer Response to ER Stress-Inducing Chemotherapies. Cancer Cell 27:354-69 PMID:25759021 PMC4356903
39. Pettazzoni1 P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi1 L, Marchesini M, Kapoor A, Yao W, Di Francesco M, Petrocchi A, Deem A, Scott K, Colla S, Mills GB, Fleming J, Heffernan T, Jones P, Toniatti C, DePinho R, Draetta G. 2015 Genetic events that limit the efficacy of targeted therapies in a mouse model of KRAS-driven pancreatic cancer Can Res 75:1091-101 PMID:25736685 PMC4446709
40. Burstein, M., Tsimelson A., Poage G., Covington K., Contreras A., Fuqua S., Savage M., Osborne CK., Hilsenbeck SG., Chang JC., Mills GB., Lau CC Brown P., 2015 Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer Clin Can Res 21:1688-98 PMID:25208879 PMC4362882
41. Meric-Bernstam FM., Johnson A., Holla V., Bailey AM., Brusco L., Chen K., Routbort M., Patel K., Zeng J., Kopetz S., Davies M., Piha-Paul S., Hong D., Eterovic KA., Tsimberadou A., Broaddus R., Bernstam EV., Shaw K., Mendelsohn J., Mills GB. 2015 A Decision Support Framework for Genomically-Informed Cancer Therapy J Natl Can Institute107 pii: djv098. PMID:25863335 PMC4651038
42. Kwong LN., Boland G., Frederick DT., Helms TL., Zou L., Miller JP., Jian S., Cooper ZA., Song X., Kamar J., Protopopos A., Mills GB., Flaherty K., Wargo JA., and Chin L., 2015 Co-clinical assessment of patterns of BRAF inhibitor resistance J Clin Invest 125:1459-70 PMID:25705882 PMC4396463
43. Martinez E., Yoshihara, K., Kim H., Mills GB., Trevino V., Verhaak RGW 2015 Comparison of gene expression patterns across twelve tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects Oncogene 34:2732-40 PMID:
44. Liu X-D., Yao J., Tripathi DN, Ding Z., Xu Y., Sun M., Zhang J., Bai S., German P., Hoang A., Zhou L., Jonasch D., Zhang X., Conti C., Efstathious Tannir NM., Eissa T., Mills GB., Walker CL., Jonasch E., 2015 Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis Oncogene 34:2450-60 PMID:24998849 PMC4286517
45. Zenali M., DeKay J., Liu Z., Hamilton S., Zuo Z., Lu XS Bakkar R., Mills G and Broaddus R 2015 Retrospective Review of c-MET Gene Mutations Oncoscience 2:533-41 PMID:26097886 PMC4468339
46. Choi MJ., Cho KH., Lee SJ., Bae YJ., Jeong KJ., Rha SY., Choi EJ., Park JH., Kim JM. LeeJS., Mills GB and Lee HY 2015 hTERT mediates norepinephrine-induced Slug expression and ovarian cancer cell progression Oncogene 34:3402-12 PMID:25151968
47. Ince TA., Sousa AD., Jones MA., Harrel C., Krohn M., Selfors LM., Liu W., Chen K., Yong M. Buchwald P., Hale KS., Kozhekbaeva Z., Foster R., Rueda B., Crum CP., Brugge JS., and Mills GB, 2015 Characterization of twenty-five novel ovarian tumor cell lines that phenocopy primary tumors Nature Comms 6:7419 PMID:26080861 PMC4473807
48. Miller T., Dillon LM., Bean JR., Yang W., Shee K., Symonds LK., Balko JM., McDonald W., Liu S., Gonzalez-Angulo AM., Mills GB., Arteaga C., 2015 P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT, and MEK/ERK signaling in ER+ breast cancer Oncogene 34:3968-76 PMID:25284585 PMC4387124
49. Liu Y., Sato M., Chen K., Hu L., Broaddus R., Ding L., Mardis E., Spellman P., Levine DA., Mills GB., Shmulevich I., Sood AK., and Zhang W., 2015 Association of Somatic Mutations of ADAMTS Genes with Improved Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma: Jama Oncology 1:486-94 PMID:26181259 PMC4608536
50. Gong L., Govan JM., Dai H., Wang E., Lee SW., Lin JK., Mills GB., Lin SY 2015 Nuclear PTEN Tumor-Suppressor Functions Through Maintaining Heterochromatin Structure Cell Cycle 14:2323-32 PMID:25946202 PMC4614552
51. Shen J., Peng Y, Lan L., Zhang W., Yang L., Stark J., Zou L. Uray IP., Wu X., Brown PH Mills GB and Peng G. 2015 ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors Cancer Discovery 5:752-67 PMID:26069190 PMC4497871
52. Korkola, J., Collisson, E., Heiser L., Oates C., Bayani N. Itani S., Esch A., Thompson W., Griffith O., Wang N., Kuo W-L., Cooper B., Billig J., Ziyad S., Hung J., Jakkula L., Feiler H., Lu Y., Mills G., Spellman P., Tomlin C., Mukherjee S., Gray JW., 2015 Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer Plos One 10:e0133219 PMID:26181325 PMC4504492
53. Skoulidis F., Byers LA., Diao L., Papadimitrakopoulou V., Izzo J., Behrens C., Kadara H., Cuertas P., Canales J., Zhagn J., Tong P., Giri U., Gudikote J., Cortez M., Yang C., Fan Y., Peyton M., Girard L, Coombes KR., Toniatti C., Heffernan T., Weinstein JN., Herbst R., Lifton R., Wong KK., Zhang j., Sharma P., Mills GB., Minna JD., Allison JP., Futreal A., Wang J., Wistube I., and Heymach J., 2015 Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology and therapeutic vulnerabilities Cancer Discovery: 5:860-77 PMID:26069186 PMC4527963
54. Meric-Bernstam, F., Brusco L., Shaw K., Horombe C., Kopetz S., Davies M., Routbort M., Piha-Paul S., Janku F., Moulder S., Hong D., De Groot J., Ravi V., Li Y., Luthra, R., Patel K., Broaddus R., Mendelsohn J., and Mills GB., 2015 Feasibility of Large-scale Genomic Testing to Facilitate Enrollment on Genomically-matched Clinical Trials J. Clin Onc 33:2753-62 PMID:26014291 PMC4550690
55. Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR. 2015 Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma JAMA Oncol. 1:238-44 PMID: 26181029 PMC455720
56. Cardnell R., Behrens C., Diao L., Fan YH., Tang X., Tong P., Minna JD., Mills GB., Cardnell R., Behrens C., Diao L., Fan YH., Tang X., Tong P., Minna JD., Mills GB., Heymach JV., Wistuba I Wang J and Byers LA. 2015 An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors including DNA repair proteins and Nrf2. Clin Cancer Res. 21:3480-91 PMID:25878335 PMC4526428
57. Boland GM, Piha-Paul S, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Johnson A, Broaddus, R, Luthra R, Shaw K, Aldape KD, Mendelsohn J, Mills GB, Meric-Bernstam F. 2015 Clinical next generation sequencing to identify actionable aberrations in a Phase I program. Oncotarget 6:20099-110 PMID:26015395 PMC4652990
58. Liang J., Xu Z-X., Ding Z., Lu Y., Yu Q., Werle KD., Zhou G., Park YY., Peng G., Gambello MJ., Mills GB., 2015 Myristoylation Confers Noncanonical AMPK Functions in Autophagy Selectivity and Mitochondrial Surveillance Nature Comms 6:7926 PMID: 26272043
59. McAuliffe PF., Evans KW., AKcakanat A., Chen K., Zheng X., Zhao H, Eterovic A., Sangail T., Holder A., Sharma C., Chen H., Do KA., Tarco E., Gagea M., Naff KA., Sshin A., Multan AS., Black D., Mittendorf EA., Bedrosian I., Mills GB., Gonzalez-Angulo AM., Meric- Bernstam F., 2015 Ability to Generate Patient-Derived Breast Cancer Xenografts is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes Plos One: 10:e0136851 PMID: 26325287 PMC4556673
60. Zhao D., Besser A., Wander S., Sun J., Wang B., Ince T., Zhou W., Guo W., Mills G., Theodorescu D., Slingerland J., 2015 Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation Oncogene 34:5447-59 PMID:25684140 PMC4537852
61. Roy-Chowdhuri SR., Gagliato D., Routbort MJ., Patel KP., Singh RR., Broaddus R., Lazar AJ., Sahin A., Alvarez RH., Moulder S., Wheler JJ., Janku F., Gonzalez-Angulo A., Chavez- MacGregor M., Valero V., Ueno N., Mills GB., Mendelsohn J., Yao H., Aldape K., Luthra R., Meric-Bernstam F. 2015 Multigene Clinical Mutational Profiling of Breast Carcinoma using Next Generation Sequencing (NGS) American Journal of Clinical Pathology 144:713-21 PMID: 26486734
62. Lee E., Yang J., Ku M., Kim NH., Park Y., Suh JS., Park ES., Yook JI., Mills GB., Huh YM., Cheong JH 2015 Metabolic stress induces a Wnt-dependent cancer stem cell-like state transition Cell Death and Disease 6:e1805 PMID:26136078 PMC4650724
63. Westin SN., Ju Z., Broaddus RR., Krakstad C., Li J., Pal N., Lu KH., Hennessy B., Klempner SJ., Werner HM., Salvesen J., Cantley LC., Mills GB., Myers AP 2015 PTEN loss is a context dependent determinant of patient outcomes in obese and non-obese endometrioid endometrial cancer patients. Molecular Oncology 9:1694-703 PMID:26045339 PMC4584169
64. Cheung LWT Walkiewicz KW., Besong T., Guo H., Hawke DH., Arold ST., and Mills GB 2015 Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium. Elife 4:e06866 PMID: 26222500 PMC4518712
65. Fabian CJ, Kimler BF, Phillips TA, Box JA, Kreutzjans AL, Carlson SE, Hidaka BH, Metheny T, Zalles CM, Mills GB, Powers KR, Sullivan DK, Petroff BK, Hensing WL, Fridley BL, Hursting SD. 2015 Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women. Cancer Prev Res 8:912-21 PMID: 26438592 PMC6053670
66. Fabian CJ., Kimler BF., Phillips TA., Nydegger JL., Kreutzjans AL., Carlson SE., Hidaka BH., Methen T., Zalles CM., Mills GB., Powers KR., Sullivan DK., Petroff BK., Michaels WL., Fridley BL., and Hursting SD., 2015 Modulation of Breast Cancer Risk Biomarkers in Postmenopausal Women by High Dose Omega-3 Fatty Acids: A Phase II Pilot Study Cancer Prevention Research. 8:922-31 PMID: 26276744 PMC4596784
67. Han L., Li J., Diao L., Yu S., Zhang R., Yang Y., Werner HMJ., Eterovic KA., Yuan Y., Nair N. Minelli R., Cheung LWT., Park YY., Lu Y., Scott KL., Li JB., Mills GB., and Liang H 2015 The genomic landscapes of A-to-I RNA editing in human cancer Cancer Cell 12;28:515-28 PMID: 26439496 PMC4605878
68. Yan X., Hu Z., Feng Y., Ju X., Zhao S., Zhang Y., Yang L., he Q., Shan W., Kandalaft L, Tanyi J., Li C., Yuan C-X., Fan L., Zhang D., Hua K., Huang Q., Montone K., Lu Y., Luo B., Xu X., Katsaros K., Fan Y., Coukos G., Boyd J., Rebbeck T., Mills GB., Dang CV., Zhang L., 2015 Comprehensive Genomic Characterization of Long Non-Coding RNAs across Human Cancers Cancer Cell 28:529-40 PMID: 26461095 PMC477735
69. Zhao J., Zhao D., Poage GM., Mazumdar A., Zhang Y., Hill J., Hartman Z., Savage M., Mills GB., Brown P., 2015 DAPK-1, a Death Signaling Transducer, is Critical for the Tumorigenicity of p53 Mutant Breast Cancer J Clin Invest 125 2707-20 PMID: 26075823 PMC4563671
70. Zhou W., Chen T., Cong Z., Rohrdanz M, Melott J., Wakefield C., Zeng J., Weinstein J., Meric- Bernstam F., Mills GB., and Chen K., 2015. TransVar: a trans-level variant annotator for precision genomics Nature Methods: 12:1002-3 PMID: 26513549 PMC4772859
71. Sehgal V, Seviour EG, Moss TJ, Mills GB, Azencott R, Ram PT 2015 Robust Selection Algorithm (RSA) for multi-omic biomarker discovery; integration with functional network analysis to identify miRNA regulated pathways in multiple cancers PLOS One 10:e0140072 PMID: 26505200 PMC4623517
72. Cheraghchi-Bashi, A., Parker C., Curry E., Salzar JF., Gungor H., Saleem A., Cunnear P., Rama P., Salinas C., Mills G., Morris S., Kumar R., Gabra H., and Stronach E., 2015 A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway Oncotarget 6:41736-49 PMID: 26497682 PMC4747185
73. Dogruluk T., Tsang Y., Espatia M., Chen F., Chen T., Chong Z., Appadurai B., Dogruluk A., Eterovic AK., Bonnen P., Creighton C., Chen K., Mills GB., Scott KL., 2015 Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. Cancer Res: I75:5341-54 PMID: 26627007 PMC4681596
74. Labidi-Galy, SI., Clauss A., Ng V., Duraisamy S., Elias KM., Bilal E., Davidowitz, RA., Lu Y., Badalian-Very G., Gyorffy B., Kang U-B., Ficarro S., Ganesan S., Mills GB., Marto J., Drapkin R., 2015 Elafin drives poor outcomes in hihg-grade serous ovarian cancers and basal like tumors Oncogene 34:373-83 PMID: 24469047 PMC4112176
75. Rupaimoole R., Lee J., Haemmerle M., Ling H., Previs R., Pradeep S., Wu S., Ivan C., Ferracin M., Dennison JB., Zacharias Millward N., Nagaja A., Gharpure K., McGuire M., Sam N., Armaizena G., Sadaoui N., Rodriguez-Aguaro C., Calin G., Drapkin R., Kovac J., Mills GB., Zhang W., Lopez-Berestein Bhattacharya P., and Sood A. 2015. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports 13:2395-402 PMID: 26686630 PMC469155
76. Roy A., Skibo J., Kalume F., Ni J., Rankin S., Lu Y., Dobyns WB., Mills GB., Zhao J., Baker SJ and Millen KJ 2015 Mouse models of human PIK3CA-related brain overgrowth have treatment-responsive epilepsy eLIFE 4:pil: e12703 PMID: 26633882 PMC4744197
77. Wang C., Zhu X., Feng W., Yu Y., Jeong K., Guo W, Lu Y., Mills GB 2015 Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm American Journal of Cancer Research 6:27-37 PMID: 27073720 PMC4759394
78. Li H, Wheeler S, Park Y, Ju, Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U1, Bauman JE, Mills GB, Grandis JR 2015 Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts Mol Can Res. 14:278-86 PMID: 26685214 PMC4794346
79. Aure MR., Jernstrom S., Krohn, M., Vollan HKM., Due EU., Rodland E., OSBREAC, Ram P. Lu Y., Mills GB., Sahlberg KK., Borresen-Dale A-L., Lingjaerde OC., Kristensen VN., 2015 Integrated analysis reveals microRNA networks coordinately expressed with key proteins inbreast cancer. Genome Med. 7:21 25873999 PMID:25873999 PMC4396592
80. Moss TJ., Luo Z., Seviour EG., Lu Y., Hill SM Sehgal V., Sood A., Azencott R., Gray JW., Mukerjee X., Mills GB., and Ram PT 2015 Genome-wide perturbations by miRNAs map onto functional cancer pathways, identifying regulators of chromatin modifiers npj Systems Biology and Applications 1:15001 doi:10.1038/npjsba PMID: 28725457 PMC5516802
81. Mo W., Dai H., Lin CJ., Liu Q., Peng Y., Liang Y., Meric-Bernstam F., Mills G., Li K., Lin SY. 2016 mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 expression in triple-negative breast cancer Clinical Cancer Research 22:1699-712 PMID: 26546619 PMC4858320
82. Huang S., Tu W., Ju Z., Poage GM., Brewster A., Lin S-Y., Mills GB., Wang H., and Peng G., 2016 A five-gene signature inferred from transcriptome profiling of homologous recombination- mediated DNA repair predicts clinical outcome of patients with cancer Jacobs Journal of Biomarkers. 2:014
83. Chen F., Zhang Y., Senbabaoglu Y., Ciriello G., Yang L., Reznik E., Shuch B., Micevic G., De Velasco G., Shinbrot E., Noble M., Lu Y., Covington K., Xi L., Drummond J., Muzny D., Kang H., Lee J., Tamboli P., Reuter V., Shelley CS., Kaipparettu B., Bottaro D., Godwin A., Getz G., Kucherlapati R., Park P., Sander C., Henske E., Zhou J., Kwiatkowski D., Ho T., Choueiri T., Hsieh J., Akbani R., Mills G., Hakimi A., Gibbs R., Wheeler D., Creighton C., 2016 Multilevel Genomics-based Taxonomy of Renal Cell Carcinoma Cell Reports 14:2476-89 PMID: 26947078 PMC4794376
84. Krepler C., Xiao M., Sproessar K., Brafford P., Shannan B., Beqri M. Liu Q., Xu W., Garman G., Nathanson K., Xu X., Karakousis G., Mills GB., Lu Y., Ahmed TA, Caponigro G., Boehm M., Peters M., Schuchter L., Weerarantna A., and Herlyn M., 2016 Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models identify second line combination therapies Clin Can Res 22:1592-602 PMID: 26673799 PMC4818716
85. Marcotte R., Sayad A., Brown K., Sanchez-Garcia F., Reimand J., Hadier M., Virtanen C., Bradner J., Bader G., Mills GB., Pe’er D and Neel BG. 2016 The functional genomic landscape of human breast cancer cell lines Cell 164:293-309 PMID: 26771497 PMC4724865
86. Seviour E, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SM, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguay C, Roopaimoole R, Pecot C, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT 2016 Functional proteomics identifies miRNA to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer Oncogene 35:691- 701 PMID:25639871 PMC4522411
87. Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JS. 2016 Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology 63:159-72 PMID: 26389641 PMC4881866
88. Carvalho S., Lindzen M., Lauriola M., Shirazi N., Sinha S., Abdul-Hai A., Levanon K., Korach J., Barshack I., Cohen Y., Onn A., Mills GB., Yarden Y., 2016 An antibody to amphiregulin, an abundant factor in patients’ fluids, inhibits ovarian tumors Oncogene 35:438-47 PMID: 25915843
89. Timah, Z., Ahmed Z., Ivan C., Gagea M., Berrout J., Zhou Y., Armaiz-Pena GN., Hu Y., Wallie C., Kingsley CV., Lu Y., Hancock JF., Gladde AB., Mills GB., Lopez-Berestein G., Hung MC., Sood AK., Bogdanove M., and Ladbury JE., 2016 Grb2 depletion under non-stimulated conditions inhibits PTEN promoting Akt-induced tumor formation and poor prognosis in ovarian cancer Oncogene: 35:2186-96 PMID:26212011 PMC4792786
90. Nanos-Webb A., Carey J., Mills GB., Hunt KK., Keyomarsi K. 2016 PKC iota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene 35:2428-40 PMID: 26279297 PMC4856585
91. Hew K., Miller P., El-Ashry D., Sun J., Wei Z., Zhang G., Goa W., Lu Y., Brafford P. Mills G., Ince T., Slingerland JM and Simpkins F., 2016 MAPK kinase activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance by altering signaling, cell cycle and survival pathways in high grade serous ovarian cancer Clin Cancer Research 22:935- 47 PMID: 26482043 PMC4755805
92. He N., Kim N., Jeong E., Lu Y., Mills GB., Yoon S 2016 Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines. Int J Oncol. 48:67-72 PMID: 26573869 PMC4734611
93. Hill SM, Heiser LM, Cokelaer T, Unger M, Nesser NK, Carlin DE, Zhang Y, Sokolov A, Paull EO, Wong CK, Graim K, Bivol A, Wang H, Zhu F, Afsari B, Danilova LV, Favorov AV, Lee WS, Taylor D, Hu CW, Long BL, Noren DP, Bisberg AJ; HPN-DREAM Consortium, Mills GB, Gray JW, Kellen M, Norman T, Friend S, Qutub AA, Fertig EJ, Guan Y, Song M, Stuart JM, Spellman PT, Koeppl H, Stolovitzky G, Saez-Rodriguez J, Mukherjee S. 2016 Inferring causal molecular networks: empirical assessment through a community-based effort. Nature Methods 13:310-8 PMID: 26901648 PMC4854847
94. Budina-Kolomets, A., Webster M., Leu J., Jennis M., Krepler C., Guerrino A., Kossenkov A., Xu W., Karakousis G., Shachter L., Amaravadi R., Wu H., Yin S., Liu Q., Lu Y., Mills GB., Su X., George D., Weeraratna A., Murphy W., 2016 HSP70 inhibition limits FAK-dependent invasion and enhances the durability of BRAF inhibitor treatment in melanoma Cancer Research 76:2720-2730 PMID: 26984758 PMC4939897
95. Meric-Bernstam F., Brusco L., Daniels M., Wathoo C., Bailey A., Strong L., Shaw K., Lu K., Qi Y., Lare-Guerra H, Litton J., Arun B, Zhao H., Eterovic A., Aytac U., Routbort M., Subbiah V., Janku F., Davies M., Kopetz S., Mendeloshn J., Mills GB., Chen K., 2016 Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Anals Oncology 27:795-800 PMID: 26787237 PMC4843184
96. Tsang Y-H., Dogruluk T., Espita M., Lu H., Ramanathan S., Chong Z., Chen F., Nair N., Minelli R., Tedeschi P., Chang Q., Dennison J., Li M., Ying H., Bertino J., Gingras M-C., Ittman M., Chen K., Creighton CJ., Eterovic AK., Potts T., Mills GB., Scott KJ 2016 Functional Annotation of Rare Gene Aberration Drivers of Pancreatic Cancer Nature Communications 7:10500 PMID: 26806015 PMC4737758
97. Chaluvally-Raghavan P., Jeong K., Pradeep S., Yu S., Liu W., Moss T., Sehgal V., Rodriguiez- Aguayor K., Zhan D., Lopez-Berestin G., Ram P., Liu J., Lu Y., Sood A., and Mills GB 2016 Direct up regulation of STAT3 by microRNA-551b deregulates growth and metastasis of ovarian cancer Cell Reports 15:1493-504 PMID: 27160903 PMC4914391
98. Yuan Y., Liu L., Chen H., Wang Y., Xu Y. Mao H., Li J., Mills GB., Shu Y., Li L., Liang H., 2016 Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients Cancer Cell 29:711-22 PMID: 27165743 PMC486495
99. Bissig-Choisat B., Kettlun-Leyton C., Legras XD., Zorman B., Barzi M., Chen L., Amin M., Huang Y-H., Pautler R., Hampton O., Prakash M., Muzny D., Doddapeneni H., Hu J., Shi Y., Baber W., Hicks J., Thompson P., Lu Y, Mills GB., Finegold H., Goss J., Parsons DW., Vasudevan S., Sumazin P., Lopez-Terrad D., Bissig K-D., 2016 Novel Patient-Derived Xenograft and Cell Line Models for Therapeutic Testing of Pediatric Liver Cancer. Journal of Hepatology 65:325-33 PMID: 27117591 PMC5668139
100. Boulay, P-L., Mitchell L., Turpin J., Huot-Marchand, J-E., Lavoie C., Sanguin-Gendreau V., Jones L., Mitra S., Livingstone JM., Campbell S., Hallet M., Mills GB., Park M., Chodosh L., Strathdee D., Norman JC, and Muller WJ., 2016 Rab11-FIP1C is a critical negative regulator in ErbB2-mediated mammary tumor progression Cancer Research 76:2662-2674 PMID: 26933086 PMC5070470
101. den Hollander P., Rawls K., Tsimelson A., Shepherd J., Mazmuder A., Hill J., Fuqua S., Chang J., Osborne K., Hilsenbeck S., Mills GB., and Brown PH 2016 Phosphatase PTP4A3 promotes triple negative breast cancer growth and predicts poor patient survival Cancer Research 76:1942-1953 PMID: 26921331 PMC4873402
102. Janku F., Huang H., Claes B., Falchook G., Fu S., Hong D., Ramzanali N., Nitt G., Cabrillo G., Tsimberidou A., Naing A., Piha-Paul S., Wheler JJ., Karp D., Holley VR., Zinner RG., Subbiah B., Luthra J., Kopetz S., Overman M., Kee B., Patel S., Devogelaere B., Sablone E., Maertens G., Mills GB., Kurzrock R., and Meric-Bernstam F. 2016 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Molecular Cancer Therapy 15:1397-404 PMID: 27207774
103. Overman, MJ., Morris V., Kee B., Fogelman D., Xiao L., Eng C., Dasari A., Shroff R., Mazard T., Shaw K., Vilar E., Raghav K., Shureiqi T., Liang L., Mills GB., Wolff RA., Hamilton S., Meric-Bernstam T., Abbruzzese J., Morris J., Maru D., and Kopetz S 2016 Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker- selected clinical trials. Annals Oncology27:1068-74 PMID: 27045102 PMC6276928
104. Jeong AL, Han S, Lee S, Su Park J, Lu Y, Yu S, Li J, Chun KH, Mills GB, Yang Y. 2016 Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC- JNK-c-Jun pathway. Sci Rep 6:27391. doi: 10.1038/srep27391 PMID: 27272709 PMC4895347
105. Jinesh GG., Molina JR., Huang L., Laing NM., Mills GB., Bar-Eli M and Kamat AM 2016 Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield- mediated transformation after apoptosis Cell Death and Discovery 2:16003 PMID: 27551498 PMC4979437
106. Telli M., Timms K., Reid J., Hennessy B., Mills GB., Jensen K., Saallasi Z., Barry W., Winer E., Tung N., N., Isakoff S., Ryan PD.,Greene-Colozzi A., Gutin A., Sangale Z., Iliev D., Neff C., Abkevich V., Jones J., Lanchbury J., Hartman A, Garber J., Ford J., Silver D., Richardson A.,2016 Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer. Clinical Cancer Research 22:3764-73 PMID: 26957554 PMC6773427
107. Ledgerwood, L., Kumar D., Eterovi A., Wick J., Chen K., Zhao H., Chien J., Manna P., Kerley S., Joshi R., Want L., Chiosea S., Tsue T., Grandis J., Mills GB and Thomas S., 2016 The degree of intra-tumor mutational heterogeneity varies by primary tumor sub-site Oncotarget 7:27185-98 PMID: 27034009 PMC5053641
108. German P., Bai S., Liu X-D., Sun M., Zhou L., Kalra S., Zhang X., Minelli R., Scott KL., Mills GB., Jonasch E., Ding Z., 2016 Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function Oncogene 35:4973-80 PMID: 26973240 PMC5086402
109. Yang JY., Werner HMJ., Li J., Westin SN., Lu Y., Salvesen HB., Mills GB., and Liang H 2016 Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer Clinical Cancer Research 22:513-23 PMID: 26224872 PMC4715969
110. Mazumder A., Poage GM., Tsimelson A., Hartman Z., Den Hollander P., Hill J., Zhan Y., Chang J., Hilsenbeck S., Fuqua S., Osborne CK., Mills GB., and Brown PH., 2016 Analysis of Phosphatases in ER-negative Breast Cancers Identifies DUSP4 as a Critical Regulator of Growth and Invasion Breast Cancer Res. Treat 158:441-54 PMID: 27393618 PMC4963453
111. Kim N., He N., Lee CJ., Lee M-H., Park C., Kim S., Jeong E., Song M., Kim W-Y., Mills GB, Cho YY and Yoon S., 2016 Cardiac glycosides display selective efficacy for STK11 mutant lung cancer Sci Rep. 6:29721. doi: 10.1038/srep29721 PMID: 27431571 PMC4949473
112. Chen T, Wang Z, Zhou W, Chong Z, Meric-Bernstam F, Mills GB, Chen K. 2016 Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. BMC Genomics. 17 Suppl 2:394. doi: 10.1186/s12864-016-2727-x. PMID: 27356755 PMC4928158
113. Dennison JB., Shahmoradgoli M., Liu W., Ju Z., Meric-Bernstam F., Perou CM., Sahin A., Welm A., Oesterreich S., Sikora M., Brown RE and Mills GB. 2016 High intra-tumoral stromal content defines reactive breast cancer as a low-risk subtype Clinical Cancer Res. 22:5068-5078 PMID: 27172895 PMC5103285
114. Mitra S, Federico L, Zhao W, Dennison J, Sarkar TR, Zhang F, Takiar V, Cheng KW, Mani S, Lee JS, Mills GB. 2016 Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. Oncotarget 7:40252-40265 PMID: 27259233 PMC5130006
115. Berns K., Sonnenblick A., Gennissen A., Brohee, S., Hijmans EM., Evers B., Fumugalli D., Desmedt C., Loibl S., Denkert C., Neven P., Guo W., Zhang F.., Knijnenburg TA., Bosse T., van der Heijden MS., Hindriksen S., Nijkanp W., Wessels LFA., Joensuu H., Mills GB., Biejersbergen RL., Sortirou C., and Bernards R., 2016 Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance Clinical Cancer Research 22:5238-5248 PMID: 27172896
116. Haukaas TH., Euceda LR., Giskeodegard G., Lamichhane S., Krohn M., Jernstrom, S., Aure MR., Lingjaerde OC., Schlichting E., Garred O., Due EU., Mills GB., Sahlber KK., Borresen- Dale AL., Bathen TF., The Oslo Breast Cancer consortium (OSBREAC), 2016 Metabolic clusters of breast cancer in relation to gene- and protein- expression subtypes Cancer Metab. 4:12. PMID: 27350877 PMC4922058
117. Roszik, J., Haydu L., Hess KR., Oba J., Joon A., Siroy A., Karpinets TV., Stingo F., Baladandayuthapani V., Tetzlaff M., Wargo J., Chen K., Forget M-A., Haymaker C., Chen J., Meric-Bernstam F., Eterovic A., Shaw K., Mills GB., Gershenwald J., Radvanyi L., Hwu P., Futreal A., Gibbons D., Lazar A., Bernatchez C., Davies M., and Woodman S., 2016 Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set BMC Med 14:168 PMID: 27776519 PMC5078889
118. Turpin J., Ling C., Swanson I., Rayment J., Ursini-Siegel J., Hartman Z., Gray J., Griffith O., Chodosh L., Renhack J., Andrechek., E., Ozcelik J., Hallett M., Mills GB., Cardiff R., and Muller W., 2016 The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Oncogene 35:6053-6064 PMID: 27157621 PMC5102823
119. Muranen, T., Selfors LM., Hwang J., Gallegos LL., Coloff JL., Thoreen CC., Mills GB and Brugge JS., 2016 The balance of ERK and p38 MAPK Activity Determines the Sensitivity to PI3K/mTOR Inhibition Through Regulation of MYC and YAP Cancer Research 76:7168-7180 PMID: 27913436 PMC5161652
120. Basho R., Gagliato D., Ueno N., Wathoo C., Chen H., Wei C, Alvarez R., Moulder S., Sahing A., Chowdhuri SR., Chavez-MacGregor M., Litton J., Valero V., Luthra R., Zeng J., Shaw KR., Mendelsohn J., Mills GB., Tripathy D., and Meric Bernstam F., 2016 Clinical Outcomes Based on Multigene Profiling in Metastatic Breast Cancer Patients Oncotarget 7:76362-76373 PMID: 27806348 PMC5363515
121. Ryasen GW., Hattersly M., Yao Y., Dulak A., Wang W., Petteruti P., Dale I., Boiko S., Cheung T., Zhang J., Wen S., Castriotta L., Lawson D., Collins M., Bao J., Ahdesmake M., Walker G., O’Connor G., Yeh T., Rabow A., Dry J., Reimer C., Lyne P., Mills GB., Fawell S., Waring MJ., Zinda M., Clark E., and Chen H., 2016. AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies Mol Can Ther 15:2563-2574 PMID: 27573426
122. Lisanti S., Garlick D., Bryant K., Tavecchio M., Mills GB., Lu Y., Kossenkov A., Showe L., Languno L., and Altieri D., 2016 Transgene expression of mitochondrial chaperone TRAP1 accelerates prostate cancer development J Biol Chem 291:25247-25254 PMID: 27754870 PMC5122790
123. Lucenay K., Doostan I., Karakas C., Bui T., Ding Z., Mills GB., Hunt K., Keyomarsi K., 2016 Cyclin E associates with the lipogenic enzyme ATP-citrase lyase to enable malignant growth of breast cancer cells Cancer Research 76:2406-18 PMID: 26928812 PMC4873469
124. Zhang G., Frederick DT., Wei Z., Wu L., Krepler C, Chae YC., Xu X., Wu L., Choi H., DimWamwa E., Shannan B., Besu, D., Zhang D., Guha M., Srinivasan S., Xiao M., Liu S., Sproesser K., Xu W., Karakousis GC., Schuchter LM., Gangadhar T., Amaravadi RK., Xu C., Ghosh A., Xu W., Zhang J., Liu Q., Brafford P., Woo J., Weeraratna A., Davies MA., Wargo JA., Avadhani NG., Mills GB., Altierii DC., Flaherty KT., and Herlyn M., 2016 Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors J Clin Invest 126:1834-56 PMID: 27043285 PMC4855947
125. Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, Mills GB, O’Reilly EM, Knudsen ES. 2016 Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer Cell Reports 16-2017-31 PMID: 27498862 PMC5287055
126. Bhuvanesh D., Gonzalez D., Liu Z-B., Li X., Wong H., Ezzeddine N., Sieglaff, D., Ensor J., Miller K., Radovich M., Eterovic A., Gross S., Elemento O., Mills GB., Gilcrease M., and Chang J. 2016 Role of RPL39 in metaplastic breast cancer J Natl Cancer Inst.109. pii: djw292. PMID: 28040796 PMC6245334
127. Hill S., Nesser N. Johnson K., Jeffress M., Johnson A., Boniface C., Spencer S., Lu Y., Heiser L., Lawrence Y., Pande N., Korkola J., Gray JW., Mills GB., Mukherjee S., and Spellman P. 2017 Context-specificity in causal signaling networks revealed by phosphoprotein profiling Cell Systems 4:73-83 PMID:28017544 PMC5279869
128. Seviour E, Sehgal V, Mishra D., Rupaimoole R., Rodriguez-Aguayo, Lopez-Berestein G., Lee JS., Sood AK., Kim MP Mills GB Ram PT 2017 Targeting KRas-dependent tumor growth, circulating tumor cells and metastasis in vivo by clinically significant miR-193a-3p Oncogene 36:1339-1350 PMID: 27669434 PMC5344721
129. Chen F., Zhang Y., Parra E., Rodriguez J., Behrens C., Akbani R., Lu Y., Kurie J., Gibbons DL., Mills GB., Wistuba I., Creighton C., 2017 Multiplatform-based Molecular Subtypes of Non- Small Cell Lung Cancer Oncogene 36:1384-1393 PMID: 27775076 PMC5344748
130. Liu J., Plakurthi S., Zeng Q., Zhou S., Ivanova E., Huang W., Zervantonakis I., Selfors L., Shen Y., Pritchard C., Zheng M., Wulf G., Paweletz C., English J., Kirschmeier P., Mills G., Livingston D., Brugge J., Matulonis U., and Drapkin R., 2017 Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics Clin Can Res. 23:1263-1273 PMID: 27573169 PMC5332350
131. George E., Kim H., Krepler C., WenzB., Makvandi M., Tanyi J., Brown E., Zhang R., Brafford, Pl, Jean S., Mach R., Lu Y., Mills GB., Herlyn M., Morgan M., Zhang R., Soslow R., Drapkin R., Johnson N., Zheng, Y., Cotsarelis G., Nathanson KL., and Simpkins F., 2017 A patient derived xenograft platform to study BRCA-deficient ovarian cancers JCI Insight 2(1):e89760 PMID: 28097235 PMC5214535
132. Li J., Zhao W. Akbani R., Liu W., Ju Z., Ling S., Vellano C., Roebuck P., Eterovic AK., Byers LA., Davies MA., Dent W., Gopal YNV., Chen G., von Euw E., Slamon D., Conklin D., Heymach J. Minna J., Lu Y., Mills GB., and Liang H. 2017 Characterization of Human Cancer Cell Lines by Reverse-Phase Protein Arrays Cancer Cell 31:225-239 PMID: 28196595 PMC5501076
133. Wang C., Gu C., Zhang D., Jeong K., Guo W., Bai S., Lu Y., Ju Z., Panupinthu N., Yang J., N K-S., Zhang F., Mills GB 2017 YAP and TAZ upregulate GAB2 leading to increased sensitivity to growth factor induced activation of the PI3K pathway Cancer Research 77:1637-1648 PMID: 28202507 PMC6026015
134. Kang M-H., Jeong K-J., Kim WY., Lee HJ., Gong G., Suh N., Byorffy B., Kim S., Jeong SY., Mills GB., and Park YY 2017 Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer Oncogene 36:1745-1752 PMID: 27593929
135. Matulonis, U., Barry M., Wulf G., Birrer M., Westin S., Farooq S., Bell-McGuinn K., Obermayer E. Whalen C., Spagnoletti T., Aghajanian, C., Solit D., Mills GB., Cantley L., and Winer E., 2017 Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer. Anals Oncology 28:512-518 PMID: 27993796 PMC5834157
136. Verma N., Muller AK., Kothari C., Panayotopoulou E., Kedan A., Selitrennik M., Mills GB., Nguyen LK., Karn T., Holtrich U., and Lev S., 2017 Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. Cancer Research 77:86-99 PMID: 27793840
137. Aure M., Vitelli B., Jernstrom S., Kumar S., Krohn M., Due E., Haukaas T., Leivonen SK., Vollan H., Luders T. Rodland E., Vaske C., Moller E., Nord M., Biakeodegard G., Bathen T., Kukholm I., OSBREAC., Naume B., Schlichtin E., Sauer T., Mills GB., Karesen R., Maelandsmo T., Lingjaerd O., Frigessi A., Kristensen B., Borresen-Dale A-L., Sahlber KK., 2017 Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome Breast Cancer Research 19:44 PMID: 28356166 PMC5372339
138. Ying Y., Shen Q., Zhang P., Tao R., Chang W., Li R., Xie G., Liu W., Zhang L., Kapoor P., Song S., Ajani J., Mills GB. Chen J., Tao K. and Peng G. 2017 Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer American Journal of Cancer Research 7:473-483 PMID: 28401005 PMC5385637
139. Bauman J., Duvvuri U., Gooding W., Rath T., Gross N., Song J., Jimeno A., Yarbrough W., Johnson F., Wang L., Chiosea S., Sen M., Kass J., Johnson J., Ferris R., Kim S., Hirch F., Flaherty J., Mills GB and Grandis J. 2017 Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer JCI Insight 2:e90449. PMID: 28352657 PMC5358497
140. Federico L., Chong Z., Zhang D., McGrail D., Zhao W., Jeong K., Vellano C., Ju Z., Gagea M., Liu S., Mitra S., Dennison J., Lorenzi P., Cardnell R., Diao L., Wang J., Lu Y., Byers LA., Perou CM., Lin S-Y., and Mills GB 2017 A preclinical syngeneic model for breast cancer precision medicine Science Advances 3:e1600957 PMID: 28439535 PMC5397135
141. Yi S., Lin S., Li Y., Zhao W., Mills GB., and Sahni N., 2017 Functional Variomics and Network Perturbation: Connecting Genotype to Phenotype in Cancer Nature Reviews Genetics 18:395- 410 PMID: 28344341 PMC6020840
142. Song M., Lee H., Nam MH., Jeong E., Kim S., Hong Y., Kim N., Yim H., Kim JS, Kim JS., Mills GB, Kim WY and Yoon S. 2017 Loss-of-function screens of druggable targetome of cancer stem-like cells Faseb Journal: 31:625-635 PMID 27811063 PMC5240669
143. Hwang MH., Cho KS., Jeong KJ., Park YY., Kim JM., Yu SL., Park CG., Mills GB., and Lee HY 2017 RCP induces Slug expression and cancer cell invasion by stabilizing β1 integrin Oncogene 36:1102-1111 PMID: 27524413
144. Paez-Arango N., Brusco L., Mills Shaw K., Chen K., Eterovic A., Holl V., Johnson A., Litzenburger B., Khotskaya Y., Sancheez N., Bailey A., Zheng X., Horombe C., Kopetz S., Farhangfar C., Routbort., Broaddus R., Bernstam E., Mendelsohn J., Mills GB and Meric- Bernstam F. 2017 A Feasibility Study of Returning Clinically Actionable Somatic Genomic Alterations Identified in a Research Laboratory Oncotarget 8:41806-41814 PMID: 28415679 PMC5522029
145. Kurnit K., Fellman B., Urbauer D. Mills GB., Zhang W., and Broaddus RR 2017 CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence Modern Pathology 30:1032-1041 PMID: 28281553 PMC549352
146. Zoeller JJ., Bronson RT., Selfors LM., Mills GB., Brugge JS. 2017 Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo NPG Breast Cancer 3:18. PMID: 28649658 PMC5460247
147. McGrail D., Lin C., Garnett J., Liu Q., Mo W., Dai H., Lu Y., Yu Q., Ju Z., Yin J., Vellano C, Hennessy B., Mills GB and Lin S-Y 2017 Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm NPG Systems Biology and Applications 3:8. PMID: 28649435 PMC5445594
148. Sun C., Fang Y., Yin J., Chen J., Ju Z., Zhang D., Chen X., Vellano C., Bhola N., Lu Y., Westin S., Grandis J., Lin S-Y., Scott K., Peng G., Brugge J., and Mills GB 2017 Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers Science Translational Medicine 9. pii: eaal5148 PMID: 28566428 PMC5919217
149. Wang Y., Xu. X., Yu S., Jeong KJ., Zhou Z., Han L., Tsang Y., Li J., Chen H., Mangala S., Yuan Y., Eterovic K., Lu Y., Sood AK., Scott K., Mills GB and Liang H., 2017 Systematic Characterization of A-to-I RNA Editing Hotspots in MicroRNAs across Human Cancers Genome Research 27:1112-1125 PMID: 28411194 PMC5495064
150. Zhang D., Zhang G., Hu X., Wu L., Feng Y., He S., Yang l., Jy Z., Zhang Y., Tian T., Cu W., Wei Z., Lu Y., Flaherty K., Zhong X., Mills G., Bimotty P., Xu X., Herlyn M., and Zhang L., 2017 Oncogenic Ras regulated long non-coding RNA Orilnc1 in human cancer Cancer Research 77:3745-3757 PMID: 28473531 PMC5511552
151. Zhao W., Fitzgibbon M., Bergan L., Clegg N., Crispin D., Mills GB and MacIntosh M 2017 Identifying abundant immunotherapy and other targets in solid tumors: integrating RNA- seq and Mass Spectrometry proteomics data sets Cancer J 23:108-114 PMID: 28410298 PMC5839124
152. Iida Y., Ciechanover A., Marzese D., Hata K, Bustos M., Ono S., Salomon MP., Tran K., Hsu S., Nelson N., Kravtsova-Ivantsiv Y., Mills GB., Davies MA., Hoon D., 2017 KPC1 Ubiquitin Ligase mediates Melanoma Metastasis Through Proteasomal Processing of NF-κB1 p105 into p50 Clinical Cancer Research 23:4831-4842 PMID28389511 PMC5559338
153. Janku F., Zhang S., Waters J., Huang H., Subbiah V., Hong D., Karp D., Fu S., Cai X., Ramzanli N., Madwant K., Cabrilo G., Andrews D., Zhao Y., Javle M., Kpoetz S., Luthra R., Kim H., Gnerre S., Satya R., Kurglyak K., Toung J., Liu L., Zhao C., Shen R., Heymach J., Meri-Bernstam F., Mills GB., Fan J-B., Salatis N., 2017 Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Can Research 23: 5648-5656 PMID: 28536309 PMC5600825
154. Zervantonakis, IK., Iavarone C., Chen HY., Selfors LM., Palakurthi S., Liu JF., Drapkin R., Matumonis U., Leverson JD., Sampath D., Mills GB and Brugge JS., 2017 Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nature Comms 8:365 PMID 28848242 PMC5573720
155. Städler N. Dondelinger F., Hill SM, Akbani, K., W, Lu, Y., Mills GB., Mukherjee S., 2017 Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case study. 33:2890-2896 PMID: 28535188 PMC5590725
156. Wang Z., Kim TB., Peng B., Karam JA., Creighton C., Joon A., Jonasch E., Chow C-W., Canales JR., Tamboli P., Tannir N., Wood C., Monzon F., Baggerly K., Czerniak B., Wistuba I., Mills GB., Shaw K., Chen K., and Sircar K., 2017 Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clinical Cancer Research 23:6686-6696 PMID:28710314 PMC5683086
157. Kurnit K., Bailey A, Zeng J., Johnson A., Shufen M., Litzenburger B., Sanchez N., Khotskaya Y., Holla B., Simpson A., Mills GB., Mendelsohn M., Bernstam EV., Shaw K., Meric-Bernstam F., 2017 [http://WWW.PERSONALIZEDCANCERTHERAPY.ORG:](http://WWW.PERSONALIZEDCANCERTHERAPY.ORG/) A publicly available precision oncology resource Cancer Research 77 e123-e126 PMID: 29092956 [PMC5774617](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774617/)
158. Daniels M., Wathoo C., Brusco L., Lu KH., Shaw K., Dumbrava E., Arun B., Strong L., Litton J., Eterovic K., Aytac U., Mendelsohn J., Mills GB., Chen K., and Meric-Bernstam F 2017 Active Disclosure of Secondary Germline Findings to Deceased Research Participants’ Personal Representatives: Process and Outcomes JCO Precision Oncology DOI: 10.1200/PO.17.00074 PMID 31552380 PMC6759057
159. Lu H., Villafane N Dogruluk T., Grzeskowiak C., Kong K., Tsang YH., Pantazie A., Yang L., Neill N., Kim YW Creighton C., Park P., Mills GB., Kucherlapati R., Scott KL 2017 Economical, Scalable Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer. Cancer Research 77:3502-3512 PMID: 28512244 PMC5568774
160. Mitra S., Montgomery JE., Kolar MJ., Li G., Jeong KJ., Peng B., Verdine GL., Mills GB., Moellering G. Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer. Nature Communications 2017 8:660 PMID: 28939823 PMC5610242
161. Johnson A., Khotskaya Y., Brusco L., Zeng J., Holla V., Bailey AM., Litzenburger B., Sanchez N., Shuean M., Shaw K., Mills G., Mendelsohn J., and Meric-Bernstam F., 2017 Clinical Utilization of Precision Oncology Decision Support JCO Precision Oncology doi: 10.1200/ PO.17.00036 PMID:30320296 PMC6179148
162. Han G., Zhao W., Song X., Ng P., Karam JA., Jonasch E., Mills GB., Zhao Z., Ding Z., Jia P., 2017 Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. BMC Genomics 18: 678 PMID: 28984208 PMC5629613
163. Li J., Akbani R., Zhao W., Lu Y., Weinstein J., Mills GB and Liang H., 2017 Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. Cancer Research 77 e51-e54 PMID: 29092939 PMC5679242
164. Nidoye A., Budina A., Kugel C., Webster M., Kaur A., Hehera R., Rebecca B., Li L., Nanda V., Davies M., Mills GB., Herlyn M., Soengas M., Amarvadi R., Murphy M., and Weerarantna A., 2017 ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. Cancer Research 77:5873-5885 PMID: 28887323 PMC5718045
165. Mjos, S., Werner HMJ., Birkeland E., Holst F., Berg A., Halle M., Tangen I., Kusonmano K., Mauland K., Oyan A., Kalland KH., Lew A., Mills GB., Krakstad C., Trovik J., Salvesen H., and Hoivik EA., 2017 PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports 7:10240 PMID 28860563 PMC5578954
166. Krepler C., Sproesser, K., Brafford P., Beqiri M., Xia M., Shannan B., Watters A., Perego M., Zhang G., Vulture A., Uin X., Liu Q., Garman G., Anastopoulos I., Wubbernorst G., Wilson M., Xu W., Torigan D., Karagousis G., SXu S., Amaravadi R., Gangadhar T., Elder D., Jaydu L., Wargo JA., Davies M., Lu Y., Mills GB., Frederick DT., Barzily M., Flaherty KT., Hoon D., Guarino M., Bennet J., Petrelli N., Shields C., Sato T., Aplin A., Roesch A., Darr D., Angus S., Kumar R., Halilovic E., Caponigro G., Jeay S., Wuerther J., Walter A., Ocker M., Bxer M., Schuchter L., Nathanson K., and Herlyn M., 2017 A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports 21:1953-1967 PMID 29141225 PMC5726788
167. Sabir S., Krishnamurthy S., Gupta S., Mills GB., Wei W., Cortes A., Mills KR., Luthra R., Wallace MJ., 2017 Characteristics of Percutaneous Core Biopsies Adequate for Next Generation Genomic Sequencing Plos One 12: e0189651 PMID: 29281680 PMC5744968
168. Korphaisarn K., Loree J., Nguyen V., Coulson T., Holla V., Litzenburger B., Chen K., Mills GB., Maru D., Meric-Bernstam F., Shaw K., and Kopetz S. 2017 Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: A case report and review of the literature Oncotarget 8: 57882-8 PMID:28915719 PMC5593691
169. Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Sonatg CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W 2017 PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 550: 133-136 PMID 28953887 PMC5891348
170. Rebecca VW., Nicastri M., McLaughlin N., Fennelly C., McAfee Q., Ronghe A., Nofal M., Lim C-Y., Witze E., Chude C., Zhang G., Alidea G., Piao S., Murugan S., Ojahl R., Levi SM., Wei Z., Barger-Rotenberg J., Murphy M., Mills GB., Lu Y., Rabinowitz J., Marmorstein R., Liu Q., Liu S., Xu X., Herlyn M., Zoncu R., Brady D., Speicher D., Winkler J., Amaravadi R., 2017 A Unified Approach to Targeting the Lysosome’s Degradative and Growth Signaling Roles. Cancer Discovery 7:1266-1283 PMID: 28899863 PMC5833978
171. Mauland KK., Ju Z., Tangen I., Berg A., Kallard K., Oyan A., Bjorge L., Westin S., Karkstad C., Trovik J., Mills GB., Hoivik E., Werner HMJ., 2017 Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signalling proteins in obese versus non-obese patients Oncotarget 8: 106989-107001 PMID: 29291005 PMC5739790
172. Litton JK, Scoggins M, Ramirez DL, Murthy DK, Whitman G, Hess K, Adrada G., Moulder S, Barcenas C, Valero V, Schwartz Gomez J, Mittendorf E, Thompson A, Mills GB, Piwnica- Worms H, Arun B 2017 A Pilot Study of Neoadjuvant Talazoparib for Early-stage Breast Cancer Patients with a BRCA Mutation NPG Breast Cancer 3:49 PMID: 29238749 PMC5719044
173. Evans K., Yuca E., Akcakanat A., Scott SM., Arango N., Zheng X., Chen K., Tapia C., Tarco E., Eterovic A., Black D., Litton J., Yap T., Tripathy D., Mills GB, and Meric-Bernstam F., 2017 A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 23:6468-6477 PMID: 29093017 PMC5679124
174. Clarke C., Lee M., Wei W., Manyam G., Jian gZ-Q., Lu Y., Morris J., Broom G., Menter D., Vilar-Sanchez., Raghav K., Eng C., Chang G., Simon Iris., Bernards R., Overman M., Mills GB., Maru D., and Kopetz S., 2017 Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol 24: 4051-4058 PMID 28936799 PMC6063735
175. Al Emran A., Marzese DM., Menn DR., Stark MS., Torrano J., Hammerlindl H., Zhang G., Brafford P., Saloman MP. Nelson N., Hammerlindl S., Gupta D., Mills GB., Lu Y., Sturm RA., Flaherty K., Hoon DS. Gabrielli B., Herlyn M., Schaider H., 2017 Distinct histone modifications denote early stress induced drug tolerance in cancer Oncotarget 9:8206-8222 PMID: 29492189 PMC5823586
176. Krishnamurthy K., Cortes A., Lopez M., WallaceM., Sabir S., Shaw K., Mills GB 2018 Ex-vivo confocal fluorescence microscopy for rapid evaluation of tissues in surgical pathology practice Arch Pathol Lab Med 142:396-401 PMID: 29266968
177. Ng PWS., Li J., Jeong K., Shao S., Chen H., Tsan Y., Sengupata S., Want Z., Bhavana V., Tran R., Soewito S., Minussi D., Moren D., Kong K., Dogruluk T., Lu H., Gao J., Tokheim C., Zhou D., Zeng J., Ip CKM., Ju Z., Wester M., Yu S., Li Y., Vellano C., Schultz N., Karchin R., Ding L, Lu Y., Cheung LWT., Chen K., Shaw KR. Meric-Bernstam F., Scott KL., Yi S., Sahni N., Liang H. Mills GB. 2018 Systematic Functional Annotation of Somatic Mutations in Cancer Cancer Cell 33:450-62 PMID 29533785 PMC5926201
178. Jeong BY., Cho KH., Jeon KJ, Park YY., Kim JM., Rha SY., Park CG., Mills GB, Cheun JH. and Lee HY 2018 Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/ VEGF-A/Snail signaling axis and expression of fascin Experimental and Molecular Medicine 50:e435. PMID: 29371698 PMC5799805
179. Brusco L., Wathoo C., Shaw KR., Holla M., Bailey A., Johnson A., Khotskaya Y., Sanchez N., Zeng J., Bernstam E., Eng C., Kee B., R., Routbort M., Mills GB., Mendelsohn J., and Meric- Bernstam F. 2018. Physician Interpretation of Genomic Test Results and Treatment Selection. Cancer124:966-972 PMID: 29165790 PMC5821595
180. Watson SS., Dane M., Chin K., Tatarova Z., Liu M., Liby T., Thompson W., Smith R., Nederlof M., Bucher E., Kilburn D., Whitman M., Sudar D., Mills GB., Heiser L., Jonas O., Gray J., and Korkola J. 2018 Microenvironment Mediated Mechanisms of Resistance to HER2 Inhibitors Differ Between HER2+ Breast Cancer Subtypes Cell Systems 6:329-342 PMID: 29550255 PMC5927625
181. Xiang Y, Ye Y., Lou Y., Yang Y., Ozguc F., Diao L., Karmouty-Quintana H., Xia Y., Blackburn M., Kellems R., Chen Z., Yoo S-H., Shyu A-B., Mills GB., Han L., 2018 Comprehensive characterization of alternative polyadenylation in human cancers Natl Cancer Inst. 110:379- 389 PMID: 29106591 PMC6059203
182. Ye Y., Xu J., Xiang Y., Ozguc F., Kim Y., Liu C-J., Hu Q. Diao L., Lou Y., Ln C., Guo A-Y., Chen Z., Takahashi J., Mills GB., Yoo S-H, Han L., 2018 The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy Cell Systems 28;6:314- 328 PMID: 29525205 PMC6056007
183. Meric-Bernstam, F., Zheng X., Shariati M., Damodaran S., Wathoo C., Demirhan M., Tapia C., Eterovic A., Basho R., Ueno N., Moulder S., Janku F., Sahin A., Rodon J., Brusco L., Broaddus R., Kim TB., Mendelsohn J., Shaw K., Tripathy D., Mills GB., and Chen K. 2018 Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer JCO Precision Oncology doi/10.1200/PO.17.00245 PMID 30035249 PMC6050977
184. Sun C., Yin J., Yin J., Fang Y., Chen J., Jeong KJ., Chen X., Vellano CP., Ju Z., Zhao W., Zhang D., Lu Y., Meric-Bernstam F., Yap TA., Hattersley M., O’Connor M., Chen H., Fawell S., Lin S-Y., Peng G.., Mills GB., 2018 BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency Cancer Cell 33:401-416. PMID: 29533782 PMC5944839
185. McGrail D., Lin CC., Dai H., Mo W., Li Y., Stephan C., Davies P., Lu Z., Mills GB., Lee J-S and Lin SY 2018 Defective replication stress response is inherently linked to the cancer stem cell phenotype Cell Reports 23:2095-2106 PMID: 29768207
186. McGrail DJ., Federico L., Lu Y., Mills GB., Yi S., Lin S-Y., and Sahni N., 2018 Multi-omics network analysis reveals neoantigen-independent infiltration in copy-number driven cancers Nature Comms 9:1317 PMID: 29615613 PMC5882811
187. Aslan O., Cheung L., Cremona M, Morgan C., Mills GB., Hennessy B 2018 Preclinical evaluation and reverse phase protein array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro BMC Cancer. 18:168. PMID: 29426295 PMC5807759
188. Park KC., Kim SW., Jeon JY., Jo AR., Choi H., Kim JM., Lee JG., Kim YJ., Mills GB., Noh SH. Lee MG., Park ES., Cheong JH 2018 Survival of cancer stem-like cells under metabolic stress via CaMK2α-mediated upregulation of sarco/endoplasmic reticulum calcium ATPase expression Clinical Cancer Research 24:1677-1690 PMID: 29279319
189. Oh SC., Sohn BW., Cheong JH., Kin S-B., Lee JE., Park KC., Lee SH.., Park J-L., Park YY., Kin S-C., Heo J., Chu I-S., Jand YJ., Mok YJ., Jung W., Kim B-H., Kim A., Cho JY., Lim JY., Hayash Y., Elimova E., Siozaki H., Lee JH., Bhutani MS., Lu Y., Liu W., Lee J., Kang WK., Kim S., No SH., Mills GB., Kim SY., Ahani JA and Lee JS., 2018 Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype Nature Communications 9:1777 PMID: 29725014 PMC5934392
190. Zhang G., W L, Mender I., Barzily M., Hammond M., Ope O., Cheng C., Randell S., Sadek N., Xiao M., Tian T., George E., Kim H., Krepler C., Brafford P., Sproesser K., Murugan S., Somasundaram R., Garman B., Wubben horst B., Desrichard A., Woo J., Zhang J., Liu J., Uin X., Liu Q., Frederic D., Miao B., Xu W., Karakousis G., Xu X., Schuchter L., Gangadhar R., Watson I., Kwong L., Amaravadi R., Lu Y., Chan T., Boland G., Ince R., Simpkins R. Wei A., Nathanson K., Mills G., Flaherty K., Herlyn M., and Shay J., 2018 Induction of telomere dysfunction prolongs disease control in therapy-resistant tumors. Clinical Cancer Research 24:4771-4784 PMID: 29563139 PMC6150856
191. Zhang J., Dulak, A., Hattersley M., Willis B., Nikkila J., Wang A., Lau A., Reimer C., Zinda M., Fawell S., Mills GB., and Chen H., 2018 BRD4 Facilitates Replication Stress-induced DNA Damage Response Oncogene 37:3763-3777 PMID: 29636547 PMC6101970
192. Shen J., Ju Z., Zhao W., Wang L., Peng Y., Ge Z., Nagel Z., Zou J., Wang C., Kapoor P., Ma X., Ma D., Liang J., Liu J., Samson LD., Li G., Liang H., Shen X., Mills GB and Peng G., 2018 ARID1A deficiency promotes mutability and potentiates therapeutic anti-tumor immunity unleashed by immune checkpoint blockade Nature Medicine 24:556-562. PMID: 29736026 PMC6076433
193. Peng X., Xu X., Wang Y., Hawke DH., Yu S., Han L., Zhou Z., Mojumdar K., Jeong K., Labrie M., Tsang Y., Zhang M., Lu Y., Hwu P., Scott K., Liang H., and Mills GB 2018 A-to-I RNA Editing contributes to Proteomic Diversity in Cancer Cancer Cell 33:817-828 PMID: 29706454 PMC5953833
194. Echevarria-Vargas, Reyes-Uribe P., Yin X., Krepler C., Kossenkov A., Liu Q., Cheng C., Zhang G., Wei Z., Somasundaram R., Karokousis B., Xu W., Burd C., Lu Y., Mills GB., Weeraratna A., Amaravadi R., Schuchter LM., Aplin A., Xu X., and Villanueva J., 2018 Co-targeting BET and MEK as effective salvage therapy for MAPK and checkpoint inhibitor resistant melanoma EMBO Mol Med 10. pii: e8446 PMID: 29650805 PMC5938620
195. Lee J., Demirkan G., Geiss G., Vellan C., Filanoski B., Lu Y., Ju Z., Xu S., Akbani R., Hegde A., Guo H., Bogatzki L., Carter W., Meredith R., Warren S., Ding Z., Sahin A., Beechem J., and Mills GB., 2018 Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies Mol Cell Prot 17:1245-1258 PMID: 29531020 PMC5986246
196. Kang M-H., Lee Y-S., Oshina M., Cheong J-H., Choi H-S., Kweon M-N., Pack C-G., Mills GB., Myung S-J., Park YY., 2018 Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer by antagonizing the Wnt-signaling Nature Comms 9:1920 PMID: 29765046 PMC5954140
197. Takahashi N., Chen HY., Harris IS., Stover D., Yeung T., Bronson R., Takemura K., Kitaio A., Deraedt T., Cichowski K., Mori Y., Mills GB., Brugge J., 2018 Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell 33:985-1003 PMID: 29805077 PMC6100788
198. Wang Z., Ng KS., Chen T., Kim T-B., Shaw K., Meric-Bernstam F., Mills GB and Chen K., 2018 Cancer driver mutation prediction through Bayesian integration of multi-omic data Plos One 3:e0196939 PMID: 29738578 PMC5940219
199. Lee J-H., Liu R., Li J., Wang Y., Tan L., Li X-J Qian X., Zhang C., Xia Y., Xu D., Guo W., Ding Z., Du L., Zheng Y., Chen Q., Lorenzi P., Mills GB., Jian T., Lu Z. 2018 EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation Molecular Cell 70:197- 210 PMID: 29677490 PMC6114939
200. Kuppa S., Jia W., Liu S., Nguyen H. Smyth S., Mills GB., Dobbin K., Hardman WJ., Murph M., 2018 Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p Cancer Letters. 432: 84-92 PMID: 29859298 PMC6075675
201. Simpkins F., Hew K., Jang K., Azzam D., Kim M., Sun J., Zhao D., Ince T., Liu W., Guo W., Mills G., Wei Z., Zhang G., Slingerland J., 2018 Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells Clinical Cancer Research 24:4874-4886 PMID: 29959144 PMC6557165
202. Parekh A., Das S., Parida S., Das CK., Dutta D., Mallick S.,Wu PH., Kumar P., Bharti R., Dey G., Banerjee K., Rajput S Bharadwaj Pal I., Dey KK., Rajesh Y., Jena BC., Biswas A.,Banik K.,Pradhan AK.,., Pradhan A., Das S., Das A., Dhara S., Fisher P., Wirtz D., Mills G.B., Mandal M., 2018 Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo. Oncogene 37:4546-4561 PMID: 29743594
203. Zhao W., Li J., Akbani R., Liang H., Mills GB 2018 Credentialing individual samples for proteogenomic analysis Mol Cell Proteomics 17:1515-1530. PMID: 29716986 PMC6072548
204. Grzeskowiak C., Kundu S., Mo X., Ivanov A., Zagorodna O., Lu H., Chapple RH., Tsang Y., Moreno D., Mosqueda M., Eterovic K., Fradette J., Ahmad S., Chen F., Chong Z., Chen K., Creighton C., Fu H., Mills GB., Scott KL., Gibbons DL 2018 In Vivo Screening Identifies GATAD2B as a Metastasis Driver in KRAS-Driven Lung Cancer Nature Comms 9:2732 PMID: 30013058 PMC6048166
205. Ip CKM., Ng PNS., Jeon KJ., Ju Z., Leonard PG., Scott KL., Mills GB 2018 Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies Nature Comms:9:4583 PMID: 30389923 PMC6214970
206. Chen, G., Huang AC., Zhang W., Zhang G., Wu M., Xu W., Zhong W., Yu Z., Xia H., Man Q., Antelo LF., Wu B., Xiong X., Guan L., Lu X., Sun H., Somasundaram R., Mills G., Lu Y., Chen Y., Dong H., Zhao Y., Gangdhar T., Schucter L., Herlyn M., Wherry J., Xu X., Guo W., 2018 Exosomal PD-L1 Mediates Tumor Immunosuppression and is Associated with Patient Response to anti-PD-1 Immunotherapy. Nature 560:382-386 PMID: 30089911 PMC6095740
207. Anthony J., Zanini E., Kelly A., Tan T., Karali E., Alomary M., Jung Y., Nixon K., Cunnea P., Fotopoulou C., Paterson A., Roy-Nawathe S., Mills GB., Huang RY., Thiery JP., Recchi C., and Gabra H., 2018 The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. Embo Reports: 19 pii e45670 PMID: 29907679 PMC6073217
208. Hsieh H-J., Zhang W., Lin S-H., Yang W-H., Wang JZ., Shen J., Zhang Y., Lu Y., Wang H., Yu J., Mills GB., and Peng G. 2018 Systems biology approach reveals that mTORC1 regulates G2/M DNA damage checkpoint recovery Nature Communications 9:3981 PMID: 30266942 PMC6162282
209. Du D, Ma W., Yates M., Chen T., Lu KH., Lu Y., Weinstein J., Broaddus R., Mills GB., Liu Y., 2018 Predicting high-risk endometrioid endometrial carcinomas using protein markers Oncotaget 9:19704-15 PMID: 29731976 PMC5929419
210. Lee H, Kim N, Yoo YJ, Kim H, Jeong E, Choi S, Moon SU, Oh SH, Mills GB, Yoon S, Kim WY., 2018 β-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer Oncogene 37:5466-5475 PMID: 29895971
211. Wang J., Zhao W., Guo H., Bai S., Li Y., Yu Q., Lu Y., Jeong K., Chen X., Gao M., Kwok- Sjomh P., Liang J., Li W., Tiang X., Jonasch E., Mills GB., Ding Z., 2018 AKT isoform-specific expression and activation across cancer lineages BMC Cancer 18:742 PMID: 30012111 PMC6048698
212. Rhyasen GW, Yao Y, Zhang J, Dulak A, Castriotta L, Jacques K, Zhao W, Gharahdaghi F, Hattersley MM, Lyne PD, Clark E, Zinda M, Fawell SE, Mills GB, Chen H., 2018 BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer PLOS One 13: e0200826 PMID: 30036377 PMC6056044
213. Li Y, McGrail DJ, Xu J, Li J, Liu NN, Sun M, Lin R, Pancsa R, Zhang J, Lee JS, Wang H, Mills GB, Li X, Yi S, Sahni N 2018 MERIT: Systematic analysis and characterization of Mutational Effect on RNA Interactome Topology. Hepatology. doi: 10.1002/hep.30242. PMID:30153342 PMC6538468
214. Mach J., Atkins M., Gajewski K., Mottier-Pavie V., Sansores-Garcia L., Xie J., Mills RA, Kowalczyk W, Van Huffel L, Mills GB and Halder G. 2018 Modulation of the Hippo pathway and organ growth by RNA processing proteins Proc Natl Acad Sci 115:10684-10689 PMID: 30257938 PMC6196505
215. Liu S, Zhang G, Guo J, Chen X, Lei J, Ze K, Dong L, Dai X, Gao Y, Song D, Ecker B, Yang R, Feltcher C, Peng K, Feng C, Chen H, Lee RX, Kerestes H, Niu J, Kumar S, Xu W, Zhang J, Wei Z, Martin JS, Liu X, Mills G, Lu Y, Guo W, Sun L, Zhang L, Weeraratna A, Herlyn M, Wei W, Lee FS, Xu X. 2018 Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis Nat Commun. 9:5426. PMID:30575721 PMC6303344
216. Ha M., Banerjee S., Akbani R., Liang H., Mills GB., Do K-A., Baladandayuthapani V., 2018 Personalized Integrated Network Modeling of The Cancer Proteome Atlas Scientific Reports 8:14924. PMID: 30297783 PMC6175854
217. Zhang M., Fritsche J., Roszik J., Williams L., Peng X., Chiu Y., Tsou C., Hoffgaard F., Goldinger V. Schoor O., Talukder A., Forget MA, Haymaker C, Bernatchez C, Han L, Tsang YH, Kong K, Xu X, Scott KL, Singh-Jasuja H, Lizee G, Liang H, Weinschenk T, Mills GB, Hwu P., 2018 RNA editing derived epitopes function as cancer antigens to elicit immune responses Nature Comms: 9:3919 PMID: 30254248, PMC6156571
218. Keene K., King T., Hwang S., Peng B., McGuire K., Tapia C., Zhang H., Bae S., Nakhilis F., Klauber-Demore N., Meszoely I., Sabel M., Willey S., Eterovic A., Hudis C., Wolff A., De Los Santos J., Thompson A., Mills GB and Meric-Bernstam F., 2018 Molecular Determinants of Post-Mastectomy Breast Cancer Recurrence NPJ Breast Cancer 4:34 PMID: 30345349 PMC6185974
219. Mitri Z., Pamar S., Johnson B., Kolodzie A., Keck J., Morris M., Guimares A., Beckett, G., Borate U., Lopez C., Kemmer K., Alumkal J., Beer T., Corless C., Mills GB., Gray JW., Bergan RC 2018 Implementing a Comprehensive Translational Oncology Platform: From Molecular Testing to Actionability Journal of Translational Medicine. 6:358. PMID: 30551737 PMC6295039
220. Pilie P., Tang C., Mills GB., Yap T 2019 State of the art strategies for targeting the DNA damage response in cancer: Nature Reviews Clinical Oncology 16:81-104. PMID:30356138
221. Krishnamurthy, S., Ban K., Shaw K., Mills GB., Sheth R., Tam A., Gupta S., Sabir S., 2019 Confocal fluorescence microscopy platform suitable for rapid evaluation of small fragments of tissue in surgical pathology practice Archives of Pathology and Lab Medicine doi: 10.5858/arpa.2018-0352-OA PMID: 30376375 PMC6185974
222. Holst F., Werner H., Mjos S., Hoivik E., Kusonmano K., Wik E., Berg A., Birkeland E., Gibson W., Halle M., Trovik J., Cherniak A., Kalland K., Mills GB., Singer C., Krakstad. C., Beroukhim R., and Savelsen HB 2019 PIK3CA amplification associates with aggressive phenotype but not markers of AKT-MTOR signaling in endometrial carcinoma. Clin Can Res 25:334-345. PMID: 30442683 PMC6384094
223. Liu S., Li S., Wang B., Liu W., Gagea M., Chen H., Sohn J., Parinyanitikul N., Primeau T., Do K-A., Vande Woude G., Mendelsohn J., Meric-Bernstam F., Ueno NT., Mills GB., Tripathy D., Gonzalez-Angulo A., 2019 Cooperative effect of oncogenic MET and PIK3CA in an HGF-dominant environment in breast cancer Mol Can Ther 18:399-412. PMID: 30518672
224. Tuna M., Amos CL., and Mills GB 2019 Genome-wide analysis of head and neck squamous cell carcinomas reveals HPV, TP53, smoking and alcohol-related allele-based acquired uniparental disomy genomic alterations Neoplasia 21:197-205 PMID 30616092 [PMC6321975](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321975/)
225. Shen J., Zhao W., Ju Z., Wang L., Peng Y., Labrie M., Yap T., Mills GB., Peng G., 2019 PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness Cancer Research 79:311-319 PMID: 30482774 PMC6588002
226. Hedberg ML., Peyser N., Bauman J., Goodin W., Li H., Grant R., Jordan R., Vanden Berg S., Olivas V., Bivona T., Chiosea S., Wang L., Mills GB., Johnson J., Duvvuri U., Ferris R., Ha P., Johnson D., and Grandis J., 2019 Chronic non-steroidal anti-inflammatory drug use predicts improved survival for PIK3CA-altered head and neck cancer J. Exp. Med 216:419-427. PMID: 30683736 PMC 6363423
227. Konstantinopoulos P. , Barry W., Birrer M., Westin S, Cadoo K., Shapiro J., Mayer E., O’Cearbhaill R., Coleman R., Kochupurakkal B., Whalen C., Curtis J., Farooq S., Luo W., Eismann J., Buss M., Aghajanian C., Mills GB., Palakurthi S., Kirschmeier P, Liu J., Cantley L., Kaufmann S., Swisher E., D’Andrea A., Winer E., Wulf G., Matulonis U., 2019 Oral Poly(ADP-Ribose) Polymerase (PARP) Inhibitor Olaparib and Oral alpha Specific PI3-Kinase Inhibitor Alpelisib (BYL719): A Phase 1b Dose-Escalation Study with Dose Expansion in Patients with Ovarian Cancer Lancet Oncology 20:570-580 PMID:30880072
228. Rozanov D., Cheltsov A, Nilsen A., Boniface C., Tyner J., Tognon C., Korkola J., Gray J., Mills GB., Spellman 2019 Targeting mitochondria could provide a basis for the selective anti-cancer activity PLOS One 14:e0205623 PMID: 30908483 PMC: 6433232
229. Iavarone C., Zervantonakis I., Selfors L., Palkurithi S., Liu M., Drapkin R., Maurlone U., Leverson J., Sampath D., Mills GB, Brugge J., 2019 Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness Molecular Cancer Therapeutics 18:642-655. PMID: 30679390 PMC6399746
230. Li X., Mak VC., Zhou Y., Wang C., Wong E., Sharma R., Lu Y., Cheung AN., Mills GB., Cheung LW 2019 Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer Nature Communications 10: 716 PMID:30755611 PMC6372715
231. Wang Z., Sun K., Xiao Y., Feng B., Mikule K., Ma X., Feng N., Vellano C., Federico L., Marszlaek J., Mills GB., Hanke M., Ramaswamy S., Wang J., 2019 Niraparib activates interferon signaling and synergizes therapeutically with anti-PD-1 antibody Scientific Reports: 9:1853 PMID:30755715 PMC6372650
232. Tuna M., Amos C., Mills GB 2019 Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors Oncotarget 10:2095-2111 PMID:31007851 PMC6459343
233. Baffi T., Ngoc Van A-A., Zhao W., Mills GB., Newton AC., 2019 Protein Kinase C quality control by phosphatase PHLPP1 unveils loss-of-function mechanism in cancer Molecular Cell 74:378-392 PMID 30904392 PMC6504549
234. Zheng S., Alfaro-Munoz K., Wei W., Want X., Wang F., Eterovic AK., Shaw KM., Mills GB., Meric-Bernstam F., Fuller GN., Verhaak R., Chen K., Yung WK., Weather S-P., de Groot JF., 2019 Prospective Clinical Sequencing of Adult Glioma Mol Can Ther 18:991-1000 PMID: 30926639 PMC6497568
235. Li BT., Janku F., Jung B., Hou C., Madwani K., Alden R., Razavi P., Reis-Filho J., Shen R., Isbell J., Blocker A., Eattoci N., Gnerre S., Satya R., Xu H., Zhao C., Hall M., Hu Y., Sehner A., Brown D., Ladanyi M., Rudin C., Hunkapiller N., Mills GB., Pawelez C., Baselga J., Janne P., Solit D., Riely G., Aravanis A., and Oxnard G., 2019 Detection of oncogenic drivers and resistance mechanisms by ultra-deep next generation sequencing of prospectively collected plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium Anals Oncology  30:597-603 PMID: 30891595 PMC6503621
236. Xing Y., Lin N., Mauer M., Chen H., Mahvash A., Sahin A., Akcakanat A., Li Y., Abramson V., Litton J., Chavez-McGregor M., Valero V., Piha-Paul S., Hong D., Do KA., Tarco E., Riall D., Eterovic KA., Wulf GM., Cantley L., Mills GB., Doyle A., Winer E., Hortobagyi G., Gonalez-Angulo A., Meric-Bernstam F., 2019 Phase II Trial of AKT Inhibitor MK2206 in Patients with Advanced Breast Cancer Who Have Tumors with PIK3CA or AKT Mutations, and/or PTEN Loss/PTEN Mutation Breast Cancer Research 21: 78 PMID 31277699 PMC6612080
237. Wang F., Zhang S., Kim T-B., Lin Y-Y., Iqball R., Wang Z., Sircar K., Karam J., Wendl M., Meric-Bernstam F., Weinsten JN., Ding L., Mills GB., Chen K., 2019 Integrated Transcriptomic-Genomic tool Texomer profiles cancer tissues.Nature Methods 16:401-404 PMID: 30988467
238. Johansson H., Zhu Y., Socciarelli G., Vacanti N., Haugen M., Zhu Y., Siavelis I., Fernandez A., Aure M., Sennblad B., Vesterlund M., Branca R., Orre L, Huss Mikael., Fredlund E., Beraki E., Garred O., Boekel J., Sauer T., Zhao W., Nord S., Hoglander E., Haukaas T., Bathen T., Schlichting E., Naume B., OSBREAC., Borgen E., Kristensen V., Russnes H., Lingdaerde O., Mills GB., Sahlberg K., Borresen-Dale A-L., Lehtio J., 2019 Breast cancer quantitative proteome and proteogenomic landscape Nature Comms. 10:1600 PMID 30962452 PMC6453966
239. Xu X., Wang Y., Mojumdar K., Zhou Z., Jeong K., Mangala L., Yu S., Tsang Y-H., Rodriguez-Aguayo C., Lu Y., Lopez-Berestein G., Sood A., Mills GB., Liang H. 2019 A-to-I edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis J Clin Invest pii: 123396. PMID 31682236 PMC6877318
240. Maric G., Annis MG., MacDonald PA., Russo C., Perkins C., Siwak D., Mills GB and Siegel PM., 2019 GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity Oncogene 38:5294-5307 PMID 30914799
241. Ghandi M., Huang FW., Jane-Valbuena J., Kryukov G., Lo C., McDonald R, Barretina J., Gelfand E., Bielski C., Li H., Hu K.,Andreev A., Hess J., Haas B., Aguet F., Weir B., Rothberg M., Paolella B., Lawrence M., Akbani R., Lu Y., Gokhale P., deWeck A., Oh C., Shih J., Hadi K., Venkatesan L., Reddy A., Sonkin D., Liu M., Lehar J., Korn J., Porter D., Jone MD., Stransky N., Imielinski M., Maruvka Y., Cherniak A., Tsherniak A., Vazquez F. Jaffe J., Lande A., Weinstock D., Johannenssen C., Morrissey M., Stegmeier F., Sclegel R., Hahn WC., Getz G., Mills GB., Boehm J., Golub TR., Garraway LA., and Seller W., 2019 Cancer Cell Line Encyclopedia II: Comprehensive Characterization of the Cell Lines in the Cancer Dependency Map Nature 569:503-508 PMID:31068700 PMC6697103
242. Lluch, A., Gonzalez-Angulo A., Casadevall D., Eterovic A., de Duenas E., Zheng X., Guerrero-Zotano A., Liu S., Perez R., Chen K., Chacon J., Mills GB., Antolin S., Blanca I., Lopez-Serra P., Carrasco E., Caballero R., Prat A., Rojo F., Gonzalez-Perez A. Meric-Bernstam F., and Albanell J., 2019 Dynamic clonal remodeling in breast cancer metastases is associated with subtype conversion Eur J. Cancer 120:54-64 PMID: 31491604
243. Yin Y., Liu W., Shen Q., Zhang P., Wang L., Tao R., Li H., Ma X., Zheng X., Cheong J-H., Song S., Ajani J., Mills G., Tao K., and Peng G., The DNA endonuclease Mus81 regulates ZEB1 expression and serves as a target for BET4 inhibitors in gastric cancer Mol Can Ther 18:1439-1450 PMID31142662
244. Fang Y., Sun C., Labrie M., Cheng X., Zhang D., Ju Z., Vellano C., Lu Y., Li Y., Jenong KJ., Ding Z., Liang J., Wang S., Dai H., Lee S., Sahni N., Kim T-B., Chen K., Mercado-Uribe I., Westin SN., Liu J., O’Connor M., Yap T., Mills GB 2019 Sequential administration of PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy Cancer Cell 35:851-867 PMID 31185210 PMC6642675
245. Labrie M., Kim T-B., Ju Z., Lee S., Zha W., Fang Y., Lu Y., Chen K., Ramirez P., Frumovitz M., Meyer L., Fleming N., Sood A., Coleman R., Mills GB and Westin S., 2019 Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options Oncotarget 10:3533-3546 PMID 31191824 PMC6544405
246. Ruan H., Xiang Y., Ko J., Li S., Jing Y., Zhu X, Ye Y., Zhang Z, Mills T., Feng J., Liu C., Cao J., Zhou B.k Wang L., Zhou Y., Lin C. Guo A., Chen X., Diao L., Li W., Chen Z., e X., He X., Mills GB., Blackburn M., and Han L., 2019 Comprehensive characterization of circular RNAs in 1000 human cancer cell lines Genome Med 11: 55 PMID 31446897 PMC6709551
247. Lindermann A., Patel A., Silver N., Tang L., Liu Z., Want L., Tanaka N., Rao X., Takahashi H., Maduka N., Zhao M., Chen T., Liu W., Want J., Frank S., Hittelman W., Mills GB., Myers J., and Osman A., 2019 COTI-2, a novel thiosemicarbazone derivative exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms Clinical Cancer Research In press PMID 31308060 PMC6759991
248. Buj R., Chen C., Dahl E., Leon K., Kuskovsky R., Maglakelidze N., Navaratnarajah M., Zhang G., Doan M., Jiang H., Zaleski M., Kutzler L., Lacko H., Lu Y., Mills GB., Gowda R., Robertson G., Warrick J., Herlyn M., Imamura Y., Kimball S., DeGraff D., Snyder N Aird K., 2019 Suppression of p16 induces mTORC1-mediated nucleotide metabolic reprogramming Cell Rep., 28: 1971-1980 PMID 31433975 PMC6709551
249. Chen M-J., Li J., Akbani R., Wang Y., Lu Y., Mills GB and Liang H., 2019 TCPA v6.0: An Integrative Platform to Explore the Pan-cancer Analysis of Functional Proteomic Data Mol Cell Proteomics 18:S15-S25 PMID31201206 PMC6692772
250. Mazumdar A., Tahaney W., Bollu L., Poage G., Hill J., Zhang Y., Mills GB., Brown PH 2019 The Phosphatase PPM1A Inhibits Triple Negative Breast Cancer Growth by Blocking Cell Cycle Progression NPG Breast Cancer 5:22 PMID 31372497 PMC6659706
251. Liu Z-B., Ezzedine N., Eterovic A., Ensor J., Huang H., Albanelle J., Choi D., Lluch A., Liu Y., Rojo F., Wong H., Martinez-Duenas E., Guerrero-Zotano A., Yu K-D., Shoa Z-M., Yang W-T, Darcourt J., Oblitas J., Gomez H., Mills GB., Dave B., Chang JC., 2019 Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases Breast Cancer Res Treat 178:251-261 PMID 31388936
252. Rader JS. Pan A., Corbin B., Iden M., Ju Z., Vellano CP., Akbani R., Mills GB., Simpson P., 2019 Identification and validation of a prognostic proteomic signature for cervical cancer Gyne Oncology Pii:S0090-8258(19)31473-8 PMID 31477280 PMC6825895
253. Fan X., Huang Y., Wu P., Yin X., Yu X., Fu X., Fenf L., Wang Y., Yi H., Chen Z., Yin J., Zhang D., Feng W., Bai S., Kim T., Mills GB., Lu Y., Wan X., Wang L., 2019 J Cancer 10:4978-4988 PMID 31598170 PMC6775519
254. Tuna, M., Liu W., Amos C., Mills GB., 2019 Genome-wide profiling of acquired uniparental disomy reveals prognostic factors in head and neck squamous cell carcinoma Neoplasia 21:1102-1109 PMID 31734631 PMC6889229
255. Zhang Z., Lee J-H., Ruan H., Ye Y., Krakowiak J., Hu Q., Xiang Y. Gong J., Zhou B., Wang L., Lin C., Diao., L., Mills G., Li W., Han L 2019 Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer Nature Comms 10:4562 PMID: 31594934 PMC6783481
256. Fan X-J., Huang Y. Wu. P-H., Yin X-K., Yu X-H., Fu XiH., Feng L-L., Wang Y.L., Yi H-J., Cheng Z-T., Zhang D-L., Feng W-X., Bai S-M., Kim T., Mills GB., Lu Y-L., Wan X-B., Want L., 2019 Impact of Cold Ischemic Time and Freeze-Thaw Cycles on RNA, DNA and Protein Quality in Colorectal Cancer Tissues Biobanking J Cancer 10:4978-4988 PMID 31598170 PMC6775519
257. Westin SN., Sil MW., Coleman R., Waggoner S., Loore K., Mathews C., Maring L., Modesitt S., LeeS., Ju Z., Mills GB., Schilder R., Fracasso P., Aghajanian C., 2019 Safety Lead-In of the MEK Inhibitor Trametinib in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent Endometrial Cancer: An NRG Oncology: Gynecologic Oncology Group Study Gynecological Oncology pii: S0090-8258(19)31548-3 PMID 31623857 PMC6922584
258. Dumbrava EI., Brusco, L., Daniels M., Wathoo C., Shaw K., Lu K., Zheng X., Strong L., Litton J., Arun B., Eterovic AK., Routbort M., Patel K., Piha-Paul S., Subbiah V., Hong D., Rodon J., Kopetz., S., Mendelsohn J., Mills GB., Chen K., and Meric-Bernstam F., 2019 Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations JCO Precis Oncol 3: 10.1200/PO.18.00143 PMID: 31517177 PMC6741435
259. Parashar D., Geethadevi A., Aure M., Tahiris A., Zhao W., Nair G., Lu Y., Mangala L., Rodriguuea-Aguayo C., Lopez-Berestein G., Rader J., Ramchandran R., You M., Sood AK., Kristensen V., Mills GB., Pradeep S., Chalauvally-Raghavan P., 2019 miRNA551b-3p Activates an Oncostatin M Signaling Module for Breast Cancer Progression Cell Reports: 4389-4006.e10 PMID 31875548
260. Myers AP., Konstantinopoulos P., Barry W., Luo W., Broaddus R., Makkerd B., Drapkin R., Liu J., Doylee A., Hrowitz N., Meric-Bernstam F., Van Hummelen P., Birrer M., Aghajanian C., Coleman R., Mills G.B, Cantley L., Matulonis U., and Westin S., 2019 Phase II, 2-Stage, 2-Arm, PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent Endometrial Cancer Int J. Cancer In Press PMID31714586
261. Ye Y., Hu Q., Chen H., Liang K., Yuan Y., Xiang Y., Ruan H., Zhang Z., Song A., Zhang H., Liu L., Diao L., Lou Y., Zhou B., Wang L., Zhou S., Gao J., Jonasch E., Lin S., Xia Y., Lin C. Yang L., Mills GB., Liang H., Han L., 2019 Characterization of Hypoxia-associated Molecular Features for Hypoxia-Targeted Therapy Nature Metabolism 1:431-444 PMID 31984309 PMC6980239
262. Li B., Janku F., Jung B., Hou C., Madwani K., Alden R., Razavi P., Reis-Filho J., Shen R., Isbell J., Blocker A., Eattock N., Gnerre S., Satya R., Xu H., Zhao C., Hall M., Hu Y,Sehnert A., Brown D., Ladanyi M., Rudin C., Hunkapiller N., Feeney N., Mills G., Paweletz C., Janne P., Solit D., Riely G., Aravanis A., Oxnard G., 2019 Ultra-deep Next-Generation Sequencing of Plasma Cell-Free DNA in Patients With Advanced Lung Cancers: Results From the Actionable Genome Consortium Ann. Oncol 30: 597-603 PMID: 31987277
263. Yu K., Lin C., Hatcher A., Lozzi B., Kong K., Huang-Hobbs E., Cheng Y., Beechar V, Zhu W., Zhang Y., Mills GB., Mohila C., Creighton C., Noebels J., Scott KL., and Deneen B., 2020 PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis Nature 578:166-171. PMID 31996845
264. Wu CC., Beird H., Livinston JA., Advani S., Mitra A., Cao S., Reuben A., Ingram D., Wang W-L., Ju J., Leung C., Lin H, Zheng Y., Roszik J., Wang W., Patel S., Benjamin R., Somaiah N., Conley A., Mills G., Hwu P., Gorlick R., Lazar A., Daw N., Lewis V., and Futreal PA 2020 Immuno-genomic landscape of osteosarcoma Nature Comms 11:1108 PMID 32081846 PMC7035358
265. Tuna, M., Ju Z., Yoshihara K., Amos C., Tanyi J., Mills GB 2020 Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers British Journal of Cancer In Press. PMID: 31780779
266. Hazim A., Mills GB., Prasad V., Haslam A., Chen EY 2020 The relationship between response and dose in published, contemporary phase 1 oncology trials Journal of the National Comprehensive Cancer Network 18: 428-433 PMID 32259790
267. Merritt CR., Ong G., Church S., Barker K., Geiss G., Hoang M., Jung J., Liang Y., Mckay- Fleishc J., Nguyen K., Sorg K., Spargue I., Warren C., Warren S., Zhou Z., Zollinger D., Dunaway DL., Mills GB., Beechem JM 2020 High multiplex, digital spatial profiling of proteins and RNA in fixed tissue using genomic detection methods Nature Biotechnology In Press (bioRxiv 559021; doi: <https://doi.org/10.1101/559021>)
268. Sun C., Li X., Guo E., Li N., Zhou G., Lu H., Huang J., Xia M., Shan W., Li K., Weng D., Xu.X., Goa Q., Wang S., Hu J., Lu Y., Mills GB., Ma D., and Cheng G., 2020 MCP-1/CCR-2 axis in adipocytes and cancer cell respectively fascilitates ovarian cancer peritoneal metastasis Oncogene In Press PMID 31705064
269. Bollu L., Shepherd J., Zhao D., Ma Y., Tahaney W., Speers C., Mazumder A., Mills GB., and Brown PH., 2020 Mutant p53 induces MELK expression by release of wild-type p53 dependent suppression of FOXM1 NPG Breast Cancer DOI: [10.1038/s41523-019-0143-5](https://doi.org/10.1038/s41523-019-0143-5) PMID: 31909186 [PMC6941974](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6941974/)
270. Berg H., Ju Z., Myrvold M., Fasmer K., Halle M., Hoyvik E., Westin S., Trovik J., Haldorsen I., Mills GB., Krakstad C, and Werner H., 2020 Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma Br J Cancer 122, 1014–1022
271. McGrail D., Garnett, J., Yin J., Dai H., Shih D., Nguyen T., Lam A., Li Y., Sun C., Li Y., Schmandt R., Wu J., Hu L., Liang Y., Peng G., Jonasch E., Menter D., Yates M., Kopetz S., Lu K., Broaddus R., Mills GB., Sahni N., Lin S-Y., 2020 Proteome instability is a therapeutic vulnerability in mismatch repair deficient cancer Cancer 37:371-386 PMID 32109374
272. Lee EK., Tan-Wasielewski Z., Aghajanian C., Coleman R., Curtis J., Matulonis UA., Cantley, LC., Mills GB., Doyle A., Liu J., 2020 Results of an Abbreviated Phase II Study of AKT Inhibitor MK-2206 in the Treatment of Recurrent Platinum-Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Gynecologic Oncology Reports 32:100546 PMID 32083163 PMC7021536
273. Chen H., Li J., Wang Y., Ng PK-S, Tsang YH., Shaw KR., Mills GB., Liang H., 2020 Comprehensive assessment of computational algorithms in predicting cancer driver mutations Genome Biology 21:43 PMID: 32079540
274. Ye Y., Mills GB and Han L 2020 Sex-associated molecular differences for cancer immunotherapy efficacy Nature Comm 11:1799 PMID: 32286310 PMC: 7156379
275. Krishnamurthy, S., Sabir S., Ban K., Sheth R., Shaw K., Mills GB., Bassett R., Hamilton S., Hicks, M and Gupta S., 2020 Comparison of real-time fluorescence confocal digital microcroscopy with hematoxylin-eosing-stained sections of core-needle biopsy specimens JAMA Network Open DOI: 10.1001/jamanetworkopent.220.0476 PMID 32134465 PMC7059022
276. Kalachand RD., Stordal B., Madden S., Chandler B., Cunningham J., Goode E., Ruscito I., Braicu E., Sehoull J., Ignatov A., Yu H., Katsaros D., Lu L., Mills GB., Lu KH., Carey MS., Timms K., Rzepecka I., Kupryjanczyk J., McAlpine J., Gilks CB., Swisher EM., Harrel M., Agnew K., O’Riain C., O’Toole S., O’Leary J., The Australian Ovarian Cancer Study Group, Thomas D., Prieske K., Chaudhry P. Srinivasan R., Hafner N., Hennessy B., 2020 BRCA1 promoter methylation and clinical outcomes in epithelial ovarian cancer: a pooled analysis of individual patient data J. Natl Cancer Inst. In press
277. Lee S., Zhao L., Rojas C., Bateman N., Yao H., Lara O., Celestino J., Morgan M., Nguyen T., Conrads K., Rangel K., Dood R., Hajek R., Fawcett, G., Chu R., Wilson K., Loffredo J., Viollet C., Jazaeri A., Dalgard C., Mao X., Song X., Zhou M., Hood B., Banskota N., Wilkerson M., Te J., Soltis A., Roman K., Dunn A., Cordover D., Eterovic A., Liu J., Burks J., Baggerly K., Fleming N., Lu K., Westin S., Coleman R., Mills G.B., Casablanca Y., Zhang J., Conrads T., Maxwell G., Futreal A., Sood A., 2020 Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer Cell Reports 31:107502 PMID32294438
278. Gris-Oliver A., Palafox M., Monserrat, L, Braso-Maristany R., Odens A., Sanchez-Guixe M., Ibrahim Y., Villacampa B., Grueso J., Pares M., Guzman M., Rodriguez O., Bruna A., Hirst C., Vellano C., Barnicle A., De Bruin E., Reddie A., Schiavon G., Arribas J., Mills GB., Caldas C., Dienstman R, Prat A., Nuciforo P., Razavi P., Scaltriti M., Turner N., Saura C., Davies B., Oliveira M., and Serra V., 2020 Genetic alterations in PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer-derived xenografts Clinical Cancer Research in Press. PMID:32220884
279. Tuna M., Amos C., and Mills GB., 2020 Acquired uniparental disomy regions are associated with disease outcome in patients with oral cavity and oropharynx but not larynx cancers Translational Oncology In press
280. Ramos R., Bustos M., Wu J., Jones P., Chang S., Kiyohara E., Tran K., Zhang X., Matsuba C., Salomon M., Stern S., Israely S., Witz I., Davies M., Mills GB., Kelly D., Irie R., and Hoon D. 2020 Upregulation of cell surface GD3 ganglioside phenotype associated with human melanoma brain metastasis Molecular Oncology In Press.PMID 3235899
281. Liang J., Wang L., Wang C., Shen J., Su B., Maisetty, A., Fang D., Kassab C., Jeong K., Zhao W., Lu Y., Jain Z., Zhou Z., Liang H., Sun S-C., Lu C., Xu Z-X, Yu Q., Shao S., Chen X., Gao M., Claret F-X., Ding Z., Chen J., Chen P., Barton M., Peng G., Mills GB., and Heimberger A. 2020 Verteporfin inhbits PD-L1 through autophagy and the STAT1-IRF1-TRIM28 signaling axis exerting antitumor efficacy Cancer Immunology Research: In press PMID32265228
282. Chen M-J., Li J., Mills GB., Liang H., 2020 Predicting cancer cell line dependencies from protein expression data from reverse phase protein arrays JCO Clinical Cancer Informatics 4:357-366 PMID 32330068
283. Tsang Y., Wang Y., Kong K., Grzeskowiak C., Zagorodna O., Dogruluk T., Lu H., Villafane N., Bhavana H., Moreno D., Elsea SH Liang H., Mills GB., Scott KL 2020 Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression eLife 9:e48963 PMID 32270762 PMC7164953
284. Rao L., Mak V., Zhou Y., Zhang D., Li X., Fung C., Sharma R., Gu C., Lu Y., Tipoe G., Cheung A., Mills GB., and Cheung LWT 2020 p85β regulates autophagic degradation of AXL to ​activate oncogenic signaling Nature Comms In Press
285. Ngan H-L., Liu Y., Fong AY., Poon P., Yeung C., Chan S., Lau A., Piao W., Li H., Tse J., Lo K., Chan S., Su Y-X., Chang J., Lau C., Mills GB., Grandis JR., Lui VWY., 2020 MAPK Pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. Life Science Alliance: In Press
286. Zervantonakis IK., Poskus M., Scott A., Selfors LM., Lin J-R., Dillon D., Pathania S., Sorger PK., Mills GB Brugge JS., 2020 Fibroblast-tumor cell signaling limits HER2 kinase therapy via activation of mTOR and anti-apoptotic pathways Proc Natl Acad Sci In Press.
287. Wang, X., Bustos M., Zhang X., Ramos R., Tan C., Iida Y., Chang S., Salomon M., Tran K., Gentry R., Kravtsova-Ivantsiv Y., Kelly DF., Mills GB., Ciechanover A., Mao Y., and Hoon DSB 2020 Downregulation of the Ubiquitin-E3 Ligase RNF123 promotes upregulation of the NRkB1 target Serpin E1 in aggressive glioblastoma tumors Cancers 12:E1081 PMID: 32349217
288. Zhao W., Li J., Chen M-J., Ju Z., Nesser N., Johnson-Camachjo K., Boniface C., Lawrence Y., Pande N., Spellman P., Davies M., Herlyn M., Muranen T., Zervantonakis I., Brugge J., Gray J., Von Euw E., Slamon D., Schultz A., Kumar S., Korkut A, Akbani R., Lu Y., Mills GB and Liang H 2020 Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines Submitted
289. Ng. P., Li, J., Ip C., Jeong K., Tran R., Tsang Y., Lu Y., Shaw K., Meric-Bernstam F., Mills GB Liang H., 2020 Large-scale Annotation of Cancer Fusion Genes using a Functional Genomic Approach Submitted
290. Molina JR., Morlacchi P., Dennison JB., Silva L., Hawke D., Kaluarachi, McMurray J., Lorenzi P., Weinstein J., and Mills GB., 2020 Reverse glycolysis during nutrient stress allows extracellular lactate to promote cell survival through generation of reducing power and structural building blocks exposing a therapeutic liability Submitted
291. Bernardi R., Dominguez-Vidana R., Bland CS., Scorsone KA., Tyagi S., Orellana M., Herrera- Abreu M., Aarts M., Rexer B., Schmitt E., Mao S., Nagi C., Shea M., Mitchell T., Rao M., Nanda S., Ward RM., Wang T., Dubrulle J., Stossi G., Arteaga C., Turner NC., Mills GB., Hilsenbeck SG., Osborne K., Shaw C, Rimawi M., Schiff R., Westbrook T., 2020 HER2- amplified breast cancers harbor a non-canonical mitotic checkpoint that can be targeted therapeutically Submitted
292. Novak, M., Hood J., MacDuffie, E., Lester J., Parkash V., Mills GB., Karlan BY., Oren M., and Drapkin R., 2020 Downregulation of the RNF20 ubiquitin ligase and monoubiquitylation of its substrate H2B occurs early in high-grade serous ovarian cancer promoting oncogenic behavior Submitted
293. Brafford P., Xiao M., Sproesser K., Kossenkov A., Vultur A., Watters A., SchultzD., Kerekovic A., Hills R., Wasserman B., Garman B., Wubbenhorst W., Mathanson K., Lu Y., Mills B. Xu W., Xu X., Schuchter L., Altiere D., Herlyn M., and Krepler C., 2019 Identification of a Protein Biomarker Signature for Mitochondrial HSP90 - FAK Inhibitor Synergy in Melanoma Submitted.
294. Liu J., Fukunaga-Kalabis M., Zhang G., Krepler C., Connelly T., Gutierrez A., Zhang J., Cheng C., Wei A., Aza-Glanc P., Yang CC., Tong C., Huang Y., Delvadia M., Li L., Xiao M., Morais A., Sproesser K., Braffor P., Wang J., Bequire M., Vulture A., Wu L., Lu Y., Mills GB., Xu W., Karkousis G., Xu X., Schuchter l., Gangadhar T., Amaravadi R., Kwong L., Frederi D., Boland G., Flaherty K., Ronai Z., and Herlyn M., 2020 LPAR signaling activated in neural crest stem cells promotes melanoma cell growth, invasion and therapy resistance Submitted.
295. Guo H., Fang Y., Zhang D., Zhao W, Bai S., Wang J., Sun C., Barnes S., Guo L., Gao M., Yu Q., Lu Y., Ling J., Lorenzi P., An Z., Klein WH., Jonasch E., Mills GB., 2020 AKT2—but not AKT1—protein stability depends on isoform-specific turn-motif phosphorylation Submitted.
296. Piha-Paul S., Xiong W., Moss T., Hess K., Mostorino R., Tapia C., Sedelmeier S., Fu S., Hong D., Janku F., Karp D., Naing A., Rodon J., Subbiah V., Tsimberidou A., Yap T., Javle M., Shaw K., Eterovic K., Mills GB., Meric-Bernstam F., 2020 A Phase II Study of Talazoparib Tosylate in Advanced Cancer Patients with Somatic and Germline (Not Breast or Ovarian Cancer) Alterations of BRCA 1/2, Mutations/Deletions in Other BRCA Pathway Genes and PTEN or PTEN loss Submitted
297. Doberstein K., Spivak R., Reavis H., Hooda J., Feng Y., Kroeger P., Stuckelberger S., Mills GB., Devins K., Schwartz L., Iwanicki M., Fogel M., Altevogt P., Drapkin R., 2020 L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary Submitted
298. Gu G., Tian L., Herzog S., Glesomino L., Gao M., Kim J., Dustin D., Lo F., Beyer A., Grimm S., Edwards D., Tsimelzon A., Huang H., Fernandez N., Hilsenbeck S., Liu D., Xu J., Alaniz A., Li Z., Mills GB., Janku F., Foulds C., Coarfa C., Zhang X., Ando S., Fuqua S., 2020 Unexpected therapeutic hormonal vulnerability of ESR1 mutant metastasis Submitted.
299. Li Y., Liu N-N., Xu J., Li X., Want H., Yi S., Mills GB., Sahni N., 2020 e-MutPath: Edgetic mutation prioritization based on network perturbation paths Submitted
300. Kim SB., Sho BW., Kim S-K., Park YY., Park ES., Lee HS., Jang HJ., Lee KW., Jeong W., Chu IS., Lu Y., Davies. MA., Mills GB and Lee JS. 2020 Identification of cell signaling pathways regulated by miRNAs in cancer cells using a systems biology approach Submitted
301. Fang Y., Lai H., Zhao X., Qin Y., Chen R., Li G., Wang Z., Ding Y., Hu J., Labrie M., Stommel J., Wang C-Y., Ding Z., Mills GB., Ma D., Zhou J., Chen G and Gao Q., 2020 Rictor orchestrates β-catenin/FOXO balance by maintaining redox homeostasis during development of ovarian cancer Submitted
302. Pilie P., Zhou L., Peterson C., McGrail D., Peng Y., Peng G., Liu X., Zhang X., WoodC., Karam J., Sircar K., Gay C., Yap T., Bronk L., Mao X., Zhang J., Ding Z., Lin S-Y., Mills GB., Futreal A., and Jonasch E., 2020 Defective Tip60 Activation and Homologous Recombination Repair Due to VHL loss in Renal Cell Carcinoma Submitted
303. Huang K-L., Scott A., Zhou D., Wang L-B., Weerasinghe A., Liu R., Wu Y., Wendl M., Wyczalkowski M, Baral J., Sengupta S., Lai C-W., Ruggles K., Payne S., Raphael B., Fenyo D., Chen K., Mills GB., Ding L., 2020 Spatially Interacting Phosphorylation Sites and Mutations in Cancer Submitted
304. Peng Y., Zhao W., Shen J., Wang L., Ju Z., Hsieh H-J., Yap T., Mills GB., and Peng G 2020 The GATOR1 complex component NPRL2 links genome maintenance to tumor-intrinsic innate immunity Submitted
305. Westin S., Shinbrot E., Ju Z., Liu Z., Broaddus R., Hoivik E., Krakstad C., Lu K., Coleman R., Werner H., Salvesen H., Gibbs R., Covington K., Wheeler D., Mills GB 2020 Mutations in the Exonuclease Domain of Polymerase Epsilon (POLE) Yield Improved Prognosis and a Unique Mutational Profile in Endometrial Cancers Submitted
306. Amara S., Kuiken H., Selfors L., Butler T., Leung M., Leung C., Lunsford E., Kolarova T., Hage C., Ganesh K., Foster R., Rueda G., Spellman P., Ince T., Navin N., Mills GB., Bronson R., Brugge J., 2020 Transient commensalism drives metastasis in a model of ovarian clear cell carcinoma Submitted
307. Kim S-J., Ju J-S., Won J., Lee H., Gong G., Gyorffy B., Han H-D., Mills GB and Park Y-Y., 2020 The TNBC-specific RNA-binding protein, NONO and the Stat3 axis contribute to cancer cell growth and confer drug resistance Submitted
308. Wang L., Yang L., Zhao W., Ju Z., Zhang W., Shen J., Peng Y., Chen C., Liu J., Shen X., Wang D., Song S., Yao TA., Ajani J., Mills GB., Chen M., Peng G., 2020 Inhibition of the ATM-Chk2 axis synergizes with immune checkpoint blockade in *ARID1A*-deficient tumors by promoting cancer cell-intrinsic innate immunity beyond antigenicity Submited.
309. Li A., Keck J., Mills GB., Mitri Z., 2020 Serial biopsies reveal extensive evolution of subtypes among metastases in a breast cancer patient Submitted.
310. Xu H., George E., Kinose Y., Kim H., Medvedev S., Barger C, Devins K., Schwartz L., Jean S., Mills GB., Nathonson K., Karpe A., Drapkin R., Brown E., Simpkins F., 2020 Combination inhibition of WEE1 and ATR causes tumor regression in a CCNE1 dependent manner Submitted
311. Kim H., Xu H., George E., Hallberg D., Jagannathan B., Medvedev S., Kinose Y., Devins K., Ly k., Schwartz L., Wang Y., Johnson N., Scharf R., Mills GB., Velculescu V., Brown E and Simpkins F., 2020 PARP-ATR inhibition caused complete and durable respoinse in PARP inhibitor and platinum resistant OVCA Submitted.
312. Nair B., Parashar D., Geethadevi A., George J., Tasih S-W., Nair G., Nair A., Chen C., Lu Y., Jeong KJ., Lu Z., Liu J., Ram P., Mills GB., Pradeep S., and Chaluvally-Raghavan 2020 Modeling peritoneal spread of ovarian cancer in vitro identifies therapy vulnerabilities regulated by FOXM1 and ERBB2 Submitted.
313. Anderson C, Cidado J., Proia T., Criscione S., Boiko S., Shen M., Lawson D., Su N., Wu A., Grondine M., Gregory G., Todorovski I., Johnstone R., Mills GB., Fawell S., Janne P., Drew L., 2020 Altered apoptotic signaling contributes to acquired resistance to the selective CDK9 inhibitor, AZ’5576 in hematologic cancer models Submitted.
314. Haugen M., Lingjaerde O., Hedenfalk I., Garred O., Borgen E., Loman N., Hatschek T., Borresen-Dale A-L., Naume B., Mills GB., Maelandsmo G., and Engebraten O., 2020 Protein signature predicts response to neoadjuvant combination treatment with chemotherapy and bevacizumab in HER-2 negative breast cancers Submitted.
315. Chen H-Y., Zayas-Bazan D., Goldman A., Reyes-Uribe P., Basu S., Guterres A., Kossenkov A., Ying X., Axelrod M., Lu Y., Weber M., Liu Q., Mills GB., Schug Z., Murphy M., Speicher D., Villanueva J., 2020 Selective disruption of S6K2 perturbs lipid homeostasis triggering apoptosis and ferroptosis in MAPKi-resistant NRAS-mutant melanoma Submitted
316. Jing Y., Ye Y., Lin SH., Mills GB., Han L., 2020 Multi-dimensional prediction of immune related adverse events during checkpoint immunotherapy Submitted
317. Yang B., Li X., Fu Y., Guo E., Li F., Lu F., Liu C., Jia H., Wang Z., Qing T., Xiao R., Peng G., Mills GB., Sun C., Chen G. 2020 MEK inhibition remodels the immune landscape of KRAS mutant tumors to overcome resistance to PARP and immune checkpoint inhibitors Submitted
318. Reinhold WC., Elloumi F., Varma S., Roberts J., Mills GB., Pommier Y 2020 Molecular events in drug-target genes, and their relationship to pharmacological response Submitted.
319. Ye Y., Hu Q., Zhang Z., Diao L., Sun C., Zhou B., Wang L., Lin C., Gao J., Lou Y., Lin S., Liu H., Mills GB., Han L., 2020 Systematic landscapes of associations among immune feature reveal dynamic profiling to predict immunotherapy efficacy Submitted
320. Wu B., Guan L., Chin L., Dang H., Xu Y., Ren J., Li T., Chen Y., Mills G., Radhakrishnan R., Further E., Want X-W., Wells R., Guo W., 2020 Stiff Matrix Induces Exosome Secretion and Promotes Tumor Progression Submitted
321. Vinik, Y., Ortega, G., Mills GB., Barshack I., Jurkowicz M., Gutman M., Lev S., 2020 Proteomic analysis of circulating exosomes identifies potential makers of progression recurrence and response. Submitted.
322. Yan G., Wang H., Luna A., Bozorgui B., Li X., Sanchez M., Dereli Z., Mak N., Kara G., Chen X., Lu Y., Babur O., Cokol M., Ozpolat B. Sander C., Mills GB., Korkut A., 2020 Adaptive response to BET inhibition induces therapeutic vulnerability to MCL1 inhibitors in breast cancer Submitted.
323. Hua X., Li Y., Guo L., Xu M., Qi D., Huang J., Bhat A., Zhou Y, Wu E., Mills G., Sahni N., Yi S., 2020 Systematic characterization of somatic mutation-mediated microRNA regulatory network perturbations in cancer Submitted
324. Georgopoulou D., Callari M., Rueda O., Martin A., Shea A., Giovannettie A., Qosaj F., Dariush A., Chin S-F., Carnevalli L., Provenzano E., Greenwood W., Esmaeilishirazifard E., O’Reilly M., Serra V., Bressan D., IMAXT Consortium., Mills GB., Cosulich S., Hannon G., Brun A., and Caldas C. 2020 Mass cytometry reveals complex cellular phenotypic diversity in breast cancer patient-derived tumour xenografts Submitted.
325. Mak M., Diao L., Gibbons D., Tong P., Wang J., William W., Ng P., Cardnell R., Giri U., Danilova L, Mukherjee S., Lou Y., The Cancer Genome Atlas Network., Jones S., Warner S., Bearss D., Mollard A., Lippman S., Myers J., Coombes K., Weinstein J., Heymach J., El-Naggar A., Mills GB., Hayes D., Cope L., Robertson G., Byers LA., 2020 Global molecular alterations in squamous head and neck and lung cancers after epithelial-mesenchymal transition (EMT) Submitted
326. Chen W., Iwanicki M., Ince T., Drapkin R., Mills GB and Brugge J 2020 Apoptotic priming drives MYC-mediated vulnerability to NAMPT inhibition in high grade serous ovarian cancer Submitted
327. Sasaki N., Iwaya T., Chiba T., Fujita M., Ju Z., Endo F., Yaegashi M., Hachiya T., Sugimoto R., Sugai T., Siwak D., Liotta L., Lu Y., Mills GB., Nakagawa H., Nishizuka S., 2020 Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA Submitted
328. Yaegashi M., Iwaya T., Sasaki N., Fujita M., Ju Z., Siwak D., Hachuya T., Sato K., Endo F., Kimura T., Otsuka K., Sugimoto R., Sugai T., Liotta L., Lu Y., Mills G., Nakagawa H., Nishizuka S., Frequent post-treatment monitoring of colorectal cancer using individualized ctDNA validated by multi-regional molecular profiling Submitted
329. Li A., Keck J., Patterson J., Parmar S., Labrie M., Thomas G., Creason A., Johnson B., Kolodzie A., Corless C., Mills GB., Gray JW., Bergan R. and Mitri Z. Identifying Tumor Heterogeneity and Treatment Resistance of Breast Cancer through Serial Biopsies Submitted
330. Widker C., Hunt BG., Krishnan S, Parajuli S, Palackdharry S., Elaban WR., Mills GB., Wise-Draper T., Waltz S., Takiar V. 2020 Glutaminase inhibition improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. Submitted.
331. Verma N., Vinik Y., Saroha A., Nair N., Ruppin E., Mills GB., Karn T., Dubey V., Khera L., Mohan-Raju H., Maina G., and Lev S 2020 Synthetic lethal combination targeting of BET uncovers intrinsic susceptibility of TNBC to ferroptosis Submitted
332. Li Y., Dunn B., McGrail D., Li Y., Awasthi S., Li Q., Eckhardt SG., Mills GB., Yi S., Sahni N., 2020 Systematic characterization of human essentialome reveals context specificity: Insights into synthetic lethality Submitted.
333. Labrie, M., Li A., Creason A., Betts C., Keck J., Johnson B., Sivagnanam S., Boniface C., Ma H., Blucher A., Chan YH., Chin K., Vuky J., Guimares A., Lim Y., Gao L., Siex K., Parmar S. Kolodozie A., Spellman P., Goecks J., Coussens L., Corless C., Bergan R., Gray J., Mills GB and Mitri Z., 2020 Multi-omics analysis of serial samples from metastatic TNBC patients treated with olaparib demonstrates therapeutic opportunities for rational combination therapy trials Submitted
334. Jing Y., Zhang Y., Ye Y, Liu Y., Lin S., Diao L., Liu H., Mills GB., Han L., 2020 Association between sex and immune-related adverse events during immune checkpoiont inhibitor therapy. Submitted.

# TEAM SCIENCE AS PART OF CONSORTIA

1. Narod SA, Sun, P, Ghadirian, P, Lynch, H, Isaacs, C, Garber, J, Weber, B, Karlan, B, Fishman, D, Rosen, B, Tung, N, Neuhausen, SL. 2001, (as part of the consortium) Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 357:1467-1470 PMID:11377596
2. Kelloff, G.J., Lippmann S.M. Dannenberg, A.J…..Mills G.B., …Levin B., Nelson W.G., Hong W.K. 2006 Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia (IEN) and Cancer A Plan to Move Forward (AACR Cancer Prevention Task Force) Clinical Cancer Research 12:3661-97 PMID:16778094
3. Metcalfe, K.A., Carmelis D., Lubinski, J., Lynch H., Moller P., Ghadirain P., Foulkes W., Friedman E., Kim Sing, C., Ainswork P., Rosem B., Domchek S, Isaacs, C., Wagner T., Tung, N., Manoukian S., Ciouch F., Sun P., Narod. S. and the Hereditary breast cancer clinical study group (as part of the group). 2008 International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 122:2017-22 PMID:18196574 PMC2936778
4. Addona, T., Abbatiello, S., Skates, SJ., ……. The NCI Clinical Proteomic Technology Assessment for Cancer (CPTAC) Network (as part of the network) 2009 Multi-site assessment of precision and reproducibility of multiple reaction montoring-based measurements of proteins in plasma Nature Biotech 27:633-41 PMID:19561596 PMC2855883
5. Rudnick, PA, Clauser KR., Kilpatrick LE, … The NCI Clinical Proteomic Technology Assessment for Cancer (CPTAC) Network (as part of the network) 2010 Performance metrics for evaluating liquid chromatrograpy-Tandem Mass Spectrometry Systems in proteomics analysis by the CPTAC Network Mol Cell Proteomics 9:225-41 PMID:19837981 PMC2830836
6. Paulovich, AG., Billheimer, D. Ham AJ ……….. The NCI Clinical Proteomic Technology Assessment for Cancer (CPTAC) Network (as part of the network) 2010 A reference yeast proteome for benchmarking LC-MS platform performance Mol Cell Proteomics 9:242-54 PMID:19858499 PMC2830837
7. Tabb, DL., Vega-Montoto, L., Variyath AM. …… The NCI Clinical Proteomic Technology Assessment for Cancer (CPTAC) Network (as part of the network) 2010 Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry J Proteome Research 9:761-776 PMID:19921851 PMC2818771
8. The Cancer Genome Atlas Research Network 2011 Integrated Genomic Analysis of Ovarian Cancer Nature. 474:609-15 PMID:21720365 PMC3163504
9. The Cancer Genome Atlas Research Network 2012 Comprehensive molecular portraits of human breast tumors Nature: 490:61-70 PMID:23000897 PMC3465532
10. Brennan C., Verhaak RWG., McKenna A., Campos B., Noushmehr H., Salamama S., Zheng S., Chakravarti D., Sanborn JZ., Berman S., Beroukhim R., Bernard B., Wu C-J., Genovese G., Shmulevich I., Barnholtz-Sloan J., Zou L., Vegesna R., Shukla S. Cirello G., Lu Y., Yung WK., Zhang W., Kcuherlapati R., Perou CM., Gibbs R,., Marra M., Gastier-Foster JM., , Mills GB., Lander E., Spellman P., Wilson R., Sander C., Weinstein J., Meyerson M., Laird PW., Haussler D., Gabriel S., Getz G., Chin L., and the TCGA Research Network 2013 The Somatic Genomic Landscape of Glioblastoma Cell 155:462-77 PMID:24120142 PMC3910500
11. The Cancer Genome Atlas Research Network 2013 Integrated Genomic Characterization of Endometrial Carcinoma. Nature 497:67-73 PMID:23636398 PMC3704730
12. Stuart JM., Weinstein J, Collisson E., Shmulevich I., Sander C., Mills GB., Shaw K., Ozenberger B., Ellrott K., 2013 The cancer genome atlas pan-cancer analysis project Nature Genetics;45:1113-20 PMID:24071849 PMC3919969
13. The Cancer Genome Atlas Research Network 2013 Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 499:43-9 PMID:23792563 PMC3771322
14. The Cancer Genome Atlas Research Network 2014 Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507:315-22 PMID:24476821 PMC3962515
15. The Cancer Genome Atlas Research Network 2014 Comprehensive Molecular Profiling of Lung Adenocarcinoma Nature 511:543-50 PMID:25079552 PMC4231481
16. The Cancer Genome Atlas Research Network 2014 Comprehensive Molecular Characterization of Gastric Adenocarcinoma Nature 513:202-9 PMID:25079317 PMC4170219
17. Mertins P., Liu T., Man DR., Petyuk V., Yang F., Gajadhar A., Johnson H., Zhang H., Levine D., Toswnsend R., Davies S., Gillette M., Ruggles K., Fenyo D, Clauser K., Qiao J., Gritsenko M., Li S., Zhang B., Tian Y., Moore R., Olvera N., Dao F., Rodriguex H., Chan D., Liebler D., Rodland K., Mills GB., Smith R., Paulovich A.,Ellis M., White F., Carr S., and NCI CPTAC consortium 2014 Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Molecular and Cellular Proteomics 13:1690-704 PMID: 24719451 PMC4083109
18. Hoadley K, Yau C., Wolf DM., Cherniack AD., Tamberero D., Ng S., Leiserson MD, Niu B., McLellan MD., Paull EO., Uzunangelov B., Kandoth C., Akbani R., Shen H., Lu Y., Ju. Z., Van’t Beer L., Lopez-Bigas N., Collisson EA., Mills GB., Laird PW., Raphael BJ., Ding L., Byers LA., Van Waes C., Cheng Z., Weinstein J., TCGA Network, Benz C., Perou CM., Stuart JM., Multi-platform integration of 12 cancer types reveals cell-of-origin classes with distinct molecular signatures Cell 158:929-44 PMID:25109877 PMC4152462
19. The Cancer Genome Atlas Research Network 2014 The somatic genomic landscape of chromophobe renal cell carcinoma Cancer Cell 26:319-30 PMID:25155756 PMC4160352
20. The Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014 159:676-90 PMID:25417114 PMC4243044
21. The Cancer Genome Atlas Research Network 2014 Comprehensive, Integrative Genomic Characterization of Diffuse Lower-Grade Gliomas New England Journal of Medicine 372:2481-2498 PMID: 26061751 PMC4530011
22. The Cancer Genome Atlas Network; 2014 Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 111:15544-9 PMID:25313082 PMC4217452
23. The Cancer Genome Atlas Research Network 2015 Comprehensive genomic characterization of head and neck squamous cell carcinomas Nature 517:576-82 PMID:25631445 PMC4311405
24. The Cancer Genome Atlas Research Network 2015 Genomic Classification of Cutaneous Melanoma Cell 161(7):1681-96 PMID:26091043 PMC4580370
25. Ciriello G., Gatza ML., Beck AH Wilkerson M., Rhi S., Pastore A., Zhang H., McLellan M., Yau C., Hoadley K., Kandoth C., Bowlby R., Hayaat S., Lester S., Tse G., Factor R., Collins L., Allison K., Chen Y-Y., Jensen K., Johnson N., Mills GB., Cherniack A., Robertson G., Benz C., Sander C., Laird P., King T., The Cancer Genome Atlas Network and Perou CM., 2015 Comprehensive molecular portraits of invasive lobular breast cancer Cell 163(2):506-19 PMID: 26451490 PMC4603750
26. The Cancer Genome Atlas Research Network 2015 The Molecular Taxonomy of Primary Prostate Cancer. Cell 163:1011-25 PMID: 26544944 PMC4695400
27. The Cancer Genome Atlas Research Network 2015 Comprehensive Molecular Characterization of Papillary Renal Cell Carcinoma N Engl J Med 374:135-45 PMID: 26536169 PMC4775252
28. Klionsky et al 2016 Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy: Autophagy 8:445-544 PMID: 22966490 PMC3404883
29. The Cancer Genome Atlas Research Network 2016 Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma Cancer Cell 29:723-36 PMID: 27165744 PMC4864952
30. The Cancer Genome Atlas Network 2016 Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma Cell 164:550-563 PMID 26824661 PMC4754110
31. The Cancer Genome Atlas Research Network 2016 Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics 48: 607- 616 PMID: 27158780 PMC4884143
32. The Cancer Target Discovery and Development Network 2016: Initial steps to transforming Big Data into cancer-relevant insight: A multi-tier approach to assess reproducibility and relevance Mol Can Res 14:675-82 PMID: 27401613 PMC4987219
33. The Cancer Genome Atlas Research Network 2017 Comprehensive Molecular Characterization of Oesophageal Carcinoma Nature 541:169-175 PMID:28052061 PMC5651175
34. The Cancer Genome Network Atlas 2017 Integrated genomic and molecular characterization of cervical cancer Nature 543:378-384 PMID:28112728 PMC5354998
35. The Cancer Genome Network Atlas 2017 Comprehensive molecular characterisation of phaeochromocytoma and paraganglioma Cancer Cell 31:181-193 PMID:28162975 PMC5643159
36. Huo D., Ha H., Suhn R., Gamazon E., Cherniak A., Liu J., Yoshimatsu T., Pitt J., Hoadly K., Troester M., Ru Y., Lichtenber T., Sturtz L, Shelly C., Benz C., Mills GB., Laird P., Shriver C., Perou C., Olopade F. 2017 Comprehensive Comparison of Breast Cancer Molecular Portraits by African and European Ancestry in The Cancer Genome Atlas Jama Oncology 3:1654-1662 PMID:28472234 PMC5671371
37. Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB; Cancer Genome Atlas Research Network., Weinstein JN, Zhang J, Akbani R, Levine DA.2017 Integrated Molecular Characterization of Uterine Carcinosarcoma Cancer Cell 31:411-423 PMID:28292439 PMC5599133
38. Zhang Y., Ng KS., Kucherlapati M., Chen F., Liu Y., Tsang Y.,, de Velasco G., Jeong KH., Akbani R., Hajipanayis A., Pantazie A., Bristow C., Lee E., Mahaeshwar H., Tang J., Zhag J., Yang L., Seth S., Lee S., Ren X., Song X., Sun H., Seidman J., Luquette L., Xi R., Chin L., Protopopov A., Westerbrook T., Shelly C., Choueiri T., Ittmann M., Van Waes C., Weinstein J., Liang H., Henske E, Godwin A., Park P., Kucherlapati R., Scott KL., Mills GB., Kwiatkowski D., Creighton CJ., A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations Cancer Cell 31:820-832 PMID: 28528867 PMC5502825
39. AACR Project GENIE Consortium 2017 AACR Project GENIE: Powering Precision Medicine Through An International Consortium Cancer Discovery 7:818-831. PMID: 28572459 PMC5611790
40. The Cancer Genome Atlas Network 2017 Comprehensive and integrative genomic characterization of hepatocellular carcinoma Cell 169:1327-1341 PMID: 28622513 PMC5680778
41. The Cancer Genome Atlas Network 2017 Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles, Cell Reports 18(11):2780-2794 PMID 28658632 PMC6141445
42. The Cancer Genome Atlas Network 2017 Characterization of Pancreatic Ductal Adenocarcinoma Cancer Cell 32:185-203 PMID: 28810144 PMC5964983
43. The Cancer Genome Atlas Network 2017 Integrative analysis identifies four molecular and clinical subsets in uveal melanoma Cancer Cell 32:204-220
44. The Cancer Genome Atlas Network 2017 Comprehensive molecular charterization of muscle- invasive bladder cancer. Cell. 171:540-556 PMID: 30096301 PMC 6297116
45. The Cancer Genome Atlas Network 2017 Comprehensive and integrated genomic characterization of adult soft tissue sarcomas Cell 171:950-965 PMID:29100075 [PMC5693358](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693358/)
46. Library of Integrated Network-Based Cellular Signatures 2018 The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations Cell Systems. 6:13-24 PMID: 29199020 PMC5799026
47. The Cancer Genome Atlas Network 2018 The integrated genomic landscape of thymic epithelial tumors Cancer Cell. 33:244-258 PMID: 29438696 PMC5994906
48. The Cancer Genome Atlas Network 2018 Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep. 12:3392-3406. PMID: 29898407 PMC6075738
49. The Cancer Genome Atlas Network 2018 A comprehensive cross-tumor molecular study of gynecologic and breast cancers Cancer Cell. 33:690-705 PMID: 29622464 PMC5959730
50. The Cancer Genome Atlas Network 2018 Pan-Cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas Cell Systems 6:282-300 PMID: 29596783 PMC 5892207
51. The Cancer Genome Atlas Network 2018 Mutational landscape of splicing genes and functional consequences across 33 cancer types Cell Rep. 23:282-296 PMID: 29617667 PMC5933844
52. The Cancer Genome Atlas Network 2018 Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.Cancer Cell. 34:211-224.PMID: 30078747
53. The Cancer Genome Atlas Network 2018 Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer Cell. 173:291-304 PMID: 29625048 PMC5957518
54. The Cancer Genome Atlas Network 2018 LncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell- cycle progression in Cancer. Cancer Cell. 33706-720 PMID: 29622465 PMC6143179
55. The Cancer Genome Atlas Network 2018 An integrated TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR) to drive high quality survival outcomes analytics Cell 173:400-416. PMID: 29625055 PMC6066282
56. The Cancer Genome Atlas Network 2018 Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines Cell Systems 6:271-281 PMID: 29596782 [PMC6075717](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075717/)
57. The Cancer Genome Atlas Network 2018 The cancer genome atlas comprehensive Molecular Characterization of Renal Cell Carcinoma Cell Rep. 23:313-326. PMID: 29617669 PMC6075733
58. The Cancer Genome Atlas Network 2018 Pan-cancer analysis of lncRNA regulation supports their targeting of cancer genes in each tumor context Cell Rep. 23:297-312. PMID: 29617668 PMC5906131
59. The Cancer Genome Atlas Network 2018 Spatial Organization And Molecular Correlation Of Tumor Infiltrating Lymphocytes Using Deep Learning On Pathology Images Cell Rep 23:181- 193. PMID: 29617659 PMC5943714
60. The Cancer Genome Atlas Network 2018 Systematic Analysis of Novel Splice-Site Creating Mutations in Cancer Cell Rep.23:270-281 PMID: 29617666 PMC6055527
61. The Cancer Genome Atlas Network 2018 Oncogenic Signaling Pathways in The Cancer Genome Atlas Cell. 173:321-337. PMID: 29625050 PMC6070353
62. The Cancer Genome Atlas Network 2018 Perspective on oncogenic processes at the end of the beginning of Cancer Genomics Cell 173:305-320. PMID: 29625049 PMC5916814
63. The Cancer Genome Atlas Network 2018 Immune landscape of cancer Immunity. 48:812-830 PMID: 29628290 PMC5982584
64. The Cancer Genome Atlas Network 2018 Comprehensive Discovery and Characterization of Driver Genes and Mutations in Human Cancers. Cell 173:371-385 PMID: 30096302
65. The Cancer Genome Atlas Network 2018 Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers Cell Reports 23:255-269. PMID:29617665 PMC5916795
66. The Cancer Genome Atlas Network 2018 Genomic, pathway network, and immunologic features distinguishing squamous carcinomas Cell Reports 23:194-212 PMID:29622463 PMC6028190
67. The Cancer Genome Atlas Network 2018 Driver Fusions and Their Implications in the Development and Treatment of Human Cancers Cell Reports 23:227-238 PMID:29617662 PMC5916808
68. The Cancer Genome Atlas Network 2018 Pathogenic Germline Variants in 10,389 Adult Cancers Cell 173: 355-370. PMID:29625052 PMC 5949147
69. The Cancer Genome Atlas Network 2018 Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types Cell Reports 23: 213-226 PMID:29617661 PMC5916807
70. The Cancer Genome Atlas Network 2018 Genomic and Molecular Landscape of DNA Damage Repair Deficiency Across The Cancer Genome Atlas Cell Reports 23: 239-254. PMID: 29617664 PMC5961503
71. The Cancer Genome Atlas Network 2018 Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas Cancer Cell 33;721-735 PMID:29622466 PMC5966039
72. The Cancer Genome Atlas Network 2018 Genomic and Functional Approaches to Understanding Cancer Aneuploidy Cancer Cell 33:676-689 PMID:29622463 PMC6028190
73. The Cancer Genome Atlas Network 2018 Systematic Functional Annotation of Somatic Mutations in Cancer Cancer Cell 33:450-462 PMID 29533785 PMC5926201
74. The Cancer Genome Atlas Network 2018 Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Rep. 23:172-180 PMID: 29617658 PMC5918694
75. The Cancer Genome Atlas Network 2018 Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation Cell 173:338-354. PMID:29625051 PMC5902191
76. The Cancer Genome Atlas Network 2018 A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell. 173:386-399 PMID: 29625054 PMC:5890960
77. The Cancer Genome Atlas Network 2018 Comprehensive molecular characterization of the Hippo Signaling Pathway in Cancer Cell Reports 5:1304-1317 PMID: 30380420 PMC6326181
78. The Cancer Genome Atlas Network 2018 A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily Cell Systems 7:422- 437 PMID: 30268436 PMCID6370347
79. The Cancer Genome Atlas Network 2018 The chromatin accessibility landscape of primary human cancers Science 362 pii: eaav1898. PMID: 30361341 PMC6408149
80. The Cancer Genome Atlas Network 2018 Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 8:1548-1565. PMID: 30322867 PMC6310008
81. Niepel M., Hafner, M., Mills C., Subramanian K., Williams E., Chung M., Gaudio B., Barrette A., Stern A., Hu B., Korkola J., LINCS Consortium, Gray JW., Birtwistle M., Heiser L., Sorger P., 2019 A multi-center study on the reproducibility of drug responses in mammalian cell lines Cell Systems 9:35-48 PMID 31302153
82. ICGC/TCGA 21?? 2Pan-Cancer Analysis of Whole Genomes Consortium 2020 Pan-cancer analysis of whole genomes Nature 578:82-93 PMID: 32025007
83. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Genomic basis for RNA alterations in cancer Nature.578:129-136. PMID 32025019
84. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 The repertoire of mutational signatures in human cancer Nature 578:940-101 PMID 320250153.
85. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Analysis of non-coding somatic drivers in 2,658 cancer whole genomes Nature 578:102-111 PMID 320250134
86. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 The evolutionary history of 2,658 cancers Nature 578: 122-128 PMID 320250125
87. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Patterns of somatic structural variation in human cancer genomes Nature 578:112-121 PMID32025012
88. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing Nature Genetics In press PMID 32025003
89. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 The landscape of viral associations in human cancers Nature Genetics In press PMID 32025001
90. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Disruption of chromatin folding domains by somatic genomic rearrangement in human cancer Nature Genetics In Press PMID32024999
91. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Pan-cancer analysis of whole genomes indentifies driver rearrangements promoted by LINE-1 retrotransposition Nature Genetics In press PMID32024998
92. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Comprehensive molecular characterization of mitochondrial genomes in human cancers Nature Genetics In Press PMID 32024997
93. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis Commun Biol 3:56 PMID 32024996
94. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Butler enables rapid cloud-based analysis of thousands of human genomes Nature Biotechnol. In press PMID 32024987
95. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Pathway and network analysis of more than 2500 whole cancer genomes Nature Commun 11:729 PMID 32024854 PMC7002574
96. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 A deep learning systems accurately classified primary and metastatic cancers using passenger mutation patterns Nature Commun 11:728 PMID:32024849 PMC7002586
97. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Integrative pathway enrichment analysis of multivariate omics data Nat Commun 11:735 PMID 32024846 PMC7002665
98. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Inferring structural variant cancer cell fraction Nature Commun 11:730 PMID: 32024845 PMC7002525
99. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig Nat Commun 11:731PMID: 32024834 PMC7002414
100. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations Nature Commun 11:736 PMID:32024823 PMC7002524
101. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Divergent mutational processes distinguish hypoxic and normoxic tumours Nature Commun 11:737 PMID 32024819 PMC7002770
102. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Combined burden and functional impact tests for cancer driver discovery using DriverPower Nat Commun 11:734 PMID32024818 PMC7002750
103. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020 Genomic footprints of activated telomere maintenance mechanisms in cancer Nature Commun 11:733 PMID:32024817 PMC7002710
104. Human Tumor Atlas Network: Charting Tumor Transitions across space and time at single-cell resolution Cell 181: 236-249 PMID 32302568
105. Galiardis A., Zong Z., Porter V., Bowlby R., Titmuss E., Namirember C., Griner N., Allen H., Bowen J., Chan S., Darragh T., Stoler M., Wright T., Gesuwant P., Dyer M., Mas Y., Mungall K., Nakisige C., Novik K., Orem J., Origa M., BCC GSC Group., Gastier-Foster J., Yarchoan R., Casper C., Mills GB., Rader J., Ojesina A., Gerhard D., Mungall A., and Marra M., 2020 Human papillomavirus in cervical carcinomas from Uganda result in clade-specific epigenome and transcriptome landscapes Nature Genetics In Press
106. The Cancer Genome Atlas Network 2020 HPV-Negative Cervical Cancers in TCGA: A Conundrum Submitted

# INVITED ARTICLES

1. Paetkau, V., Shaw, J., Mills, G.B., and Caplan, B. 1980 Cellular origins and targets of costimulator (IL2). Immunol. Reviews 51:157-175
2. Paetkau, V., Shaw, J., Caplan, B., Mills, G.B., and Lee, K.C. 1980 Interleukin 2 in cell- mediated immune responses. J. Supramol. Structure 13:271-280
3. Mills, G.B., Hannigan, G., Stewart, A., Mellors, A., Williams, B., and Gelfand, E.W. 1985 Interferons do not signal cells through rapid alterations in phosphatidylinositide hydrolysis, cytoplasmic free calcium or cytoplasmic alkalinization. Progress in Clinical and Biological Research 202:357-368
4. Gelfand, E.W., Mills, G.B., Cheung, R.K., Lee, J.W., and Grinstein, S. 1987 Contrasting requirements for IL2 production, IL2 receptor expression, and lymphocyte proliferation. The role of calcium-dependent and calcium-independent signals. Lymphokines 14:155-175
5. Gelfand, E.W., Mills, G.B., Cheung, R.K., Lee, J.W.W., and Grinstein, S. 1987 Transmembrane ions fluxes during activation of human T lymphocytes. Role of Ca2+, Na+/H+ exchange and phospholipid turnover. Immunol. Rev. 95:59-87
6. Haliotis, T., Trimble, W., Chow, S., Mills, G.B., Girard, P., Kuo, J.F., Govindji, N., and Hozumi, N. 1988 The cell biology of ras-induced transformation: Insights from studies using an inducible hybrid oncogene system AntiCancer Research 8:935-946
7. Paetkau V., and Mills, G.B. 1989 Cytokines and the mechanisms of lymphocyte activation Immunology and Allergy Clinics of North America 9:21-44
8. Sutherland, D.R., Yeo, E., Ryan, A., Mills G.B., and Baker, M.A. 1989. A mAb to KG1a cells recognizes an antigen (gp180) on activated T lymphoblasts and activated platelets. Leukocyte Typing IV: 1045-1046
9. Marks, A., Buckman, R., Kwok, C.-S., Kerr, I., Shaw, P., Michaels, H., De Angelis, C., Reed, R., Reilly, R., Mills, G., Law, J., and Baumal, R. 1989. Preclinical and clinical studies of radioiodinated monoclonal antibody 2G3 for therapy of intraperitoneal effusions associated with carcinoma of breast and ovary. Antibodies, Immunoconjugates and Radiopharmaceuticals 2:83-92
10. Mills G.B. 1990 Activation of lymphocytes by lymphokines. Current Topics in Membranes and Transport. 35:495-535
11. Fung, M.R., Mills, G.B., and Greene, W.C. 1990 The multimeric high affinity Interleukin 2 receptor: Insights into structure and signal transduction. Serono Symposia Publications: Cytokines: Basic Principles and Clinical Applications 68:101-107
12. Mills, G.B., Zhang, N., Schmandt, R., Fung, M., Greene, W., Mellors, A., and Hogg, D. 1991 Transmembrane Signalling by Interleukin 2. Biochem Transactions 115:277-285
13. Mills, G.B., Hashimoto, S. Hurteau, J.A., Campbell, S., Rubin L. and P. Shaw 1992 Role of growth factors, their receptors, and signalling pathways in the diagnosis, prognosis, follow-up and therapy of ovarian cancer. Diagnostic Oncology 2:39-54
14. Schmandt, R., Fung, M., Arima, N., Zhang, N., Leung, B., May, C., Gibson, S., Hill, M., Green W., and Mills G.B., 1992 T lymphocyte proliferation: Tyrosine kinases in interleukin 2 signal transduction Balliere’s Clinical Hematology 5:551-573
15. Simon, H.-U., Kozlowski, M., Hogg, D., Mills, G.B., and Siminovitch K.A. 1992 Isolation of a possible human counterpart to the murine XLR genes. (Short paper) Fresenius J.Anal.Chem. 343:125-126
16. Coles, J.G., Tsao, P., Wilson, G.J., Mills G. 1993 Tyrosine kinase-dependent lymphocyte signaling during allograft rejection. (short paper) Transplantation Proceedings 25:877-878. Schmandt, R., and Mills, G.B., 1993 Genomic components of carcinogenesis. Clinical Chemistry 39: 2375-2385
17. Mills, G.B., Schmandt, R., Gibson, S., Leung B., Hill, M., May, C., Shi, Y-F., Branch D. R., Radvanyi, L., Truitt, K E., and Imboden J., 1993. Transmembrane signaling by the interleukin 2 receptor: Progress and conundrums. Seminars in Immunology. 5:345-364
18. Mills, G., 1994. Current research in ovarian cancer. Treating the female patient: 8:4-10
19. Schmandt, R., and Mills G., 1995 Growth regulation of ovarian cancer cells Contemporary Obstetrics and Gynecology: 40: 81-92
20. Wolf, J.W., Mills, G.B., Bast, R.C., Roth, J.A., and Gershenson, D.M. 1998. P53 mediated gene therapy. In Ovarian Cancer 5 Edited by Sharp, F., Blackett, T, Berek J. and Bast R.C., ISIS Medical Media, Oxford UK pp259-272
21. Bast, R.C., Xu, F., Yu, Y., Barnhill, S., Zhang, Z., and Mills G.B. 1998. CA125: The past and the future. International Journal of Biological Markers: 13:179-87
22. Pusztai, L., Siddik, Z.H., Mills, G.B., and Bast, R.C., 1998 Physiologic and pathologic drugresistance in ovarian carcinoma: Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncologica: 37:629-640
23. Siminovitch, K.A., Lamhonwah, A.M., Somani, A.K., Cardiff, R. and Mills G.B. 1999 Involvement of the SHP-1 tyrosine phosphatase in regulating B lymphocyte antigen receptor signaling, proliferation and transformation Curr Top Microbiol Immunol. 246:291-7
24. Fang, X-J., Gaudette, D., Furui, T., Mao, M., Estrella, V., Eder, A., Putstilnik, T., Sasagawa, T., Lapushin, R., Yu, S., Jaffe, R., Wiener, J., Erickson, J., and Mills, G.B., 2000 Lysophospholipid growth factors in the initiation, progression, metastases and management of ovarian cancer. Annals of the New York Academy of Science: 95:188-208
25. Erickson, J.R., Espinal, G., and Mills G.B., 2000 Analysis of the Edg2 receptor based on the structure/activity relationship of LPA. Annals of the New York Academy of Science: 95:279-81
26. Bast, R.C., Yu, Y., Xu, F., Le, X.F. and Mills GB 2000 Molecular approaches to management of epithelial ovarian cancer Int. J. Gyne Oncology:10: Supplement 1: 2-7
27. Erickson, J. R., Hasegawa, Y., Fang, X., Eder, A., Mao, M., Furui, T, Aoki, J., Morris, A., and Mills G.B., 2001 Lysophosphatidic Acid and Ovarian Cancer: A Paradigm for Tumorigenesis and Patient Management. Prostaglandins and Other Lipid Mediat. 64:63-81
28. Bast, R.C., and Mills G. B., 2000 Alterations in oncogenes, tumor suppressor genes and growth factors associated with epithelial ovarian cancer In: Methods in Molecular Medicine Vol 39: Ovarian Cancer Editor Bartlett JMS Humana Press Totowa NJ: 39: 37-47
29. Mills, G.B., Lu, Y., Fang, X. Wang, H., Eder, A., Mao, M., Swaby, R., Cheng, KW. Stokoe D., Jaffe, R., Gray, J., and Siminovitch K., 2001 The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Seminars in Oncology Oct;28(5 Suppl 16):125-41
30. Bast, R.C., Mills, G.B., and Young R., 2001 Translational Research-Traffic on the Bridge Biomed Pharmacother. 55:565-71
31. Bast, R.C., Urban, N., Shridhar, V., Smith, D., Zhang, Z., Skates, S., Lu, K., Liu, J., Fishman D. and Mills GB. 2002 Early detection of ovarian cancer: promise and reality. Cancer Treat Res 107:61-97
32. Mills, G.,B., Eder, A., Fang, X., Hasegawa, Y., Mao, M., Lu Y., Tanyi, J., Tabassam, F., Wiener, J., Lapushin, R., Yu, S., Parrot, J.A., Compton, T., Tribley, W., Fishman D., Stack, M.S., Gaudette, D., Jaffe, D., Furui, T., Aoki, J., and Erickson, J., 2002, Critical role of Lysophospholipids in the Pathophysiology, Diagnosis, and Management of Ovarian Cancer In Ovarian Cancer. Cancer Treat Res. 107:61-97
33. Cheng, K.W., Tanyi, J.L., and Mills G.B., 2002 Genomic technologies in cancer research, drug discovery and development CME Journal of Gynecologic Oncology; 7:16–24
34. Gray, J.W., Suzuki, S., Kuo, W.L. Polikoff, D., Smith McCune K., Berchuck, A., Pinkel, D., Albertson, D., Mills G.B 2003 Genome copy number abnormalities in ovarian cancer. Gynecological Oncology Supplement (Suppl): 88:S16-S21
35. Mills G.B., Fang X., Lu, Y., Hasegawa, Y., Eder A., Tanyi J., Tabassam F.H., Erickson, J., Gershenson, D., Kohn, E., Jaffe, R., Bast, R.C., Gray. J. 2003 Molecular Therapeutics Gynecological Oncology (Suppl) 88:S88-S92
36. Kohn E.C., Fidler, I.J., Fishman, D., Jaffe, R., Liotta, L.A., Van Trappen, P., Mills G.B., and Trope C., 2003 Metastasis and angiogenesis in epithelial ovarian cancer Therapeutics: Gynecological Oncology (Suppl) 88:S37-S42
37. Liotta, L.A., Petricoin, E.F., Ardekani A.M., Hitt, B.A., Levine P.J., Fusaro, V.A., Steinberg, S.M., Mills G.B., Simone C., Fishman D.A., and Kohn, E.C., 2003, Proteomic Patterns in Sera Serve as Biomarkers of Ovarian Cancer: Gynecological Oncology Supplement: 88 (Suppl) S25-S28
38. Mills, G.B., Kohn, E., Lu, Y., Eder, A., Fang, X., Wang, H., Bast, R.C., Gray, J., Jaffe, R., and Hortobagyi, G., 2003 Linking molecular diagnostics to molecular therapeutics: Targeting the PI3K pathway in breast cancer. Seminars in Oncology: 30:93-104
39. Balkwill, F. Bast R.C., Berek, J., Chevenix-Trench, G., Gore, M., Hamilton, T., Jacobs I., Mills, G.B. Souhami R., Urban, N., Ursulic S., and Smyth J. 2003 Current Research and treatment for epithelial ovarian cancer: A position paper from the Helene Harris Memorial Trust. European Journal of Cancer 39:1818-1827
40. Lu, Y., Wang H., and Mills G.B., 2003 Targeting the PI3K/AKT pathway for cancer therapy. Rev Clin Exp Hematol. 7:205-28
41. Feng, L., Mills G.B., and Prestwich, G.D. 2003 Modulators of Lysophosphatidic Acid Signaling Expert Opinions on Therapeutic Patents 13:1619-1634
42. Kohn EC. Mils GB., and Liotta L 2003 Promising directions for the diagnosis and management of gynecological cancers Int. J. Obstet Gyne 83: 203-209
43. Kohn EC., Lu, Y., Wang, H., Yu, Q., Yu., S., Hall, H., Smith, D.L., Meric-Bernstam, F., Hortobagyi, G., and Mills G.B. 2004 Molecular Therapeutics: promise and challenges Seminars in Oncology. 31:39-53
44. Umezu-Goto, M., Tanyi, J., Lahad, J., Liu, S., Yu, S., Lapushin, R., Hasegawa, Y., Lu, Y., Trost, R., Bevers, T., Jonasch, E., Aldape, K., Liu, J., James, R.A., Ferguson, C.G., Xu, Y., Prestwich, G.D., and Mills G.B., 2004 Lysophosphatidic acid production and action: Validated targets in cancer? J. Cellular Biochemistry 92:1115-40
45. Drees, B.E., Mills G.B., Rommel C., Prestwich G.D., 2004 Therapeutic potential of phosphoinositide 3-kinase inhibitors Expert Opinion on therapeutic patents. 14:703-732
46. Cheng, K.W., Lahad J.P., Mills G.B., 2004 Analysis of Molecular Aberrations in Ovarian Cancer Allows Novel Target Identification J Obstet Gynaecol Can 2004 26:461-474
47. Meric-Bernstam, F., Mills G.B. 2004 Mammalian target of rapamycin Seminars in Oncology 31 (suppl 16):10-17
48. Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M. 2004 Targeted therapy of AML new concepts. Ann Hematol. 83 Suppl 1:S51-3
49. Cheng KW, Lahad JP, Gray JW and Mills GB 2005 Emerging role of Rab GTPases in cancer and human disease: Cancer Research 65:2516-2519
50. Spitz MR, Wu X, Mills G. 2005 Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol. 23:267-75
51. Cheng, K.W., Lu Y., Mills G.B. 2005 Assay of Rab25 function in ovarian and breast cancers Methods Enzymol. 403:202-15
52. Hennessy, BT, Mills G.B., 2006 Ovarian Cancer: Homeobox genes, autocrine/paracrine growth and kinase signaling Int J Biochem Cell Biol 38:1450-6
53. Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 2006 10th biennial Helene Harris Memorial Trust meeting. Cancer Res. 66(6):2904-6
54. Davies M., Hennessy, B., and Mills G.B., 2006 Point mutations of protein kinases and individualised cancer therapy. Expert opinion in pharmacotherapy 7:2243-61 PMID 17059381
55. Murph, M., Tanaka, T., Liu, S., and Mills G.B., 2006 Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer Clinical Cancer Research 15:11030-8
56. Stemke-Hale, K., Hennessy, B., and Mills G.B., Mitra., R., 2006 Molecular screening for breast cancer prevention, early detection and treatment planning-Combining biomarkers from DNA, RNA and protein. Current Oncology Reports. 8:484-91 PMID17040626
57. Bast RC Jr, Brewer M, Zou C, Hernandez M, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. 2007 Prevention and early detection of ovarian cancer: Mission impossible? Recent Results in Cancer Research174:91-100
58. Murph M., Tanaka, T., Pang J., Felix, E., Liu, S., Trost, R., Godwin A.K., Newman R., and Mills G.B. 2007 Liquid chromatography mass spectrometry for quantifying plasma lysopholipids: potential biomarkers for cancer diagosis in Enzymology 433:1-25
59. Murph M., Mills GB 2007 Targeting the lipids LPA and S1P and their signaling pathways to inhibit tumor progression Expert Rev Mol Med 9:1-18
60. Hennessy, B.T., Murph M., Nanjundan M., Carey M., Auersperg N., Almeida, J., Coombes, K., Liu, J., Lu Y., Gray JW. Mills G. B., 2008 Ovarian cancer: Linking Genomics to New Target Discovery and Molecular Markers: The Way Ahead. Adv. Exp. Med. Biol 617:23-40, PMC2844243
61. Murph, M.M., Smith D.L., Hennessy, B., Lu, Y., Joy C. Coombes, K., and Mills G.B., 2008 Individualized molecular medicine: Linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. Adv Exp Med Biol. 622:183-95
62. Ashworth A., Balkwill R., Bast R.C., Berek J.S., Kaye A., Boyd, J. A., Mills G.B., Weinstein, J.N., Wooley K., Workman P., 2008 Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007 Gynecological Oncology 108(3):652-7
63. Agarwal R., Jurisica, I., Mills GB., and Cheng K.W 2009 The emerging role of the Rab25 small GTPase in cancer Traffic 10:1561-8, PMC3258497
64. Tuna M., Knuutila, S., and Mills G.B., 2009 Uniparental disomy (UPD) in cancer Trends in Molecular Medicine 15:120-8
65. Liu S., Murph M., Panupinthu N., and Mills G.B. 2009 ATX-LPA receptor axis in inflammation and cancer Cell Cycle 15:3695-701, PMC4166520
66. Mills G.B., Agarwal R. and Cheng KW 2009 Ras-superfamily GTP-ases in ovarian cancer Cancer Treat Res 149:229-40
67. Tabchy A., Hennessy, BT., Hortobagyi, G., Mills G.B., 2010 Systems Biology of Breast Cancer Current Breast Cancer Reports 1:238-245
68. Panupinthu, N., Mills G.B., Lee HY 2010 Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression British Journal of Cancer 102:941-6, PMC2844037
69. Gonzalez-Angulo AM., Hennessy BT., and Mills GB 2010 The future of personalized medicine in oncology: A systems biology approach J Clin Oncol 28:2777-83, PMC2881854
70. Agarwal R., Carey M., Hennessy G., Mills GB 2010 PI3K pathway-directed therapeutic strategies in cancer Current Opinion Investigative drugs 11:615-28
71. Siwak D.R., Carey, M., Hennessy, B.T., Nguyen CT., McGahren Murray MJ., Nolden L., Mills G.B., 2010 Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges J. Oncol 2010:568938, PMC2796463
72. McAuliffe PR., Mills GB., Gonzalez-Angulo AM., 2010 Deciphering the role of the PI3K/Akt/ mTOR pathway in breast cancer biology and pathogenesis Clinical Breast Cancer Supplement 10, Suppl. 3, S59-S65
73. Mitra S, Cheng KW., and Mills GB 2011 RabGTPases implicated in inherited and acquired disorders Semin Cell Dev Biol 22:57-68, PMC3395236
74. Tabchy A., Hennessy, BT., Gonzlez-Angulo AM, Bernstam FM., Lu Y., Mills GB., 2011 Quantitaive proteomic analysis in breast cancer Drugs Today 47:169-82
75. Lee JS., Kim JH, Park YY., and Mills GB 2011 Systems Biology Approaches to Decoding the Genome of Cancer Cancer Research and Treatment 43:205-11 PMID: 22247704 PMC3253861
76. Mitra S., Stemke Hale KA., Mills GB., Claerhout S., 2012 Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy Cell Science 103:400-7, PMC3395236
77. Ram P., Mendelsohn J., and Mills GB 2012 Bioinformatics and Systems Biology Molecular Oncology 6:147-54, PMC3345061
78. Blumenschein GR., Mills GB., Gonzalez-Angulo 2012 Targeting the Hepatocyte growth factor- cMet axis n cancer therapy. J Clinical Oncol 30:3287-96, PMC3434988
79. Mitra S., Cheng KW, Mills GB., Rab25 in Cancer: A brief update 2012 Biochemical Society Transactions: 40:1404-8
80. Kamel D., Hennessy B., Brady B., Tabchy A., and Mills GB 2012 Proteomic classification of breast cancer Current Drug Targets 13:1495-509
81. Meric-Bernstam, F., Farhangfar C., Mendelsohn J., and Mills GB., 2013 Building a personalized medicine infrastructure at a major cancer center. J Clin Onc 31:1849-57
82. Claerhout S., Mills GB., Weinstein, JN., Lorenzi, PL., 2012 Autophagy modulation and its therapeutic potential in cancer. Drugs of the Future 36(12)
83. Liang J and Mills GB 2012 AMPK: a contextual oncogene or tumor suppressor? Cancer Research: 73:2929-35, PMC3725287
84. Klempner, SJ., Myers AP., Mills,GB., Westin S 2013 Clinical Investigation of Receptor and Non-Receptor Tyrosine Kinase Inhibitors for the Treatment of Epithelial Ovarian Cancer. Expert Opinion on Pharmacotherapy 14:2171-82, PMC4103698
85. Bailey AM., Mao Y., Zeng J., Holla V., Johnson A., Brusco L, Che K., Mendelsohn J., Mills GB., Meric-Bernstam F 2014 Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps Discovery Medicine 17:101-14, PMC4160907
86. Akbani R., Becker K-F., Carragher N., Goldstein T., de Koning L., Korf U., Liotta L., Mills GB., Nishizuka S.S., Petricoin EF., Pollare HB., Serrels B., Shu J., For the The RPPA (Reverse Phase Protein Array) Society 2014 Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational and Basic Research: A Workshop Report Mol Cell Proteomics 13:1625- 43, PMC4083105
87. Dawood M., Mills GB., Ding Z., 2014 Shrewd AKT regulation to survive Oncoscience 1:113- 114, PMC4278283
88. Johnson AM., Zeng J., Bailey AM., Holla V., Litzenburger B.., Lara-Guerra H., Mills GB., Mendelsohn J.m Shaw KR and Meric-Bernstam F., 2015 The Right Drugs, at the Right Time, for the Right Patient: Drug Discovery Today 1359-6446:00265-2
89. Mitra S., Molina J., Mills GB., Dennison JB., 2015 Characterization of the role Rab25 in Energy Metabolism and Cancer. Methods in Molecular Biology 1298: 195-205 PMID: 25800844
90. Zhang S., Yang C., Yang Z., Zhang D., Ma X., Mills G., Liu Z., 2015 Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect Am J Cancer Res 2015 5:928-944 PMID: 26045978 PMC4449427
91. Guo H, German P, Bai S, Barnes S, Guo W, Qi X, Lou H, Liang J, Jonasch E, Mills GB, Ding Z. The PI3K/AKT Pathway and Renal Cell Carcinoma. J Genet Genomics 42:343-53 PMID: 26233890 PMC462421
92. Chaluvally-Raghavan P., and Mills GB 2015 Targeting non-coding RNAs in the 3q26.2 amplicon in ovarian cancer Oncoscience 2:671-2
93. Cheung LWT and Mills GB 2016 Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment Pharmacogenomics 17:297-307 PMID: 26807692, PMC5558511
94. Federico L, Jeong KJ, Vellano CP, Mills GB. 2016 Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. J Lipid Res. 57:25-35. PMC4689343
95. Nishizuka SS, Mills GB 2016 New era of integrated cancer biomarker discovery using reverse- phase protein arrays. Drug Metab Pharmacokinet 31:35-45 PMID: 26822993
96. Meyer L., Suidan R., Sun C., Westin S., Coleman RL., Mills GB. 2016 Management of malignant ascites and impact on qaulity of life outcomes in women with ovarian cancer Expert Review of Quality of Life in Cancer Care 1:231-238 PMID:30906877 PMC6425954
97. Takiar V., Ip CM., Gao M., Mills G.B., and Cheung LWT 2016 Neomorphic mutations create therapeutic challenges in cancer Oncogene 36:1607-1618. PMID: 27841866 PMC6609160
98. Akbani R., Lu Y., Ling S., Coombes K., Mills GB., 2016 Using Reverse Phase Protein Array (RPPA) as a pharmacodynamic assay for functional proteomics, biomarker discovery and drug development in cancer. Seminars in Oncology 43:476-83 PMID: 27663479, PMC5111873
99. Ip K., Yin J., Ng P., Lin S-Y., Mills GB., 2016 Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management AIMS Medical Sciences 3:386-416
100. Previs R., Sood Ak., Mills GB., and Westin SN 2017 The rise of genomic profiling in ovarian cancer Expert Review of Molecular Diagnostics 16:1337-1351
101. Khotskay Y., Shaw KR., Mills GB 2017 Next-generation sequencing and result interpretation in clinical oncology: Challenge of personalized Cancer therapy. Annual Review of Medicine 68:113-125. PMID: 27813876
102. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR. 2017 ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud. 3:a001115. doi: 10.1101/mcs.a001115. PMID: 28050598 PMC5171696
103. Sanchez, N., Mills-Shaw K., Mills GB 2017 Precision Oncology: Neither a silver bullet nor a dream Pharmacogenomics 18:1525-1539
104. Zhao W., Fitzgibbon M., Bergan L., Clegg N., Crispin D., Mills GB and McIntosh M., 2017 Identifying Abundant Immunotherapy and Other Targets in Solid Tumors: Integrating RNA-seq and Mass Spectrometry Proteomics Data Sets. Cancer J. 23(2):108-112018, PMC5839124
105. Kurnit K., Dumbrava E., Litzenberger B., Khotskay Y., Johnson A., Yap T., Rodon J., Zheng J., Shufean M., Bailey A., Sanchez N, Holla V., Mendelsohn J., Shaw K., Bernstam E., Mills GB., Meric-Bernstam F., 2017 Precision oncology decision support: Current approaches and strategies for the future Clin Cancer Res 24:2719-2731 PMID: 29420224, PMC6004235
106. Li Y., McGrail D., Mills GB., Yi S., and Sahni N., 2018 Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation Trends Biochem Sci. 43:576-592. PMID: 29941230, PMC6215597
107. Bast RC., Matulonis UA., Sood AK., Ahmed A., Amobi A., Balkwill F., Wielgo-Bonvallet M., Bowtell D., Brenton J., Brugge J., Coleman R., Draetta G., Doberstein K., Drapkin R., Eckert M., Edwards R., Elias K., Enniss D., Futreal A., Gershenson D., Greenber R., Huntsman D., Ji J., Kohn E., Iaveron C., Lengyel E., Levin D., Lord C., Lu Z., Mills G., Modugno F., Nelson F., Odunsi K., Pilsworth J., Rottapel R., Powell D., Shen L., Shi I-M., Spriggs D., Walton J., Zhang K., Zhan R., Zou L., 2019 Critical Questions in Ovarian Cancer Research and Treatment: Report of an AACR Special Conference. Cancer 125: 1963-1972 PMID:30835824 PMC6557260
108. Beaver J., Coleman R., Arend RC., Armstrong DK., Bala S., T., Mills GB., Sood A Herzog TJ., 2019 Advancing Drug Development in Gynecologic Malignancies Clin Can Research 25:4874-4880 PMID:31126961
109. Labrie M., Kendsersky N., Ma H., Campbell L. Eng J., Chin K., Mills GB 2019 Proteomics advances for precision therapy in ovarian cancer Expert Rev Proteomics 13:1-10 PMID 31512530
110. Labrie M., Fang Y., Kandsersky, N., Li J., Liang H., Westin S., Mitri Z, and Mills G. 2019 Using Reverse Phase Protein Arrays (RPPA) to identify and target adaptive resistance In Reverse Phase Protein arrays Adv Exp Med Biol. 2019;1188:251-266 PMID 31820393
111. Tsang S., Blucher A., Mills GB 2020 Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients Expert Reviews in Proteomics 22:1-4 PMID 32306787
112. Cummings R., Emili A., Ginsberg D., Green E., Hoots WK., Kiessling L., Masumdar R., Mills GB., Ostell J., Roberst R., Rodland K., Sarkar R., Sheeley D., Stamatoyannopoulos J., Stringer K., Subramaniam S., Taron C, Varki A., 2020 Report of the Workshop on Integration of Glycoscience into Bioinformatics and Personalized Medicine Submitted
113. Li A., Maldonado E., Mills GB., Mitri Z. 2020 Targeting BCL2 in breast cancer Submitted
114. Tognon, CE., Sears RC., Mills GB., Gray JW., Tyner JW 2020 Ex vivo analysis of primary tumor specimens for evaluation of cancer therapeutics Annual Reviews Oncology Submitted

# EDITORIALS

1. Mills G.B. 1993 Transmembrane signaling through hematopoietin receptors: Interleukin 2 and erythropoietin (Editorial) Seminars in Immunology. 5:297-298
2. Kruzelock, RP, Wiener, JR, and Mills GB 1997 Human Cancer Genetics: Science Fiction Becomes Science Fact Breast Diseases: 8:15-19
3. Mills, G.B., Schmandt, R., Gershenson, D., Bast, R.C. Jr. 1999. Should therapy of ovarian cancer patients be individualized based on underlying genetic defects. Clinical Cancer Research:5(9):2286-8
4. Mills G.B., Bast, R.C., Srivastava, S., 2001 Future for ovarian cancer screening: Novel markers from emerging technologies of transcriptional profiling and proteomics. Journal of the National Cancer Institute: 93:1437-1439
5. Mills G.B., Lu, Y., and Kohn E., 2001 Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the phosphatidylinositol 3-kinase pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Commentary Proceedings of the National Academy of Science 98:10031-3, PMC56908
6. Mills G.B. 2002 Mechanisms underlying chemoprevention of ovarian cancer Clinical Cancer Research 8:7-10
7. Petricoin, E.D., Mills G.B., Kohn, E.C., and Liotta L.A. 2002 Proteomic patterns in serum and

identification of ovarian cancer Response to comments: Lancet 360:170-171

1. Euhus DM, Esserman L, Ganz PA, Mills GB, Tomlinson G. 2002 RESPONSE: Re: Pretest Prediction of BRCA1 or BRCA2 Mutation by Risk Counselors and the Computer Model BRCAPRO.J Natl Cancer Inst.94:1583-1584
2. Lahad, J.P., Mills G.B., Coombes, K.R., Stem cell-ness: A “Magic Marker” for Cancer 2005 J. Clin Invest 115:1463-7
3. Hennessy, B, Nanjundan, M., Cheng, K.W., Nolden L., and Mills GB. 2006 Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13.5 as a putative oncogene in ovarian cancer European J. Human Genetics 14:381-3
4. Brugge, J., Hung, M-C, Mills G.B. 2007 A New Mutational AKTivation in the PI3K Pathway Cancer Cell 12: 104-107
5. Hennessy, B.T., Gonzalez-Angulo, A.M., Carey M.S., Mills G.B., 2009 Systems approach to molecular complexity in breast cancer Clinical Cancer Research 15:417-419, PMC4161015
6. Hung MC, Mills GB, and Yu D., 2009 Less Oxygen but more RTK: HIF links oxygen-sensing pathway to receptor tyrosine kinase (RTK) endocytosis Nature Med 15:246-7
7. Mills GB, Jurisica I, Yarden Y., Norman JC 2009 Genomic amplicons target vesicle recycling in breast cancer J Clin Invest 119:2123-7, PMC2719927
8. Mills GB., Yarden Y., 2010 The rebirth of a phoenix: Ovarian cancers are addicted to ErbB-3 Cancer Cell 16:217-218
9. Bast RC., Mills GB., 2010 Personalizing therapy for ovarian cancer: BRCAness and Beyond J. Clin Onc 102: 1199-25
10. Woodman SE., Mills GB 2010 Are oncogenes sufficient to cause human cancer? Proc Natl Acad Sci 107:20599-600, PMID 21084639 PMC2996413
11. Halder G., Mills GB 2010 Drosophila in Cancer Research: to boldly go where no one has gone before Oncogene 30:4063-6
12. Tabchy AT., Tigyi G., Mills GB 2010 Location, location, location: A crystal clear view of Autotaxin saturating LPA receptors Nature Structural Molecular Biology 18:117-118, PMC3584164
13. Bast RC., Mills GB., 2012 Dissecting PI3Kness: The complexity of personalized therapy for ovarian cancer Cancer Discovery: 2:16-18, PMC3354732
14. Mills GB 2012 An emerging toolkit for targeted cancer therapies Genome Research 22: 177-82, PMC3266025
15. Verhaak R and Mills GB 2012 Regulation of mRNA expression in breast cancer – a cis-temic trans-action Breast Cancer Res 14:322, PMC4053097
16. Westin SN., Mills GB and Myers AP. 2012 Repurposing the Pap Smear: One Step Closer to the Holy Grail of Gynecologic Cancer Screening Science Signaling 5:167ps1, PMC3824959
17. Muranen T., Meric-Bernstam G., Mills GB., 2014 Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors Cancer Cell 26:7-9
18. Peng G., Woodman SE., Mills GB., 2014 RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy? Cancer Discovery 4:988-90, PMC4155513
19. Cheung LWT and Mills GB 2015 p85α neomorphic mutants: splitting away from the canonical path Molecular and Cellular Oncology 2(4):e983388., PMID: 27308516 PMC4905360
20. Gray JW and Mills GB 2015 Large-Scale Drug Screens Support Precision Medicine. Cancer Discovery 5:1130-2, PMC4633700
21. Zhao, W., Li j., Liang H., and Mills GB 2017 Functional proteomic characterization of cancer cell lines Oncoscience 4:41-42, PMC5538845
22. Peng G and Mills GB 2018 Surviving ovarian cancer: an affair between defective DNA repair and RB1 Clin Can Res 24:508-510 PMID 29191971 PMC5905329
23. Dumbrava, EI., Mills GB., Yap TA., 2018 Targeting gamma secretase: have things moved up a notch? Ann Oncol.29:1889-1891. PMID: 30084907
24. Heiser L., Mills GB., Gray J., 2019 Therapeutic clues from an integrated omic assessment of East Asian triple negative breast cancers Cancer Cell 35:341-343. PMID:30889376 PMC6499473
25. Kreisberg J., Idekar T., Meric-Bernstam F., Mills GB 2020 Prospecting whole cancer genomes Nature Cancer 2020

# BOOK CHAPTERS

1. Paetkau, V., Mills, G.B., and Bleackley, C. 1982 Enhancement of antitumor responses with Interleukin 2. In: The Potential Role of T Cell Populations in Cancer Therapy. Editor: M.A. Fefer and A. Goldstein, Raven Press, New York pp: 147-159
2. Mills, G.B. 1986 Immunology of Cancer in Pregnancy. In: Cancer in Pregnancy. Editors: Allan, H. and Nisker, J., Futura Publishing Inc., pp 9-34
3. Gelfand, E.W., Cheung, R., Mills, G.B., Lee, J., Lederman, H. M., Nisbet-Brown, E., and Grinstein, S. 1986 Analysis of calcium-dependent and calcium-independent signals in triggering human T lymphocytes. In: Primary Immunodeficiency Diseases, Editors: Eibl, M. and Rosen, F. S. Elsevier Science Publishers, B. V., pp. 153-164
4. Mills, G.B., Benedict, S., Mellors, A., Grinstein, S., and Gelfand E.W. 1988. Transmembrane signaling by Interleukin 2. In: Interleukin 2. Editor K.A. Smith. Academic Press San Diego CA. pp 113-135
5. Teodorczyk-Injeyan, J.A., Mills, G.B., Sparkes, B.G., and Peters, W.J. 1989 Expression of Functional Interleukin 2 Receptors in the burn patient may be regulated by Interleukin 3 Editors: E. Saist Ninnemann and D.R. Green In: Immune consequences of trauma, shock and sepsis. Springer-Verlag Berlin pp 115-118
6. Mills G.B., and May C. 1989 Regulatory mechanisms in ascitic fluid. Ovarian Cancer: Biologic and therapeutic challenges Editors F. Sharp, W.P. Mason and R.E. Leake. Chapman and Hall Medical London England pp 55-62
7. Mills, G.B., Hashimoto, S., Hurteau, J., Schmandt, R., Campbell, S., May, C., Hill, P., Shaw, P., Buckman, R., and Hogg, D., 1992 Regulation of growth of human ovarian cancer cells. In Ovarian cancer 2-Biology Diagnosis and Management Editors F. Sharp, P. Mason, and W. Creaseman Chapman and Hall Medical London England pp 127-143
8. Mills G.B., 1993. Functional and molecular aspects of T cell activation In Developmental Immunology Editors Cooper E.L., and Nisbet-Brown, E. Oxford University Press pp 333-364
9. Xu, Y., and Mills, G.B., 1994 Activation of human ovarian cancer cells: Role of lipid factors in ascitic fluid. In Ovarian Cancer III Edited by Mason P., Sharp, F., Blackett, T., and Berek, J., Chapman and Hall Medical London England pp121-135
10. Bast R.C., Wiener J., Kassim, S., Wu, S., Boyer, C., DeSombre, K., Hurteau, J., Rodriguez, G., Mills, G. B., Berchuk, A., 1994 Cell growth regulation in ovarian cancer: Tyrosine kinases, tyrosine phosphatases and tumor necrosis factor-a. In Ovarian Cancer III Edited by Mason P., Sharp, F., Blackett, T, and Berek, J., Chapman and Hall Medical London England pp 109-114
11. Gibson, S., and Mills, G.B., 1994. EMT Expressed mainly in T cells (human) In Protein Kinase Factsbook Editors Hardie, D.G., and Hanks, S., Academic Press London England pp 85-86
12. Schmandt, R.E., Hogg, D., and Mills, G.B., 1994 TTK (Serine), threonine, tyrosine kinase (human) Protein Kinase Factsbook Editors Hardie, D.G., and Hanks, S. Academic Press London England pp 371-373
13. Bast, R., Mills, G.B, Gibson, S., and Boyer, C., 1996 Tumor Immunology In: Cancer Medicine 4th Edition Editors Holland J.F., Frei, E., Kufe D.W., Morton, D.L.and Weichselbaum R.R. Williams and Wilkins Baltimore USA pp 207-242
14. Mills, G.B., Gibson, S., Schmandt, R., Fang, X.J., and Wiener, J.R., 1996. Signal Transduction In: Transplantation Biology: Cellular and Molecular Aspects Editors Tilney, N., Strom, T.B., and Paul L. C. Lippincott-Raven Philadelphia pp31-54
15. Shi, Y.F., Mills G. B. and Wang, R. 1997 Mitogenic Cytokine Promote Apoptosis: Possible Roles in Cellular Homeostasis. In: Current advances in programmed cell death, Shi, Y.-B, Shi, Y., Scott, D., and Xu, Y. eds Plenum Publishing Corp., New York pp113-124
16. Gallion H,H., Kohn E.C., Mills, G.B and Bast R.C. 1998 Clinical Applications of Basic Science Investigations In: Current controversies in the management of ovarian cancer Editor Gershenson D. pp357-397
17. Xu, Y., Fang, X., Furui, T., Sasagawa, T., Pustilnik, T., Lu, Y., Shen, Z., Wiener, J.R., Shayesteh, L., Gray, J. W., Bast Jr., R.C., and Mills, G.B., 1998 Regulation of growth of ovarian cancer cells by phospholipid growth factors . In Ovarian Cancer 5 Edited by Sharp, F., Blackett, T, Berek J and Bast R.C., ISIS Medical Media, Oxford UK pp109-120
18. Bast, R.C., Xu, F., Yu, Y., Fang, X., Wiener, J., and Mills, G.B., 1998 Overview: The Molecular Biology of Ovarian Cancer. In Ovarian Cancer 5 Edited by Sharp, F., Blackett, T, Berek J and Bast R.C., ISIS Medical Media, Oxford UK pp87-98
19. Gray, J.W, Collins, C., Daneshvar, L., Rommens, J., Kuo, W-L., Palazzolo, M., Martin, C., Hwang, S., Kowbel, D., Mills, G., Albertson. D., and Pinkel, D., 1998 Genome Scanning to Genes: Positional cloning at 3q26 and 20q13.2 In Cancer Genomics Edited by Croce CM, Nakamura, Y., Ohki, M., Sugimura, T., Terada M., and White R.L. Princess Takematsu Cancer Research Fund pp95-97
20. Gray, J.W., Collins, C., Pinkel, D., Shayesteh, L., Lu, Y., Mills G.B. 1999 Genome scanning and gene discovery in breast and ovarian cancer Pezcoller Foundation Symposia: The Biology of Tumors: Editors. Mihich E., and Croce C., Plenum Press, New York pp 65-72
21. Mills G.B., Rieger, P., Watt, M.A., Graham, C., and Pentz, R. 1999 Genetic Predisposition to Cancer: In Manual of Clinical Oncology Seventh Edition Editor R.E. Pollock Wiley-Liss New York pp 63-97
22. Mills, G.B., Lu, Y., Shyestri, L., Pinkel, D., and Gray, J., 1999. From genetics to therapeutic targets: Phosphatidylinositol 3’kinase (PI3K) in ovarian and breast cancer. In: Cancer: investigatcion basica y aplicaciones clinicas: Editor M. Barbacid Erika Med pp6-16
23. Shaw, P., Deavers, M., and Mills G.B., 2000 Clinical Characteristics of Genetically determined ovarian cancer. In Genetic Predisposition to Female Cancers Editor: Victor Vogel Backwell Science In Malden Mass. pp94-107
24. Bast R.C., and Mills G.B. 2001 The molecular pathogenesis of ovarian cancer: In The molecular basis of cancer Editors Mendelsohn, J., Howley, P., Isreal, M and Liotta. L. W.B. Saunders Company, Philadelphia pp 361-384
25. Lu, Y., Shayestri, L., Lapushin, R., Yu, S., Cuevas, B., Fang, X., Eder, A., Furui, T., Plikoff, D., Kuo, W.L., Baldocchi, R., Vanhaesebroeck, B., Bast RC, Pinkel, D., Siminovitch, K., Jaffe, R., Gray, J., and Mills G.B., 2002 Phosphatidylinositol 3’kinase as a Target in Selected Ovarian Cancers: From Genomics to Therapeutics In Ovarian Cancer Oxford University Press. Edited by Jacobs I., Shepherd, J. Oram , D., Blackett, A., Luelsey, D., Berchuck A, Hudson C: pp 413- 422
26. Yu, Y., Xu, F., Peng H., Fang, X., Zhao, S., Li, Y., Cuevas., B, Kuo, W-L., Gray J., Siciliano, M., Pershad, R., Hogg, D., Berchuk, A., Hunt K., Mills G.B., and Bast R.C., 2002. ARHI (NOEY2) an imprinted tumor suppressor gene in epithelial ovarian cancer In Ovarian Cancer Oxford University Press Edited by Jacobs I, Shepherd, J. Oram , D., Blackett, A., Luelsey, D., Berchuck A, Hudson C. pp125-130
27. Mills G.B., Rieger, PA, 2002 Genetic Predisposition to Breast Cancer In:Breast Cancer Eds. Hunt, K., Robb, G.L., Strom E.A., and Ueno, N., Springer Verlag New York NY pp55-92
28. Bast RC and Mills GB 2003 Molecular mechanisms of pathogenesis and progression of epithelial ovarian cancer The Ovary 2nd Edition CK Leung and EY Adashi Editors Esevier Academic Press pp 625-637
29. Mills GB and Rieger PT 2004 Genetic Predisposition to Cancer UICC Manual of Clinical Oncology Eds Polloick RE., Doroshow JH., Khayat D., Nakao A., O’Sullivan B., Wiley Liss Hoboken New Jersey pp63-89
30. Kohn EC., Lu, Y., Wang, H., Yu, Q., Yu., S., Hall, H., Smith, D.L., Nolden L., Meric-Bernstam F. Hortobagyi, G., and Mills G.B. 2004 Targeted Therapeutics in Breast Cancer: Challenges to Success Diseases of the Breast Editors.Jay R. Harris, Marc E Lippman, Monica Morrow, C. Kent Lippman Lippincot–Williams & Wilkins: Philadelphia, New York, pp 392-414
31. Tanyi JL. Croetzer, D., Wolf, J., Yu, S., Hasegawa, Y., Lahad, J., Cheng, KW., Umezu-Goto, M., Prestwich, G.D., Morris A., Newman, R.A., Felix, EA., Lapis, R., and Mills G.B. 2006 “Functional Lipidomics: Lysophosphatidic Acid as a Target for Molecular Diagnosis and Therapy of Ovarian Cancer”, Functional Lipidomics (L. Feng and G.D. Prestwich, eds.), CRC Press/Taylor & Francis, New York, pp. 101-123
32. Boyce, E., Kohn, E.C., and Mills Gordon B. 2005 Applications of proteomics to clinical questions in breast cancer. Breast Cancer And Molecular Medicine Mien Chie Hung Editor pp623-339
33. Smith, D.L., Nolden, L.K. Mills G.B., Lu, Y., 2006 Chemo- and Radiation Sensitization through inhibition of PI3K/AKT signaling In D Gewirtz, S Holt, S Grant (Eds.), Apoptosis, Senescence, and Cancer. 2nd ed. 2007 pp 313-334.
34. Hennessy, B., Bast R.C., Gonzalez-Angulo A.M., Mills G.B., 2008 Early Detection of Cancer: Molecular Screening: In Molecular Basis of Cancer Mendelsohn, Israel, Gray, Thompson Editors Saunders Elsevier Philadelphia pp 335-347
35. Bast. R.C., Mills G.B., 2008 Molecular pathogenesis of epithelial ovarian cancer In Molecular Basis of Cancer Editors Mendelsohn, Israel, Gray, Thompson Editors Saunders Elsevier Philadelpia pp441-454
36. Hennessy BT, Carey M., Naora, H., Agarwal, R., and Mills G.B 2009 Ovarian Cancer: Molecular, Cellular and Clinical Biology In Ovarian cancer Editors Maurie Markman and Robert Bast Editors Remedica London In press
37. Hennessy BT., Bast RC., Mills GB., 2010 Molecular diagnostics in cancer Holland Frei Cancer Medicine VIII Editors Hong WK., Bast RC., Hait W., Kufe DW., Holland JF., Pollock RE., Weichselbaum BC Decker pp335-346
38. Iadevaia, S., Tabchy AB., Ram PT., and Mills GB 2011 Clinical Applications of systems Biology Approaches in Cancer Systems Biology Cesario A and Marcus F B (editors) Springer Dordrecht Heidelberg London New York pp409-428
39. Panupinthu N., and Mills GB 2013 Understanding the functions of lysophosphatidic acid receptors in cancer in Lysophospholipid receptors: signaling and biochemistry Chun J., Hla T., Spiegel S., and Moolenaar W. Editors John Wiley and Sons In. Hoboken, New Jersey pp 641-659
40. Mitra S., Mills GB 2013 Aberrant Vesicular Trafficking Contributes to Altered Polarity and Metabolism in Cancer In Vesicle Trafficking in Cancer Yosef Yarden and Gabi Tarcic Editors Springer Verlag Vesicle Trafficking in Cancer, 95-123
41. Bast R.C., Romero I., Mills G.B., 2014 Molecular pathogenesis of ovarian cancer In Molecular Basis of Cancer Editors Mendelsohn, Israel, Gray, Thompson Editors Saunders Elsevier Philadelphia
42. Suh, G. K., Hennessy, B. T., Verhaak, R., Yang, J. Y., Mills, G. B. & Bast, R. C. 2015 Molecular Oncology: Causes of Cancer and Targets for Treatment. In Cambridge University Press, Molecular targets for epithelial ovarian cancer p. 606-618 13 p.
43. Kalachand RD., Hennessy BT., Bast RC., Mills GB., 2017 Molecular diagnostics in cancer Holland Frei Cancer Medicine VIII Editors Hong WK., Bast RC., Hait W., Kufe DW., Holland JF., Pollock RE., Weichselbaum BC Decker <https://doi.org/10.1002/9781119000822.hfcm041>
44. Naing A., Mills GB., Meric-Bernstam F., 2016 Combination Therapies Targeting the PI3K/ AKT/mTOR Pathways In PI3K-mTOR in Cancer and Cancer Therapy Eds. Leyland-Jones, De, and Dey Springer pp151-180
45. Liang l., Mercado-Uribe I., Hiu N., Jiang Y., Cheng W., Mills GB. Scott C., Sood A and Liu J., 2017 Patient-Derived Xenograft Models of Ovarian/Gynecologic Tumors In Pateient Derived Tumor Xenograft Models Editors: Rajesh Uthamanthil, Peggy Tinkey Elsevier Press: pp257-271
46. Mitra S Mills GB 2018 Rab25 in Encyclopedia of Signaling Molecules 2nd edition S Choi Editor Springer Press https://doi.org/10.1007/978-3-319-67199-4
47. Previs R., Mills GB and Westin SN 2019 Novel Therapeutic Approaches and Targets for Ovarian Cancer In the Ovary pp547-574

Books Edited

1. Reverse Phase Protein Arrays: From Technical and Analytic Fundamentals to Applications. Yamada T., Nishizuka S. Mills G. and Liotta L editors Advances in Experimental Medicine and Biology 1188Springer Press

# EDITORIAL AND REVIEW ACTIVITIES

Associate Editor: Journal of Immunology 1991-1995

Associate Editor: Breast Diseases: A Year Book Quarterly 1998-2002

Associate Editor: Clinical Cancer Research 2000-2011

Associate Editor: Gynecological Oncology 2001-2008

Associate Editor: Int J. Cancer 2002-2008

Associate Editor Clinical Proteomics 2002-2006

Senior Editor Molecular Oncology 2006-2016

Senior Editor Molecular Cancer Research 2007-2011

Senior Editor Oncogene 2009-2018

Editor Cancer Discovery 2011-

Editor Cancer Cell 2011-

Editorial Board Member: The Breast Journal 2015

# TEACHING

|  |  |
| --- | --- |
| a) Undergraduate Courses | 1987-88 |
| Core Program Year 2 Medicine Immunology Coordinator: R. Miller, (2 lectures) |  |
| Core Program Year 2 Medicine Immunology | 1988-89 |
| Coordinator: K. Siminovitch, (3 lectures) |  |
| b) Graduate Courses |  |
| IMM 1016 | 1985-86 |
| Recent Advances in Cellular Immunology Coordinator: R. Miller, (4 lectures) |  |
| IMM 1016 | 1986-87 |
| Recent Advances in Cellular Immunology Coordinator: R. Phillips, (4 lectures) |  |
| PCL 1008Y  Biochemical Pharmacology Coordinator: C. Pace-Asciak, (4 lectures) |  |
| IMM 1017 | 1987-88 |
| Recent Advances in Molecular Immunology Coordinator: M. Schulman, (4 lectures) Bioch 2021S  Hormone action and intracellular signalling Coordinators: S. Grinstein and A. Klip, (2 lectures) |  |

IMM 1016

Recent Advances in Cellular Immunology Coordinator: G. Mills, (9 lectures)

PCL 1008Y

Biochemical Pharmacology Coordinator: C. Pace-Asciak, (4 lectures)

IMM 1016

Recent Advances in Cellular Immunology Coordinator: M. Shulman, (6 lectures)

Pediatrics

Proliferation of lymphocytes in health and disease Coordinator: M. Dosch, (2 lectures)

IMM 1016

Recent Advances in Cellular Immunology Coordinator: M. Shulman (4 lectures)

Signal transduction pathways in normal and diseased tissues Signal transduction in lymphocytes

Coordinator: Cliff Lingwood (2 lectures)

Recent Advances in Clinical Immunology Tumor Immunology

Coordinator: Reginald Gorzynski (2 lectures)

IMM 1017

Recent Advances in Cellular Immunology Coordinator: M. Schulman (2 lectures)

IMM 1017

Recent Advances in Cellular Immunology Coordinator: Tanya Watts (4 lectures)

Obstetrics and Gynecology Resident Teaching University of Toronto

General Coordinator: J. Taylor

Immunology in Obstetrics and Gynecology Autoimmune disease in pregnancy

Immunology in Obstetrics and Gynecology Immunology of Infertility

Oncogenes in Gynecology and Obstetrics Immunology of Gynecologic Cancer

Oncology: Coordinator: R. Osborne

Biology and Immunology of Gynecologic Cancer Given once every 8 weeks

1988-89

1989-90

1990-91

1991-92

1993-94

1985

1986

1988

1987-91

University of Western Ontario Coordinator: J. Nisker

Immunology in Obstetrics and Gynecology

Role of activated T lymphocytes in therapy of ovarian cancer

Immunology in Obstetrics and Gynecology Immunology of Cancer in Pregnancy

The University of Texas M.D. Anderson Cancer Center Coordinator: Laurie Owen-Schaub

Course Title: Cytokines as Regulators of Growth and Function

The University of Texas Health Science Center - School of Nursing Coordinator: Miguel F. da Cunha

Course Title: Physiologic Concepts in Human Development and Neoplasia

Cytel Corporation Coordinator: Edward S. Golub Course Title: Tumor Biology

The University of Texas M.D. Anderson Cancer Center Coordinator: Dianne Bodurka

Course Title Molecular Genetics and Cancer Predisposition for Gynecological Oncologists

The University of Texas Health Science Center - School of Nursing Coordinator: Miguel F. da Cunha

Course Title: Physiologic Concepts in Human Development and Neoplasia

The University of Texas M.D. Anderson Cancer Center Coordinator: Dianne Bodurka

Course Title Molecular Genetics and Cancer Predisposition for Gynecological Oncologists

The University of Texas M.D. Anderson Cancer Center Coordinator: Robert through

Course Title Medical Oncology

The University of Texas M.D. Anderson Cancer Center Coordinator: Linda White Hilton

Course Title PEPED

The University of Texas M.D. Anderson Cancer Center Coordinators: Jonathan Kurie and Bharat Aggarwal Course Title Medical Oncology

The University of Texas Health Science Center - School of Nursing Coordinator: Miguel F. da Cunha

Course Title: Physiologic Concepts in Human Development and Neoplasia Coordinator: Linda White Hilton

Course Title PEPED

The University of Texas M.D. Anderson Cancer Center

1985

1987

1996

1997

1998

1999

Coordinator: Linda White Hilton Course Title PEPED

The University of Texas M.D. Anderson Cancer Center Coordinator: Linda White Hilton

Course Title PEPED

The University of Texas M.D. Anderson Cancer Center Gynecological Oncology

Coordinator Dianne Bodurka Bevers Genetics of Ovarian Cancer 4 lectures

University of Texas Houston MD PhD Program Molecular Therapeutics

4 lectures

Supervisory Teaching Toronto

2000

2001

PhD Spencer Gibson Clinical Biochemistry Graduated

Bernadine Leung Immunology Transferred

Laszlo Radvanyi Clinical Biochemistry Graduated

Jacqueline Stanley Immunology Graduated

Rosemarie Schmandt Clinical Biochemistry Graduated

Masters Nan Zhang Immunology Graduated

MD Anderson

PhD Bruce Cuevas Immunology Graduated Chuan Gao Tumor Biology Graduated

Muling Mao Tumor Biology Graduated

Laura Nolden Tumor Biology Transferred

Debra Smith MD PhD Graduated

Catherine (Nguyen) Charles Tumor Biology Graduated

Meng Gao (China) Graduated

Ana Gonzalez-Angulo Graduated

Masters

John Lahad Tumor Biology Graduated

Debora Bruno Graduated

Post-Doctoral and Medical Fellows University of Toronto

Don Branch Suzanne Kreme

Xian-Jun Fang Anton Novak

Doug Gaudette David Phipps

Shuichi Hashimoto Yu Fang Shi

Jean Hurteau Hans-Uwe Simon

Post-Doctoral and Medical Fellows MD Anderson

Matthew Anderson Lakeisha Batts

Kenny Bozorgi Mark Carey

Kwai Wa Cheng Jae-Ho Cheong

John Dalrymple Michael Davies

Zhiyong Ding Bhaskar Dutta

Tatsuro Furui Makiko Goto

George Hagopian Yutaka Hasegawa

Bryan Hennessy Russell Kruzelock

John Lahad Jin Li

Jiyong Liang Shuying Liu

Mandi Murph Yasushusi Nakayama

Meera Nanjudan Terri Pustilnik

Takayo Sasagawa Ramona Swaby Fazad Haq Tabassam Tomatsu Tanaka Janos Tanyi Raoul Tibes Dimitra Tsavachidou Hongwei Wang Mary Anne Watt Steven Watt

Sofie Claerhout Marit Krohn

Christopher Vellano John Albeck (joint with Joan Brugge) Nattapon Panupinthu Maria Shahmorad

Kwok Shing Patrick Ng Chao Wang

Chao Gu Jennifer Dennison

Henrica Werner Jennifer Molina

Kang Jin Jeong Lorenzo Federico

Dalila Naci Pradeep Chaluvally-Raghavan

Wai Ting Cheung Christopher Vellano

Sraboni Mitra Shreya Mitra

Chaoyang Sun Ka Man Ip

Parisa Imanirad Yong Fang

Wei Zhao Meng Gao

**Post-Doctoral and Medical Fellows Knight Cancer Institute**

Current Marilyne Labrie Aurora Bleucher

Yong Fang Xi Li

University of Toronto Student Committees/Thesis defense

Nooshen Alaverdi Immunology

Peter Autenreid Immunology

Judy Caterini Immunology

Peter Chu Institute of Medical Science

Julie Conquer Pathology

Fula Doolaganlu Immunology

Linda Faccini Medical Genetics

Gregory Hannigan Biochemistry

Mike Kobrin Clinical Biochemistry

James Leung Clinical Biochemistry

Dianne Lu Biochemistry

Roy McGroarty Pathology

Teresa Petrocelli Physiology

Rosemarie Schmandt Clinical Biochemistry

Carol Swallow Institute of Medical Science

Yves St Pierre Immunology

Agnes Teh Institute of Medical Science

Dan Theodorescu Institute of Medical Science

Peter Tsao Pharmacology

Joe Barr Immunology

Drgan Gajic Clinical Biochemistry

Julien Ghislain Infectious Diseases

Marni Goldstein Immunology

Nazik Hammad Immunology

Student Committees

MD Anderson Rhys Adams

Heike Allgayer Tumor Biology

Lauren Byers

Dong-Joo Cheon

Chiao-Lin Cheng

Rebecca Davis

Kevin DeHoff

Veronica Estrella Tumor Biology

Chuan Gao Tumor Biology

Susan Gulling Tumor Biology

Yasmine Haddad

Floyd Holsinger

Yiu-Keung Lau Tumor Biology

Yun Lin Tumor Biology

Michael Mixon Tumor Biology

Laura Nolden Tumor Biology

Kenneth Van Owen Tumor Biology

Estrella-Pena Tumor Biology

Rongshen Ren Tumor Biology

Kimberly Syzmanski

Jacoby Tumor Biology

Jen Te Tseng Pan Tong

Claudia Vidal Tumor Biology

Angela Webb

Dianren Xia Tumor Biology

Margie Sutton

# EXTERNAL EXAMINER

James Love Physiology: University of Connecticut 1989

Alice Wong University of British Columbia 2000

Natalia Sergina UT Health Science Center, San Antonio 2001

Ui Son Khoo University of Hong Kong 2002

Yun Li University of Oslo 2004